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ABSTRACT 
Breast cancer growth is estrogen- regulated in many cases. Estrogen actions 
are mediated by estrogen receptors ERα  and ERβ. Whilst the involvement of ERβ in 
breast cancer is unresolved at present, up to 80% of breast tumours are ERα-
positive and likely to respond to endocrine therapies, such as anti-estrogens. 
However, a substantial proportion of patients develop a resistance to such 
treatments. Most resistant tumours continue to express ERα and many will respond 
to an alternative hormonal therapy, indicating that ERα continues to be important 
following the emergence of resistance. One proposed mechanism for endocrine 
resistance is post-translational modification of the ERα, particularly phosphorylation 
of ERα within the transcription activation domain AF1.  
This project investigates how the phosphorylation at residues within the AF1 
domain is linked to ERα activation and tumour cell growth in the presence of 
tamoxifen and in the absence of ligand, by stable introduction of ERα 
phosphorylation site mutants in the MCF7 human breast cancer cell line, commonly 
used as a model for ERα-positive breast cancer. Characterisation of these lines 
suggests that phosphorylation at the sites within the AF1 domain of the ER increases 
the agonist activity of tamoxifen. Further studies to determine the mechanisms by 
which ERα activity is regulated by phosphorylation within AF1 are discussed. 
 
 
 
 
 
 
 
 3 
Table of contents 
 
1 INTRODUCTION...................................................................................17 
1.1 Nuclear Receptor Superfamily .....................................................17 
1.2 Structure of nuclear receptors.....................................................18 
1.3 Gene regulation by nuclear receptors ..........................................24 
1.3.1 Coregulators of nuclear receptors .........................................27 
1.3.1.1 Coactivators of nuclear receptors ...................................27 
1.3.1.1.1 ATP-dependent chromatin remodelling complexes ......29 
1.3.1.1.1.1 SWI/SNF...........................................................29 
1.3.1.1.1.2 ISWI ................................................................30 
1.3.1.1.2 Histone/protein modifying coactivators ......................31 
1.3.1.1.2.1 p160/SRC .........................................................31 
1.3.1.1.2.2 CBP/p300 .........................................................32 
1.3.1.1.2.3 P/CAF...............................................................34 
1.3.1.1.2.4 TRAP/DRIP/ARC ................................................35 
1.3.1.1.2.5 E6-AP and RPF1 ................................................35 
1.3.1.1.2.6 PGC1α ..............................................................36 
1.3.1.2 Nuclear Receptor Corepressors ......................................37 
1.3.1.2.1 NCoR/SMRT ............................................................38 
1.3.1.2.2 LCoR and RIP140.....................................................39 
1.4 Estrogen receptors.....................................................................40 
1.4.1 Estrogen Receptor beta .......................................................42 
1.4.2 Estrogen receptor alpha.......................................................45 
1.5 Non-classical ERα response sites.................................................46 
 4 
1.6 Non-genomic actions of ERα.......................................................48 
1.7 Regulation of ERα activity by Phosphorylation ..............................51 
1.7.1 Serine 104/106/118.............................................................52 
1.7.2 Serine 167..........................................................................55 
1.7.3 Serine 236..........................................................................56 
1.7.4 Serine 305..........................................................................56 
1.7.5 Threonine 311 ....................................................................57 
1.7.6 Tyrosine 537.......................................................................58 
1.8 The development of the human breast ........................................58 
1.9 The involvement of ER in breast cancer .......................................60 
1.10 Treatment of breast cancer ........................................................61 
1.10.1 Endocrine therapies.............................................................62 
1.10.1.1 LHRH agonists..............................................................62 
1.10.1.2 Aromatase inhibitors .....................................................63 
1.10.1.3 Selective Estrogen Receptor Modulators (SERMs) ............64 
1.10.1.4 Combined SERM and aromatase inhibitor treatments .......65 
1.10.1.5 Pure estrogen receptor inhibitors ...................................67 
1.11 Resistance to endocrine therapies ...............................................69 
1.11.1 Tamoxifen resistance due to mutations in the ERα gene.........69 
1.11.2 Tamoxifen resistance due to posttranslational modifications ...71 
1.11.3 Breast cancer cell growth in a reduced estrogen environment .74 
1.11.4 Anti-estrogen-induced gene expression.................................76 
1.11.5 Transcriptional Coregulators and resistance...........................78 
1.12 Aim of study..............................................................................84 
 5 
2 MATERIALS AND METHODS.................................................................86 
2.1 Materials ...................................................................................86 
2.1.1 General chemicals and reagents ...........................................86 
2.1.2 General stock solutions........................................................86 
2.1.3 Cell culture consumables and reagents .................................87 
2.1.4 Molecular size markers ........................................................87 
2.1.5 Sundries.............................................................................88 
2.1.6 Laboratory equipment .........................................................88 
2.2 Methods....................................................................................88 
2.2.1 Routine tissue culture ..........................................................88 
2.2.2 Preparation of cell lysates using hot lysis buffer .....................89 
2.2.3 DNA Manipulations ..............................................................90 
2.2.3.1 Cell transformation using competent TG2 cells ................90 
2.2.3.2 Large scale plasmid preparation (maxi prep)...................91 
2.2.3.3 Phenol-chloroform extraction.........................................92 
2.2.3.4 DNA sequencing ...........................................................93 
2.2.3.5 Restriction enzyme digestion .........................................93 
2.2.4 MCF-7 cell transfection ........................................................94 
2.2.5 Sulphorhodamine B (SRB) Growth Assay ...............................95 
2.2.6 RNA analysis.......................................................................96 
2.2.6.1 RNA Extraction .............................................................96 
2.2.6.2 Reverse Transcription for cDNA preparation....................97 
2.2.6.3 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
 98 
 6 
2.2.6.3.1 Agarose Gel Electrophoresis......................................99 
2.2.6.4 Real-time (Quantitative) RT-PCR....................................99 
2.2.7 Microarray ........................................................................ 100 
2.2.8 Immunoaffinity Purification ................................................ 102 
2.2.8.1 Harvesting cells .......................................................... 102 
2.2.8.1.1 Harvesting cells using Sigma lysis buffer .................. 102 
2.2.8.1.2 Harvesting cells using HSLB .................................... 103 
2.2.8.1.3 Harvesting cells using modified HSLB....................... 103 
2.2.8.2 Determining protein concentration by Bradford assay .... 104 
2.2.8.3 Anti-FLAG Immunoaffinity Purification .......................... 104 
2.2.8.3.1 Elution of FLAG-tagged protein with 3x FLAG peptide105 
2.2.8.3.2 Elution of FLAG-tagged protein by acid elution ......... 105 
2.2.8.3.3 Elution of FLAG-tagged protein with Laemmli Buffer . 105 
2.2.8.4 Anti-HA Immunoaffinity Purification.............................. 106 
2.2.8.4.1 Elution of HA-tagged protein with HA peptide........... 106 
2.2.8.5 Double Immunoaffinity Purification .............................. 107 
2.2.9 Protein Analysis ................................................................ 107 
2.2.9.1 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) ..... 107 
2.2.9.2 Western Blotting......................................................... 108 
2.2.9.3 SYPRO Ruby Gel Stain................................................. 110 
2.2.9.4 Silver Stain................................................................. 110 
3 RESULTS.............................................................................................112 
3.1 Characterising MCF7-TO cell lines.............................................. 112 
 7 
3.2 Reporter Gene Assay Shows Dox-Regulated Increased Stimulation of 
ERα Activity in Stable Lines ................................................................ 118 
3.3 Expression analysis of Estrogen-Regulated genes by immunoblotting
 121 
3.4 Determination of the expression of estrogen responsive genes using 
RT-PCR and real-time PCR.................................................................. 124 
3.5 Whole-genome analysis of MCF7-TO cell lines by microarray ....... 128 
3.6 Effects of HA-ERα-FLAG and ERα mutant expression on MCF7 cell 
growth in the presence of estrogen and anti-estrogens......................... 138 
3.6.1 Growth of ERα, ERα(EEE) and ERα(AAA) expressing MCF7-TO 
cells in the presence of epidermal growth factor ............................... 142 
3.6.2 Growth of ERα, ERα(EEE) and ERα(AAA) expressing MCF7-TO 
cells in the presence of insulin......................................................... 146 
3.6.3 Cell growth in the presence of the MEK inhibitor U0126........ 149 
3.7 Identification of proteins associated with ERα using immunoaffinity 
purification........................................................................................ 151 
3.7.1 Testing lysis buffers .......................................................... 151 
3.7.2 Testing methods of elution of immunoprecipitated ERα ........ 154 
3.7.3 Testing methods of band identification................................ 157 
3.7.4 Identification of ERα and associated proteins ...................... 157 
4 DISCUSSION ......................................................................................163 
4.1 Characterising the MCF7-TO cell lines........................................ 165 
4.2 The effect of phosphorylation on the activity of ERα ................... 166 
 8 
4.3 The effect of ERα phosphorylation on the expression of endogenous 
estrogen-regulated genes................................................................... 167 
4.4 The effect of ERα phosphorylation on cell growth....................... 172 
4.5 Identification of ERα co-immunoprecipitating proteins ................ 174 
4.6 Final conclusions and future work ............................................. 176 
5 BIBLIOGRAPHY..................................................................................180 
6 APPENDIX ..........................................................................................217 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 9 
List of Figures 
 
Figure 1.1 Structure and Classification of Nuclear Receptors………………………………18 
Figure 1.2 Recognition and binding of nuclear receptors to response elements ……19 
Figure 1.3 Coactivators and corepressor of nuclear receptors……………………………..27 
Figure 1.4 Structure of ERα and ERβ…………………………………………………………………40 
Figure 1.5 Phosphorylation sites of ERα……………………………………………………………52 
Figure 2.1 Illumina gene expression probe design…………………………………………….100 
Figure 2.2 Preparing membrane and gel for electrophoresis………………………………108 
Figure 3.1 Expression levels of ERα in MCF7-TO-ERα clones……………………………..112 
Figure 3.2 Western blotting of MCF7-TO-ERα clones demonstrates Dox regulation of 
transgene expression ……………………………………………………………………………………115 
Figure 3.3 Time course of HA-ERα-FLAG induction after removal of Dox...............116 
Figure 3.4 Transduction activity of HA-Rα-FLAG constructs..................................118 
Figure 3.5 Expression of estrogen-regulated genes in the presence and absence of 
HA-ERα-FLAG constructs and estrogen…………………………………………………………...121 
Figure 3.6 Expression of estrogen-regulated genes in response to estrogen and HA-
ERα-FLAG constructs............………………………………………………………………………….124 
Figure 3.7 Expression of estrogen-regulated genes in response to estrogen and 
individual HA-ERα-FLAG constructs......................……………………………………………125 
Figure 3.8 Global clustering of normalised data………………………………………………..128 
Figure 3.9 Venn diagrams showing the selection of estrogen-regulated genes…….130 
Figure 3.10 Venn Diagram identifying genes regulated due to expression of ERα(EEE) 
in an E2-independent manner…………………………………………………………………………132 
Figure 3.11 SRB growth assays in the presence of estrogen and anti-estrogens…..138 
Figure 3.12 Cell growth in the presence of epidermal growth factor……………………142 
 10 
Figure 3.13 Cell growth in the presence of insulin…………………………………………….146 
Figure 3.14 Cell growth in the presence of MEK inhibitor U0126…………………………149 
Figure 3.15 Western blot showing different cell lysis techniques used for 
immunoaffinity purification …………………………………………………………………………….151 
Figure 3.16 Testing methods of elution of bound proteins after immunoaffinity 
purification……………………………………………………………………………………………………154 
Figure 3.17 Western blot showing artefacts detected during sample buffer elution of 
immunopurified proteins…………………………………………………………………………………155 
Figure 3.18 Silver stain and SYPRO Ruby staining of resolving gels…………………….157 
Figure 3.19 Silver stain of immunoaffinity purified proteins………………………………..158 
Figure 3.20 Silver stain of immunoaffinity purified proteins which were carried 
forward for mass spectrometory……………………………………………………………………..159 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 11 
List of Tables 
 
Table 2.1 General stock solutions……………………………………………………………………..85 
Table 2.2 Qiagen DNA maxi preparation buffers…………………………………………………91 
Table 2.3 Primer sequences for luciferase plasmid DNA sequencing……………………..92 
Table 2.4 RT-PCR primers………………………………………………………………………………..97 
Table 2.5 qRT-PCR primers………………………………………………………………………………99 
Table 2.6 Immunoaffinitiy purification buffers …………………………………………………102 
Table 2.7 Components of SDS-PAGE Gels ……………………………………………………….107 
Table 2.8 SDS-PAGE and Western Buffers……………………………………………………….107 
Table 2.9 Primary antibody information…………………………………………………………..109 
Table 2.10 Secondary antibody information……………………………………………………..109 
Table 3.2 Genes regulated due to expression of ERα(EEE)………………………………..135 
Table 3.2  Proteins identified using MALDI-TOF mass spectrometory………………….161 
 
 
 
 
 
 
 
 
 
 
 
 
 12 
Abbreviations 
ACF   ATP-utilizing chromatin assembly and remodeling factor 
ACTR   Activator for thyroid and retinoid receptors 
AD   Association domain 
AD1  Acivation domain 
AF1/AF2  Activation function 1/2 
AI   Aromatase inhibitor 
AIB1   Ampliphied in breast cancer 1 
ANOVA  Analysis of varience 
APS   Ammonium persulphate 
AR   Androgen receptor 
ARC   Activator-recruited cofactor  
ATP   Adenosine triphosphate 
BRM   Brahma 
BSA   Bovine serum albumin 
CAK   Cdk-activating kinase  
CARM1  Coactivator-associated arginine methyltransferase 1 
CBP   CREB binding protein 
cdk   Cyclin dependent kinase 
cDNA   Complimentary deoxyriblonucleic acid 
ChIP   Chromatin immunoprecipitation 
CHRAC  Chromatin accessibility complex 
CML   Chronic myeloid leukemia  
CoCoA  Coiled-coil coactivator A  
CREB   cAMP-response element binding protein  
CtBP   C-terminal binding protein 
DBD   DNA binding domain 
ddH2O  Distilled de-ionised water 
DMEM   Dulbeco’s Modified Eagles Medium 
DNA   Deoxyribonucleic acid 
DRIP   Vitamin D receptor interacting protein 
DSS   Double Stripped Serum 
DTT   Dithiothreitol 
E2   Estrogen 
E6-AP   E6 papillomavirus-associated protein 
EDTA   Ethylene diamine tetraacetic acid 
EGF   Epidermal growth factor 
EGFR   Epidermal growth factor receptor 
ER   Estrogen receptor 
ERE   Estrogen receptor element 
ERK   Extracellular signal regulated kinase 
FCS   Fetal Calf Serum 
FSH   Folicle stimulating hormone 
GAC63  GRIP1-associated coactivator 63 
GAPDH  Glyceraldehyde-3-phosphate dehydrogenase 
GPS2   G-protein pathway supressor 2 
GR   Glucocorticoid receptor 
GREB1  Gene regulated in breast cancer 1 
GRIP   Glucocorticoid receptor interacting protein 
GSK3   Glycogen synthase kinase 3 
GTF   General transcription factor 
 13 
HA   Influenza Hemaglutinin   
HAT   Histone acetyltransferase 
HDAC   Histone deacetylase 
HRE   hormone response element 
HRG-β1  heregulin-β1  
HRP   Horse radish peroxidise 
HSLB   High salt lysis buffer 
ICI   182, 780 ICI 
IGF-1   Insulin-like growth factor-1 
IGFBP5  Insulin-like growth factor binding protein 5  
IKKα   I-kappa β kinase alpha 
IP   Immunoaffinity purification 
ISWI   Imitation switch 
JNK   c-Jun N-terminal kinase 
kDa   Kilo Daltons 
LB    Luria Bertani 
LBD   Ligand binding domain 
LCoR   Ligand-dependent nuclear-receptor corepressor 
LH   Luteinizing hormone  
LHRH   Luteinising hormone releasing hormone  
LTED   Long term estrogen deprivation  
MALDI-TOF  Matrix-assisted laser desorption/ionisation time of flight 
MAPK   Mitogen activated protein kinase 
MCF7   Michigan Cancer Foundation -7 
MEK   Mitogen-activated protein kinase kinase 
MEKK1  MEK kinase 1 
MMP   Matrix metalloproteinase  
MNAR   Modulator of the non-genomic activities of ER  
MOPS   3-(N-morpholino)propanesulphonic acid 
MR   Mineralocorticoid receptor 
mRNA   Messenger RNA 
NCoA   Nuclear receptor coactivator 
NCoR   Nuclear receptor corepressor 
NGFI-β  Nerve growth factor induced-β receptor 
NL   Nuclear localization 
NR   Nuclear receptor 
NURF   Nucleosome-remodeling factor 
OHT   4-hydroxy tamoxifen 
P/CAF   p300/CBP-associated factor 
p/CIP   Cointergrator-associated protein 
P/S/G   Penicillin/streptomycin/L-glutamine  
PBS   Phosphate Buffered Saline 
PCR   Polymerase chain reaction 
PELP1   Proline-, glutamic acid-, leucine-rich protein 1 
PGC1α  PPARg co-activator 1α 
PH   Plekstrin homology domain 
PIP3   Phosphatidylinositol 3,4,5-triphosphate  
PKC   Protein kinase C 
Pol II   RNA polymerase II 
PPAR   Peroxisome proliferator activated receptor 
PPIL1   Peptidyl-propyl isomerise-like 1 
PR   Progesterone receptor 
 14 
ProTα   Prothymosin α 
qRT-PCR  Quantitative (real time) RT-PCR 
RAR   Retinoic acid receptor 
RIP140  Receptor-interacting protein 140 
RNA   Ribonucleic acid 
ROR  Retinoid-related receptor  
RPF-1   Retina-derived POU-domain factor 1 
rpm   Revolutions per minute 
RSF   Remodelling and spacing factor 
RT-PCR  Reverse transcriptase polymerase chain reaction 
RVR   Rev-ErbAa-related receptor  
RXR   Retinoid X receptor 
SDS   Sodium dodecyl sulfate 
SERM   Selective estrogen receptor modulator 
SF-1   Steroidogenic factor 1  
SMRT   Silencing mediator for retinoid and thyroid-hormone receptor 
SR   Steroid receptor 
SRC   Steroid receptor coactivator 
SREBP-1α  Sterol regulatory element binding protein 1α 
SUMO   Small ubiquitin-like modifier 
SWI/SNF  Switch/sucrose non-fermentable 
TAFII   TBP-associated factor 
TBE   Tris-Borate-EDTA 
TBL1   Transducin beta-like protein 1 
TBLR1   Transducin beta-like protein 1 related protein 
TBP   TATA binding protein 
TCA   Trichloroacetic acid 
TEMED  Tetramethylethylenediamine 
TF   Transcription factor 
TFF1   Trefoil factor 1 
TGF   Transforming growth factor  
TIF2   Transcription intermediary factor 2 
TR   Thyroid hormone receptor 
TRAM1  Thyroid hormone receptor activator molecule 1 
TRAP   TR-associated protein 
U0126   1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene 
VDR   Vitamin D3 receptor 
 
 
 
 
 
 
 
 
 15 
I hereby declare that this submission is my own work, or if not it is clearly stated and 
fully acknowledged. To the best of my knowledge this report contains no material 
previously published or written by another person, nor material which, to a 
substantial extent has been accepted for the award of any degree or diploma of 
Imperial College or any other institution of higher leaning. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 16 
Acknowledgments 
My greatest thanks go to my supervisor, Professor Simak Ali, for all his help, support 
and guidance through out my project. I would also like to thank Dr Ross Thomas for 
his guidance in the laboratory, especially with the microarray analysis, and everyone 
else in the lab who helped me and generally made my time more enjoyable. Special 
thanks go to Farah for keeping me smiling through the tough times and my mum 
who knew I could do it even when I didn’t. 
 
 17 
1 INTRODUCTION 
1.1 Nuclear Receptor Superfamily 
Lipophilic hormones including steroids, thyroid hormones and vitamin D3 were 
isolated in the early 20th century but their receptors were not discovered until the 
early 1960’s when Jensen and Jacobsen used radio-labeled estradiol to identify an 
estradiol-binding protein. This protein was found to translocate to the nucleus after 
the administration of hormones which suggested a link between hormones and gene 
regulation (Jensen and Jacobsen, 1962). The purification of the estrogen receptor 
(ER) and subsequent development of antibodies allowed the cloning of the ER gene 
(Green et al., 1986; Greene et al., 1986; Walter et al., 1985), now renamed ERα 
(Kuiper et al., 1996). The concomitant cloning of the glucocorticoid receptor (GR) 
gene (Hollenberg et al., 1985; Weinberger et al., 1985a) showed that ER and GR 
were related genes, and that they were homologous to the avian erythroblastosis 
virus v-erbA oncogene (Krust et al., 1986; Weinberger et al., 1985b), the cellular 
homologue of which (c-erbA) was subsequently shown to encode the thyroid 
hormone receptor (TR) gene (Sap et al., 1986). Subsequent cloning of the androgen 
(AR), mineralocorticoid (MR) and progesterone (PR) receptor genes further enlarged 
the family (Evans, 1988). Identification of other genes, largely through low 
stringency screening of cDNA libraries, through degenerate PCR and analysis of DNA 
sequence databases has expanded the number of nuclear receptor (NR) family 
members in man to 48, making it one of the largest families of transcription factors 
in higher eukaryotes. In addition to the steroid hormone receptors (AR, ER, GR, MR, 
PR) and TR genes, the NR superfamily now includes the vitamin D3 receptor (VDR) 
and retinoic acid receptors (RAR, RXR), as well as receptors that bind to a wide 
variety of ligands, including fatty acids, bile acids, prostaglandins, xenobiotics, 
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phospholipids and heme, as well as so-called ‘orphan nuclear receptors’ which have 
no known ligand or that may not require ligand binding for their activities (figure 1.1) 
(Chawla et al., 2001; Evans, 1988; Forman, 2005; Yin et al., 2007).  
 
1.2 Structure of nuclear receptors 
Purification of the GR led to the discovery of the three-domain structure 
which encompasses a DNA binding domain (DBD), ligand binding domain (LBD) and 
a third domain which was known to have transcriptional regulatory properties 
(Wrange and Gustafsson, 1978). Comparison of the amino acid sequences for ERα, 
GR and v-erbA with the chicken ERα identified six regions of differing amino acid 
sequence homology, termed A-F (N-terminal to C-terminal) (Krust et al., 1986). Of 
these regions, the highly conserved regions C and E, were shown to encode the DBD 
and LBD respectively (Kumar et al., 1986). Figure 1.1 shows a schematic diagram of 
the NR structure.  
The NR DBD is encoded within a 66-68 amino-acid region, comprised of two 
zinc finger motifs in which four cysteine residues in each zinc finger coordinate one 
zinc ion (Hard et al., 1990; Luisi et al., 1991; Schwabe et al., 1993; Schwabe et al., 
1990). Mutational analysis demonstrated that sequences in the so-called P-box at the 
C-terminal part of the first, or N-terminal zinc finger, determine sequence specificity 
of binding of NR to DNA response elements, whilst the second zinc finger is 
important for dimerisation (Danielsen et al., 1989; Green et al., 1988; Mader et al., 
1989; Umesono and Evans, 1989). These and other studies showed that mutational 
switching of three amino acids in the ERα DBD P-box to the corresponding amino 
acids in the GR DBD was sufficient to allow ERα to bind to a GR DNA response 
element, in preference to an ERα response element, with the converse also being  
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N CAF1 LBD/AF2DBD
A/B             C       D              E              F
 
 
AR 
ERα, β 
GR 
MR 
PR 
RAR α, β, γ 
TR α, β 
VDR 
EcR 
RXR α, β, γ   
PPAR α, β, γ  
LXR α, β, γ 
FXR 
PXR/SXR 
CAR 
SF-1 
LRH-1 
RVR α, β, γ 
DAX-1 
SHP 
PNR 
NGFI-B α, β, γ 
ROR α, β, γ   
ERR α, β, γ 
GCNF 
TR 2, 4 
HNF-4 
COUP-TF α, β, γ Heme 
Bile acids 
Figure 1.1  Structure and Classification of Nuclear Receptors 
Nuclear receptor proteins are a structurally related group of eukaryotic 
transcription factors that conform to the organisation shown in (A), where AF1 
corresponds to the N-terminal transcription activation domain, DBD to the DNA 
binding domain and LBD/AF2 to the region involved in ligand binding and the 
second transcription activation region. (B) The NR superfamily can be further 
classified according to the ligands they bind. The classic nuclear steroid receptors 
include the androgen (AR), estrogen (ER), glucocorticoid (GR), mineralcorticoid 
(MR) and progesterone receptors (PR). The adopted orphan nuclear receptors 
heterodimerize with the retinoid X receptor (RXR) and include peroxisome 
perliferator-activated  receptors (PPARs), farnesoid X receptor (FXR), pregnane X 
receptor/ steroid xenobiotic receptor (PXR/SXR), constitutive androstane receptor 
(CAR), steroidogenic factor-1 (SF-1), liver receptor homologue-1 (LRH-1) and 
Rev-ErbAα-related receptor (RVR). Thyroid hormone (TR), retinoic acid (RAR), 
vitamin D3 (VDR) and ecdysone (EcR) receptors also heterodimerize with RXR yet 
share other characteristics with endocrine receptors. Orphan receptors include 
dosage-sensitive sex reversal, adrenal hypoplasia critical region, on chromosome 
X, gene 1 (DAX-1), short heterodimer partner (SHP), photoreceptor cell-specific 
nuclear receptor (PNR), nerve growth factor-induced gene B (NGFI-B), retinoid-
related receptor (ROR), estrogen receptor-related receptors (ERR), germ cell 
nuclear factor (GCNF), testicular receptors (TR2, 4), hepatocyte nuclear factor 4 
(HNF-4) and chicken ovalbumin upstream promoter transcription factors (COUP-
TFs) (Chawla et al., 2001; Maglich et al., 2001). 
a 
b 
 
  Endocrine    Orphan   Adopted Orphan 
  Receptors    Receptors   Receptors 
Fatty acids,  
Arachadonic acid 
 
 
 
Xenobiotics 
 
Phospholipids 
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DBD DBD
AGGTCAnnnTGACCT
ER
DBD DBD
AGAACAnnnTGTTCT
AR, GR, MR, PR
DBD
RXR
DBD
X
AGGTCA  n  AGGTCA
RAR, TR, VDR, PPAR, PXR, 
LXR, FXR
n=1-5
DBD
RXR
DBD
RXR
AGGTCA n AGGTCA
RXR, COUP-TF1, HNF-4
DBD
NGFI-B
AGGTCA
NGFI-B, SF-1
DR-1 AGGTCAnAGGTCA RXR/PPAR,
RXR/RXR,
RAR/RXR,
DR-2 AGGTCAnnAGGTCA RXR/RAR (RARE) 
DR-3 AGGTCAnnnAGGTCA RXR/VDR (VDRE) 
DR-4 AGGTCAnnnnAGGTCA RXR/TR (TRE) 
DR-5 AGGTCAnnnnnAGGTCA RXR/RAR (RARE) 
 
 
 
 
 
Figure 1.2 Recognition and binding of nuclear receptors to response 
elements  
Nuclear receptors bind as homo- and heter-dimers to DNA response elements 
conforming to the consensus sequences shown. Receptors that form 
heterodimers with RXR recognise different direct repeats (DR) of the sequence 
separated by 1-5 base pairs. Adapted from (Mangelsdorf and Evans, 1995). 
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the case. Together, these studies have shown that AR, GR, MR and PR, which have 
the same P-box sequence, bind as homodimers to a palindromic DNA sequence  
conforming to the consensus sequence AGAACANNNTGTTCT (Lieberman et al., 
1993; Nordeen et al., 1990; Roche et al., 1992), whilst ERα binds as a homodimer to 
a palindromic sequence conforming to the consensus sequence AGGTCANNNTGACCT 
(Klein-Hitpass et al., 1988; Walker et al., 1984), where N is any nucleotide (Figure 
1.2). Although steroid receptors bind DNA as homodimers, other members of the NR 
superfamily form heterodimers with retinoid X receptor (RXR) and bind DNA via 
response elements containing direct repeats of the sequence 5’-AGGTCA-3’ with 
between 1-5 base pairs separating the repeats, as shown in figure 1.2 (Rastinejad et 
al., 1995; Umesono et al., 1991). 
Nuclear receptors, including the all-trans retinoic acid (RAR), vitamin D3 (VDR), 
thyroid hormone (TR), liver X (LXR), peroxisome proliferator activated receptors 
(PPAR), nerve growth factor induced-B (NGFI-B) and Rev-ErbAα-related receptor 
(RVR) form heterodimers with RXR in this way (Bugge et al., 1992; Kliewer et al., 
1992a; Kliewer et al., 1992b; Leid et al., 1992; Perlmann and Jansson, 1995; Yu et 
al., 1991), although VDR and RVR are also capable of forming homodimers (Harding 
and Lazar, 1995; Takeshita et al., 2000).  A number of orphan receptors, including 
RVR, NGFI-B, retinoid-related receptor (ROR) and the steroidogenic factor 1 (SF-1), 
are capable of binding DNA as monomers. These bind sites with one repeat of the 
consensus sequence 5’-AAAGGTCA-3’ and specific flanking 5’ sequences determine 
response element specificity (Giguere et al., 1995; Harding and Lazar, 1995; Wilson 
et al., 1993; Wilson et al., 1992).  
By carrying out studies using ERα, two transcriptional activation functions 
(AFs) were identified (Kumar and Chambon, 1988; Tora et al., 1989; Webster et al., 
1988; Webster et al., 1989). The ligand-independent AF1 is located in the A/B region 
 22 
and the ligand-dependent AF2 is located within the carboxyl terminus of the LBD in 
the E/F region. The transcriptional activation functions are capable of acting 
independently or synergistically in a promoter and cell-specific fashion. These 
observations gave rise to the hypothesis that NRs could interact with various 
promoter-specific transcription factors and cell-specific factors which mediated the 
receptor activity (Bocquel et al., 1989; Meyer et al., 1989; Tasset et al., 1990). 
Indeed, many such factors, labelled NR coactivator and corepressor proteins, have 
now been identified which facilitate gene regulation by NRs and this topic will be 
discussed in more detail with regard to ER later in this introduction. 
The LBD within the E region is connected to the DBD by a short flexible linker 
and has a three-dimensional structure common to all nuclear receptors (Wurtz et al., 
1996). The structure consists of eleven α-helices which come together to form a 
ligand-binding pocket. A twelfth α-helix (H12) forms a movable barrier to this pocket, 
the orientation of which is effected by the chemical structure of binding ligands and 
contains residues which are crucial to the function of AF2 (Bourguet et al., 1995; 
Henttu et al., 1997; Renaud et al., 1995). In the inactive state, corepressors of NR 
bind to the hydrophobic groove in the surface of the LBD formed by α-helices H3 
and H4. Generally, agonists of nuclear receptor activity promote allosteric effects 
which cause H12 to reposition in such a way as to disrupt this hydrophobic groove, 
leading to dissociation of corepressors (Shiau et al., 1998). This conformational 
change permits the AF2 α-helix to make contact via a conserved glutamate residue 
with a conserved lysine residue in the H3 of the LBD (Feng et al., 1998). This 
provides a ‘charge clamp’ which binds the ends of the LXXLL motif present in 
coactivators (where L is Leucine and X is any other amino acid) (Heery et al., 1997; 
Le Douarin et al., 1996; Torchia et al., 1997). In this way, agonist binding to the NR 
activates the AF2 and allows interaction of the receptor with coactivator complexes 
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which in turn initiate transcription of the NR-regulated genes (Glass and Rosenfeld, 
2000; Moras and Gronemeyer, 1998; Nettles and Greene, 2005; Shiau et al., 1998; 
Webster et al., 1988). 
As described above, SRs homodimerise, whereas many of the non-SRs 
heterodimerise with RXRs. Dimerisation by NRs is mediated by the DBD and LBD 
(Fawell et al., 1990a; Kumar and Chambon, 1988). The dimerization domain within 
the LBD identified in the GR and conserved in NRs, consists of a sequence of heptad 
repeats of hydrophobic residues (Fawell et al., 1990a) and has been shown to act in 
a hormone-dependent manner, whereas the dimerization domain within the DBD is 
weakly constitutively active (Kumar and Chambon, 1988). The DBD dimerization 
domain is thought to be responsible for the selection of the spacing distance between 
the two halves of palindromic response elements (Hard et al., 1990; van Tilborg et 
al., 1995). 
The molecular weight of the rat GR monomer was deduced as 87.5 kDa 
(Miesfeld et al., 1986). Studies around the same time showed that the nuclear 
envelope acted as a form of molecular sieve whereby molecules of a molecular mass 
less than ~70kDa could enter the nucleus by passive diffusion through nuclear pores 
(Lang et al., 1986; Paine et al., 1975; Peters, 1984). This gave rise to the suggestion 
that the GR, which is localized to the cytoplasm in the unbound state and transferred 
to the nucleus in the liganded state, contained nuclear localization signals; the 
activity of which is potentially controlled by hormone binding. Two nuclear 
localization (NL) signals were indeed identified in GR (Picard and Yamamoto, 1987), 
NL1, which is conserved in SRs, and NL2; NL1 is adjacent to the DBD and was shown 
to be constitutively active and NL2 is located within the LBD of GR and its activity 
was shown to be hormone-dependent. Not all NRs shuttle between the nucleus, 
however, PR and ER are constitutively present in the nucleus (King and Greene, 
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1984; Press and Greene, 1988; Puca et al., 1986) and do not contain the hormone-
dependent NL2 nuclear localization signal (Picard and Yamamoto, 1987). The 
number and position of nuclear localisation signals within the NR determines the 
requirement for hormone-dependent nuclear localization and define which 
mechanism of nuclear transportation is utilized by the receptor (Hsieh et al., 1998; 
Savory et al., 1999; Yasmin et al., 2005). 
 
1.3 Gene regulation by nuclear receptors 
In eukaryotes, the genomic DNA is stored in the nucleus in a highly packaged 
state, which is termed chromatin. Chromatin is made up of units called nucleosomes; 
the nucleosome core is composed of 147 base pairs of DNA wrapped around histone 
octamers which form protein-DNA interactions (Luger et al., 1997). Nucleosomes are 
arranged to form chromatin domains which are very stable under physiological 
conditions and create a thermodynamic barrier between the DNA and transcription 
factors, making the chromatin structure ideal for DNA compaction. However, the 
nucleosome is not a fixed structure and possesses dynamic properties that are highly 
regulated by various protein complexes (Li et al., 2007; McKenna et al., 1999).   
Covalent histone modifications, such as acetylation and phosphorylation, 
result in a change in the net charge of nucleosomes which studies have shown 
reduces the DNA-histone interactions (Hassan et al., 2006; Reinke and Horz, 2003; 
Zhao et al., 2005). Modification of histones has also been shown to effect the 
chromatin structure (Shogren-Knaak et al., 2006). The modifications are thought to 
act as ‘tags’ which are then recognised by other transcriptional regulators (Jenuwein 
and Allis, 2001; Strahl and Allis, 2000). Chromatin re-modelling proteins require ATP 
hydrolysis to alter the structure of the chromatin and work in conjunction with 
modifying complexes to alter the accessibility of nucleosomal DNA and allow 
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transcription factors, such as NRs, to access the DNA (Cosma et al., 1999; Saha et 
al., 2006; Smith and Peterson, 2005).  
 The agonist-bound NRs bind to hormone response elements (HREs) which 
can be several kilobase pairs away from the promoter region of the target gene. 
Transcription factors such as NRs allow the ordered association and dissociation of 
coactivator complexes which remodel chromatin and modify core histones in order to 
allow access to the DNA and promote gene transcription. The recruitment of the 
general transcription factors (GTFs) is a key factor in this process and is necessary 
for transcription initiation. The GTFs include RNA polymerase II (Pol II) and a variety 
of auxiliary components including TFII A-H. The initial rate limiting step of gene 
transcription involves TFIID binding to recognition sequences within the promoter 
region (Buratowski et al., 1989), a process which requires the direct interaction of 
the Mediator complex with TFIID via TATA binding protein (TBP)-associated factors 
(TAFIIs) which make up the TFIID protein complex (Baek et al., 2002). TFIID binding 
inititates the recruitment of the other GTFs leading to the recruitment of Pol II to the 
transcription start site, initiating gene transcription (Beato and Sanchez-Pacheco, 
1996; McKenna et al., 1999).  
 These processes of chromatin modification and remodelling, recruitment of 
GTFs and transcription initiation are mediated by coregulators that interact with 
transcription factors such as NRs. The sequential exchange of coregulator 
complexes, which carry out a range of enzymatic activities, controls the 
transcriptional activity of NRs. In the absence of hormone, SR monomers are 
generally believed to be associated with heat shock protein complexes such as Hsp70 
and Hsp90 which are thought to assist in protein maturation and maintain the SR in 
a stabilised, inactive form capable of binding ligand (Hernandez et al., 2002; Kosano 
et al., 1998). 
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The unliganded SR can be localized to the cytoplasm in the case of AR and 
GR (Picard and Yamamoto, 1987; Tyagi et al., 2000), to the nucleus in the case of 
ER and PR (Guiochon-Mantel et al., 1989; King and Greene, 1984) or can be 
distributed between the nucleus and cytoplasm as is the case with MR (Fejes-Toth et 
al., 1998). Upon binding hormone, the receptors dimerize, cytoplasmic receptors 
translocate to the nucleus and the receptors bind to sequence-specific hormone 
responsive elements (HRE). In the case of the non-steroid receptors that dimerise 
with RXR, the unliganded receptors are nuclear, are bound to promoters of regulated 
genes and repress gene expression through recruitment of corepressor complexes 
(Andersson et al., 1992; Cheskis and Freedman, 1994; Miyamoto et al., 1993). RXR 
itself is located in the cytoplasm in the unliganded state and forms homotetramers  
(Kersten et al., 1995a) which rapidly dissociate upon binding of 9-cis-retinoic acid 
(Kersten et al., 1995b) releasing active receptors (Kersten et al., 1998). Ligand 
binding to VDR has been shown to decrease the amount of DNA-bound homodimers 
and enhance DNA-bound monomers, which favour dimerization with RXR to form an 
active heterodimer (Cheskis and Freedman, 1994).  
ER is also nuclear in the unliganded state (King and Greene, 1984) and recent 
chromatin immunoprecipitation (ChIP) studies suggest that the unliganded ER is 
bound to promoters of estrogen responsive genes, with coactivator proteins being 
recruited in transcriptionally unproductive complexes (Metivier et al., 2004). Ligand 
binding provides an ordered and cyclical recruitment and dissociation of a large 
series of diverse coactivator and corepressor complexes, resulting in cycles of 
chromatin remodelling, histone acetylation, methylation, deacetylation and 
demethylation (Metivier et al., 2003; Shang et al., 2000). Particularly important in 
the cyclical and ordered coregulator recruitment is the association/dissociation of ER, 
brought about by proteasome-mediated ER turnover (Reid et al., 2003). 
 27 
1.3.1 Coregulators of nuclear receptors 
Unlike NRs which are highly conserved, coregulators are incredibly diverse in 
their structure and enzymatic activities which can be divided into two generic classes, 
as mentioned previously – chromatin modifiers and chromatin remodellers. 
Chromatin modifiers are capable of covalently modifying histone tails and include 
proteins which carry out activities such as acetylation/deacetylation, 
methylation/demethylation, protein kinases and phosphatases, poly(ADP)ribosylases, 
ubiquitin and SUMO ligases. Chromatin remodellers include components of a family 
of ATP-dependent remodelling complexes (Rosenfeld et al., 2006). Coregulators are 
necessary in order to alter the chromatin structure of DNA to control initiation of 
transcription and are also required for recruiting GTFs and Pol II to the promoter 
during gene transcription. Biochemical and expression cloning approaches have been 
used to identify a large number of factors that interact with NRs, many of which 
appear to function as components of large, multiprotein complexes (Glass and 
Rosenfeld, 2000; Lonard and O'Malley, 2006; McKenna et al., 1999; McKenna and 
O'Malley, 2002). The major families of coregulators are discussed below (see figure 
1.3). 
 
1.3.1.1  Coactivators of nuclear receptors 
Transcriptional coactivators have been so-termed because their co-expression 
with transcription factors stimulates the activity of the transcription factor of interest, 
at least in reporter gene studies. The notion that coactivators were involved with NR 
transcriptional activation first came about when it was shown that activation of 
multiple SRs co-expressed in a cell system caused inhibition of the SRs. Coactivators 
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Figure 1.3 Coactivators and corepressor of nuclear receptors 
Nuclear receptors bound by corepressors are transcriptionally inactive, promoting 
chromatin condensation. Ligand binding to the NR promotes corepressor 
dissociation and coactivator association, leading to chromatin remodelling and 
histone modifications which allow acess to DNA. Coactivators also recruit the basal 
transcriptional machinery to the gene promoter, initiating gene transcription. Taken 
from (Rosenfeld and Glass, 2001).  
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 were identified as being limiting factors in the transcriptional process and the 
sequestering of coactivators leading to reduced SR activity was termed squelching. 
Studies have also shown that levels of coactivators vary between cell type, leading to 
squelching and determining the relative activity of SRs in varying cell types (Bocquel 
et al., 1989; Gill and Ptashne, 1988; Meyer et al., 1989; Voegel et al., 1996).  It is 
likely that coactivators have other functions within the cell in addition to transcription 
initiation, such as alternative splicing, mRNA transport from the nucleus, mRNA 
translation and posttranslational modifications of the synthesized protein. To date, 
there are approximately 200 published NR coactivators, suggesting that the process 
of transcription intiation is a highly dynamic and orderly process involving a large 
number of protein complexes working together (Lonard and O'Malley, 2006). Here I 
shall discuss the main groups of coactivators, whose activities have been most 
clearly linked to gene regulation by NR. 
 
1.3.1.1.1  ATP-dependent chromatin remodelling complexes 
1.3.1.1.1.1 SWI/SNF 
The SWI/SNF (switch/sucrose non-fermentable) complex was originally 
identified in yeast and facilitates the binding of sequence-specific transcription 
factors to nucleosomal DNA and has the ability to alter the chromatin structure in an 
ATP-dependent manner (Owen-Hughes et al., 1996).  The main characteristic of the 
SWI/SNF family of chromatin re-modellers is the presence of a conserved ATPase 
subunit that belongs to the SNF2 superfamily of proteins (Eisen et al., 1995) and five 
other conserved core members. Homologues of SWI/SNF had been identified in 
Drosophila melanogaster  (Tamkun et al., 1992) and were shown to form part of the 
large multi-subunit complex called Brahma (BRM) (Dingwall et al., 1995). Two 
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members of the SWI/SNF family have been identified in humans, BRG1 (Kwon et al., 
1994) and hBRM (Wang et al., 1996) which show 70% homology to each other and 
are highly homologous to the Swi/Snf gene (Eisen et al., 1995). The associated 
factors to the BRG1 and hBRM catalytic subunits are termed BAFs, many of which 
share homology with factors associated with the yeast SWI/SNF ATPase (Vignali et 
al., 2000). Both Brg1 and hBrm1 have been shown to interact with ERα in a ligand-
dependent manner (Ichinose et al., 1997), whilst BAF57, a protein present only in 
the mammalian SWI/SNF complex also interacts with ERα, and in addition to its role 
in the SWI/SNF complex, interacts with the p160 NR coactivators (Belandia et al., 
2002). The ATPase activity of SWI/SNF is required for the complex to alter the 
orientation of the DNA on the surface of the nucleosome core, which in turn 
promotes transcriptional activator binding to nucleosomal DNA (Cote et al., 1994; 
Owen-Hughes et al., 1996). 
 
1.3.1.1.1.2 ISWI 
The imitation SWI (ISWI) family of chromatin re-modellers contains homology 
with the Swi/Snf gene over the region of the ATPase domain (Elfring et al., 1994) 
and the most well characterised are ACF (ATP-utilizing chromatin assembly and 
remodeling factor) (Ito et al., 1997), NURF (nucleosome-remodeling factor) 
(Tsukiyama and Wu, 1995), and CHRAC (chromatin accessibility complex) (Varga-
Weisz et al., 1997). The remodelling and spacing factor (RSF) was identified in 
humans and shown to contain the ISWI  protein within the complex (LeRoy et al., 
1998). The ISWI complexes are smaller than SWI/SNF complexes consisting of fewer 
subunits but they require ATP hydrolysis in the same manner. Whereas the ATPase 
activity of the SWI/SNF is stimulated equally by free DNA and nucleosomal DNA 
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(Laurent et al., 1993), the substrate recognised by the ISWI ATPase complex is 
amino-terminal histone tails (Tsukiyama and Wu, 1995).  
 
1.3.1.1.2  Histone/protein modifying coactivators  
Rates of gene transcription show a correlation with the degree of histone 
acetylation; hyperacetylated regions show a higher rate of transcription than 
hypoacetylated regions (Glass and Rosenfeld, 2000). This suggests that chromatin 
modifying complexes with histone acetyltransferase (HAT) activity could be required 
at promoter regions to overcome the repressive effects of the chromatin structure on 
transcription. Indeed, several HAT proteins are recruited to promoters of NR-
regulated genes in a NR-dependent manner, resulting in an increase in histone 
acetylation within promoters of target genes (Glass and Rosenfeld, 2000; Metivier et 
al., 2003; Shang et al., 2000).  
 
1.3.1.1.2.1 p160/SRC  
Proteins of approximately 160 kDa molecular mass were among the first 
factors found to interact with nuclear receptors in a ligand-dependent manner. Three 
related genes encode the p160 factors – SRC1/NCoA1, TIF2/GRIP1/SRC2/NCoA2 and 
p/CIP/AIB1/NCoA3/SRC3/ACTR/RAC3/TRAM1 (Chen et al., 1997; Li et al., 1997; 
Onate et al., 1995; Takeshita et al., 1997; Torchia et al., 1997; Voegel et al., 1996). 
The p160/SRC proteins are recruited by interacting with a hydrophobic groove 
involving α-helices 3, 4, 5 and 12 in the LBD of liganded NR, via small α-helical 
motifs containing the sequence leucine-X-X-leucine-leucine (LXXLL) in the p160/SRC 
proteins (Heery et al., 1997; Shiau et al., 1998). There are additional interactions 
between the C-terminal regions of p160/SRC proteins and the AF1 regions of NRs. It 
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is thought that the ability of p160 coactivators to interact with both AF1 and AF2 is 
important for the ability of these transactivation functions to synergize (Webb et al., 
1998). The p160/SRC coactivators appear to act as bridging factors to mediate the 
recruitment of other coactivators including SWI/SNF chromatin remodelling 
complexes (Belandia et al., 2002), whilst the N-terminal region of p160/SRC 
coactivators have been shown to interact via the association domain 2 (AD2) with 
other cofactors, such as coactivator-associated arginine methyltransferase (CARM1) 
(Chen et al., 1999a), coiled-coil coactivator A (CoCoA) (Kim et al., 2003) and GAC63 
(Chen et al., 2005). These interactions of p160/SRC proteins are regulated by post-
translational modifications such as phosphorylation, methylation and acetylation; 
phosphorylation of a specific combination of residues determines which transcription 
factors the p160 coactivators are able to activate, allowing them to function as 
regulatable cofactors for a range of signalling pathways, suggesting that there 
maybe a “phosphorylation code” required for specific gene activation by NRs and 
coactivators (Wu et al., 2005). For example, the formation of a complex between 
SRC3/AIB1 and the ER has been shown to be dependent on the phosphorylation 
state of SRC3/AIB1 (Amazit et al., 2007) and ligand-dependent phosphorylation of 
SRC2/GRIP1 by p38 MAPK has been shown to potentiate NR activity (Frigo et al., 
2006).  
 
1.3.1.1.2.2 CBP/p300 
The CBP (cAMP-response element binding protein (CREB) binding protein) 
and p300 proteins are highly homologous phosphoproteins which act as histone 
acetyltransferases during NR-dependent transcriptional activation (Bannister and 
Kouzarides, 1996; Ogryzko et al., 1996). CBP/p300 contain multiple functional 
domains (Arany et al., 1994) including a HAT domain, a bromodomain, which is a 
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conserved region found in many chromatin-associated proteins capable of 
recognising acetylated lysines (Dhalluin et al., 1999), a KIX domain and three 
cysteine-histidine (CH)-rich domains which are important in mediating protein-protein 
interactions. These functional domains allow CBP/p300 to provide a scaffold for the 
assembly of multi-component transcription coactivator complexes, the association of 
which can be mediated by post-translational modification. Recruitment of CBP/p300 
by liganded and DNA-bound NR is mediated by the p160 coactivators which interact 
with the KIX domain of CBP or p300 via the activation domain 1 (AD1) of the p160 
coactivators (Kamei et al., 1996; Meng et al., 2004a; Yao et al., 1996). CARM1 
associates with AD2 of the SRC2 p160 coactivator (Chen et al., 1999a) and has been 
shown to methylate SRC2 associated- CBP/p300 at residue R742 which appears to be 
required for SRC2 and SR-dependent transcriptional activation (Chevillard-Briet et al., 
2002), whereas methylation by CARM1 within the SRC2 binding domain of CBP/p300 
regulates the dissociation of SRC2 and CBP/p300 (Lee et al., 2005a). CARM1 is also 
involved in mediating the interaction between CBP and CREB; the cofactor CREB 
interacts with CBP via the KIX domain in a phosphorylation-dependent manner; this 
in turn is regulated by CARM1 which can methylate residues within the KIX domain, 
inhibiting the CREB-CBP interactions (Xu et al., 2001). There is evidence to suggest 
that the phosphorylation status of CBP/p300 is regulated by the cell-cycle-dependent 
kinases cyclin E/cdk2 with reported peaks in CBP/p300 HAT activity during the G1/S 
transition (Ait-Si-Ali et al., 1998), suggesting a role for CBP/p300 in promoting 
transcription of genes required for S-phase. In addition to their role in histone 
acetylation, CBP/p300 has been shown to serve a coactivator role in acetylating a 
range of substrates, including CREB, p53, Jun, Fos, p/CAF and pp90RSK (Bannister 
and Kouzarides, 1995; Bannister et al., 1995; Gu et al., 1999; Kwok et al., 1994; Lee 
et al., 1996; Nakajima et al., 1996; Yang et al., 1996). Acetylation of ERα by p300 
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within the hinge/ligand binding domain has also been show to occur in a ligand-
dependent and coactivator-dependent manner (Kim et al., 2006; Wang et al., 2001). 
Acetylation of lysine residues 266 and 268 enhances DNA-binding and is thought to 
play a role in estrogen-dependent gene regulation (Kim et al., 2006). 
 
1.3.1.1.2.3 P/CAF 
P/CAF (p300/CBP-associated factor) is homologous to the yeast protein GCN5 
which is part of the SAGA complexes found in yeast (Grant et al., 1997; Yang et al., 
1996). The SAGA complex requires the HAT activity of GCN5 in order to be 
transcriptionally active (Brownell et al., 1996) and in the same way P/CAF is part of a 
larger complex including hADAC, five TAFII-like proteins and TRAP which requires the 
HAT activity of P/CAF in order to be transcriptionally active (Ogryzko et al., 1998; 
Vassilev et al., 1998). P/CAF binds to p300/CBP, contributing to the HAT activity, and 
also contains a bromodomain which recognises acetylated lysines within histones H3 
and H4 (Kanno et al., 2004). P/CAF has been shown to be involved in gene 
expression not only by acetylating histones but also by acetylating a subset of 
transcription factors including p53 and AR (Fu et al., 2000; Gu and Roeder, 1997). 
Cyclin D1 is a member of the G1 cyclin family required for eukaryotic cell cycle 
progression and has been shown to contribute to functions of P/CAF. Competition 
between cyclin D1 and P/CAF for binding to liganded AR, has been shown to result in 
repression of hormone-dependent AR activation (Reutens et al., 2001). Conversely, 
cyclin D1 has been shown to potentiate the activity of ERα by facilitating the 
association of ERα and P/CAF (McMahon et al., 1999). 
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1.3.1.1.2.4 TRAP/DRIP/ARC 
The TR-associated protein (TRAP)/vitamin D receptor interacting protein 
(DRIP)/activator-recruited cofactor (ARC) complexes were originally identified 
separately as TR, VDR and sterol-regulated factor SREBP-1a interacting protein 
complexes, respectively (Fondell et al., 1996; Naar et al., 1998; Rachez et al., 1998). 
The three complexes have however, been shown to contain many of the same 
subunits and act as transcriptional coactivators to some extent for a wide range of 
NRs (Naar et al., 1999; Rachez et al., 1999; Yuan et al., 1998). 
DRIP205/TRAP220/ARC205 subunits contain an LXXLL motif that mediates 
recruitment to the LDB of NRs and anchors the other DRIP/TRAP/ARC subunits to 
the receptor (Naar et al., 1999; Rachez et al., 2000; Yuan et al., 1998). The Mediator 
protein complex enhances transcriptional activation by recruitment of Pol II to the 
gene promoter and  stimulates phosphorylation of the largest subunit of Pol II by 
TFIIH (Jiang et al., 1998). Subunits of the TRAP/DRIP/ARC complexes have been 
shown to be similar, if not identical to subunits of the Mediator complex (Ito et al., 
1999; Naar et al., 1999; Rachez et al., 1999) and the complexes carry out a similar 
role of Pol II recruitment and stimulation of TFIIH-mediated Pol II phosphorylation, 
enabling transcription initiation (Metivier et al., 2003).  
 
1.3.1.1.2.5 E6-AP and RPF1 
E6 papilloma virus-associated protein (E6-AP) and the closely related RPF-1, 
are E3 ubiquitin-protein ligases (Imhof and McDonnell, 1996; Nawaz et al., 1999b). 
E3 ubiquitin-protein ligases are involved in selective degradation of proteins via the 
26S proteasome pathway by tagging target proteins with ubiquitin at lysine residues. 
ERα is subject to ligand-dependent proteolysis due to ubiquitination (Alarid et al., 
1999; Horigome et al., 1988; Nirmala and Thampan, 1995) which acts to 
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continuously turn over ERα on responsive promoters in a cyclical manner by the 
cyclical association of E6-AP with the target promoter, permitting continuous 
responses to changes in the concentration of ligand (Reid et al., 2003). 
Overexpresion of E6-AP has been shown to correlate with a decrease in levels of ERα 
and AR via the ubiquitin-proteasome pathway (Gao et al., 2005). However, E6-AP 
does not appear to be involved with ubiquitin-mediated degradation of PR or TR 
(Nawaz et al., 1999a), with phosphorylation of the PR by MAPK being responsible for 
targeting the receptor for degradation (Lange et al., 2000), suggesting that E6-
AP/RPF1 have specific substrates and do not act as coactivators for the whole NR 
superfamily. Cessation of transcription is brought about by the dissociation of RNA 
polymerase from the gene. As part of this process, NRs and their coactivators are 
degraded in an ubiquitin-proteasome-dependent manner, preventing reinitiation of 
transcription (Lonard and O'Malley, 2006). Ubiquitination of coactivators and NRs by 
E3 ligases such as E6-AP and RPF1 is therefore an important mechanism for 
controlling the cyclical nature of NR transcriptional activation by targeting the 
proteins for degradation. 
 
1.3.1.1.2.6 PGC1α 
The peroxisome-proliferator-activated receptor-γ (PPARγ) co-activator 1α 
(PGC1α) was originally identified as a tissue-specific coactivator of PPARγ (Puigserver 
et al., 1998) and has been implicated in the regulation of many important 
physiological processes, including adaptive thermogenesis (Puigserver et al., 1998) 
and hepatic gluconeogenesis (Yoon et al., 2001). PGC1α interacts with PPARγ in a 
ligand-independent fashion via the hinge region of the receptor and independently of 
a LXXLL motif within the coactivator, whereas the ligand-induced interaction with 
ERα (Tcherepanova et al., 2000), TR (Wu et al., 2002b), RXR (Delerive et al., 2002) 
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and GR (Yoon et al., 2001) depends on the AF2 region of the receptor and the LXXLL 
motif of the PGC1α. The tissue-specific expression of PGC-1, which is expressed at 
high levels in tissues such as heart, skeletal muscle, kidney, and brown fat 
(Esterbauer et al., 1999; Knutti et al., 2000; Puigserver et al., 1998) is induced in 
response to particular physiological states, such as exposure to cold or fasting 
(Lehman et al., 2000; Puigserver et al., 1998; Yoon et al., 2001). Induction of PGC1α 
leads to the activation of pathways important for energy homeostasis, such as 
adaptive thermogenesis, mitochondrial biogenesis, fatty acid oxidation, and 
gluconeogenesis by tissue-specific activation of specific enzymes, coactivators and 
transcription factors, including NRs (Herzig et al., 2001; Lehman et al., 2000; 
Puigserver et al., 1998; Vega et al., 2000; Wu et al., 1999; Yoon et al., 2001). 
 
1.3.1.2 Nuclear Receptor Corepressors 
Transcriptional activation by NRs requires the cyclical recruitment and 
dissociation of NRs and their coactivators which carry out chromatin remodelling and 
histone acetylation and methylation. Importantly, this cycling also requires chromatin 
remodelling and histone deacetylation and demethylation, processes performed by 
corepressor complexes. Additionally, many NR, such as RAR and TR, repress the 
expression of regulated genes when bound to gene promoters in the unliganded 
state (Chen and Evans, 1995; Horlein et al., 1995). Furthermore, in addition to 
stimulating the expression of regulated genes, agonist-bound NR repress the 
expression of many genes. For example, gene expression microarray analyses have 
shown that 70% of the estrogen-regulated genes in the MCF7 breast cancer cell line 
are repressed (Frasor et al., 2003). Moreover, antagonists such as the anti-estrogen 
Tamoxifen, prevent coactivator recruitment, but facilitate corepressor recruitment, to 
repress the expression of genes whose expression is stimulated by estrogen 
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(Brzozowski et al., 1997; Shang et al., 2000; Shiau et al., 1998). Hence, corepressors 
are essential for gene repression by NR, as well as being required for the expression 
of genes activated by NR ligands.  
 
1.3.1.2.1 NCoR/SMRT 
The NR corepressors NCoR (Horlein et al., 1995) and SMRT (silencing 
mediator for retinoid and thyroid-hormone receptors) (Chen and Evans, 1995) are 
encoded by distinct genetic loci, however, they share substantial sequence homology 
(Ordentlich et al., 1999; Park et al., 1999) and assemble into similar or even identical 
complexes, with stabilizing factors such as TBL1/TBLR1 and GPS2 (Guenther et al., 
2000; Li et al., 2000; Yoon et al., 2003; Zhang et al., 2002a). Although they do not 
harbour intrinsic enzymatic activity themselves, NCoR and SMRT facilitate the 
recruitment of several other corepressors, including many histone deacetylases 
(Huang et al., 2000; Kao et al., 2000; Li et al., 2000; Yoon et al., 2003). Regulatory 
events that cause dissociation of NCoR/SMRT also cause the release of the remaining 
corepressor complex and a loss of repression (Glass and Rosenfeld, 2000). The 
actions of NCoR/SMRT are thought to be regulated by multiple signal transduction 
pathways. Activation of MEKK1, a member of the Raf-MAPK growth factor signalling 
cascade, leads to the inhibition of the ability of SMRT to interact with other 
corepressors and NRs and causes redistribution of SMRT to the cytoplasm (Hoberg et 
al., 2004; Hong and Privalsky, 2000), whereas NCoR is resistant to these inhibitory 
effects (Jonas and Privalsky, 2004). However, different splice variants of SMRT 
respond differently to MEKK1 signalling with the SMRTsp18 variant showing a 
resistance to kinase-induced redistribution, suggesting a mechanism whereby cells 
can control their transcriptional response to the Raf-MAPK signalling cascade by 
selective expression of SMRT splice variants (Jonas et al., 2007). 
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NCoR and SMRT are recruited to NR LBDs through α-helical regions called the 
corepressor-nuclear-receptor (CoRNR) box, having a core consensus motif, 
LXXI/HIXXXI/L (Hu and Lazar, 1999; Nagy et al., 1999; Perissi et al., 1999). This 
motif is similar to the shorter α-helical LXXLL motif of coactivators and it has been 
proposed that the conformational change of the LBD due to ligand binding favours 
interaction with this shorter α-helix and so brings about the exchange of 
corepressors for coactivators (Perissi et al., 1999).  
 
1.3.1.2.2 LCoR and RIP140 
LCoR (ligand-dependent nuclear-receptor corepressor) and RIP140 (receptor-
interacting protein 140) belong to a group of corepressors which bind agonist-bound 
NRs. Initial studies on RIP140 suggested the protein interacted with ER and other 
NRs via the LBD in such a way as to promote transcriptional activation (Cavailles et 
al., 1994; Cavailles et al., 1995; Joyeux et al., 1997; L'Horset et al., 1996). However, 
further studies showed that expression of RIP140 could not replace the function of 
SRC coactivators (Torchia et al., 1997) and indeed competed with SRC coactivators 
for binding to NRs, resulting in inhibition of NR activity (Treuter et al., 1998). 
However, this finding was due to the fact that similarly to coactivators, RIP140 and 
LCoR use a LXXLL motif to interact with the LBD of NRs (Fernandes et al., 2003; 
Heery et al., 1997). LCoR and RIP140-mediated repression is in fact brought about 
by the recruitment of HDACs and the corepressors CtBP (C-terminal binding proteins) 
(Carascossa et al., 2006; Castet et al., 2004; Fernandes et al., 2003; Wei et al., 
2000), although the involvement of CtBP has been shown to be unnecessary for the 
inhibitory action of RIP140 on AR (Carascossa et al., 2006). RIP140 recruitment is 
not only gene-specific (Castet et al., 2006) but post-translational modifications of 
RIP140 control the recruitment of associated factors and nuclear export of the 
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corepressor (Gupta et al., 2005; Huq and Wei, 2005), suggesting that corepressors 
like RIP140 and LCoR provide a mechanism for NRs to down-regulate transcription of 
target genes upon activation of the receptor in a process that can be influenced by 
other signalling pathways. 
 
1.4 Estrogen receptors 
The estrogen receptor (ER) is a steroid hormone receptor which is required for 
the development and maintenance of the female and male reproductive systems and 
secondary sexual characteristics (Hewitt et al., 2005). In the hypothalamic-pituitary-
gonadal axis, gonadotropin-releasing hormone is secreted in an episodic fashion from 
the hypothalamus to activate the production of gonadotropins, luteinizing hormone 
(LH), and follicle-stimulating hormone (FSH) from the anterior pituitary of the brain.  
LH and FSH are released in a pulsatile manner to act at the gonad to control both 
gametogenesis (spermatogenesis or oogenesis) as well as steroidogenesis. The 
major sex hormones estradiol, progesterone, and testosterone are secreted in 
response to gonadotropins and, in turn, feedback at the level of the hypothalamus 
and pituitary to control normal reproductive function (Wierman, 2007). These 
hormones exert their effects by binding to intracellular or membrane receptors, 
resulting in activation of signaling pathways and transcription factors that regulate 
gene expression. Alterations in the regulation of these signalling molecules results in 
uncontrolled cell survival and proliferation, leading to tumour initiation and 
progression (Silva and Shupnik, 2007).  
As stated above, estrogen actions are mediated by members of the NR 
superfamily of transcription factors, ERα and ERβ, encoded by distinct genes, with 
the human ERα gene being encoded on chromosome 6q and the human ERβ gene 
encoded on chromosome 14q (Herynk and Fuqua, 2004). The activity of ERα,  
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AF1 DBD LBD/AF2 CN
AF1 DBD LBD/AF2N C
A/B               C       D                  E                F
Human ERα 183                      83       39                       245  43
Human ERβ 142                84        32                     245         27
17%          97%                    60%
Figure 1.4 Structure of ERα and ERβ 
ERα and ERβ are highly homologous, with sequence homology being greatest 
within the DBD which share 97% homology and the LBD/AF2 domains, which 
share 60% homology. The other regions are considerably less well-conserved, for 
example the A/B regions (AF1) share just 17% homology.  
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especially its involvement in breast cancer, has been studied in depth but the 
activities of ERβ are less well elucidated. This thesis involves work carried out 
using ERα; hence ERβ will be discussed briefly before a more detailed 
discussion of ERα. 
 
1.4.1 Estrogen Receptor beta 
The ERβ gene was identified from a prostate cDNA library in 1996 (Kuiper et 
al., 1996). Both ERα and ERβ bind estrogen and interact with ERE sequences, 
although with differing binding and transcriptional activities (Katzenellenbogen and 
Katzenellenbogen, 2000; Katzenellenbogen et al., 2001). Mouse knock-out studies 
have shown that ERβ is involved in the normal function of tissues including ovaries, 
uterus, lung, prostate, and for neuronal function, although in all of these tissues 
except the ovary, ERα is the most abundantly expressed form of ER (Couse and 
Korach, 1999; Couse et al., 1997; Dupont et al., 2000). In the normal breast, 
whereas ERα is only detected in the nuclei of luminal epithelial cells of ducts and 
lobules, ERβ is distributed more evenly and is the dominant form of ER (Shaw et al., 
2002; Speirs et al., 2002). 
Comparison of the ERα and ERβ amino acid sequences (Figure 1.4) shows 
that they are extremely highly conserved in the DBD, with 97% amino acid sequence 
homology, and are identical in the P-box, accounting for their ability to bind to ERE 
sequences with similar specificities and affinities (Cowley et al., 1997). There is also 
a high degree of homology within the LBDs of ERα and ERβ, and both receptors bind 
estrogen and anti-estrogens with near equal affinity (Kuiper et al., 1997), although 
recent studies have identified synthetic ERα and ERβ-specific ligands (De Angelis et 
al., 2005; Harrington et al., 2003; Harris et al., 2002; Shiau et al., 2002). These 
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similarities suggest that ERα and ERβ can heterodimerise, and indeed several studies 
have shown that the receptors can form heterodimers on DNA (Cowley et al., 1997; 
Pace et al., 1997). As is observed when comparing ERα from different species, the 
A/B region of the ER is poorly conserved between the two ER isotypes, with only 
17% identity between human ERα and ERβ. Unlike ERα, the AF1 within the A/B 
region of ERβ has very low activity (Enmark et al., 1997).  
Gene expression microarray studies in the U2OS osteosarcoma cell line, in 
which ERα and ERβ were stably transfected and expressed in an inducible manner, 
show that very few ERα regulated genes are also regulated by ERβ. Rather, these 
studies showed that ERα and ERβ regulate the expression of distinct sets of genes 
(Monroe et al., 2003; Stossi et al., 2004), suggestive of specific and distinct roles for 
ERα and ERβ. In reporter gene studies ERα activates gene expression much more 
potently than ERβ, which has led to the proposal that ERβ may act as a negative 
regulator of ERα activity (Lindberg et al., 2003; Pettersson et al., 2000). Additionally, 
five alternative splice variants of ERβ have been described; the full length ERβ 
(ERβ1) and the other splice variants known as ERβ2/ ERβcx, ERβ3, ERβ4 and ERβ5 
(Moore et al., 1998).  Of these variants, most work has concentrated on ERβ1 and 
ERβ2/ ERβcx. These studies have shown that whereas ERβ1 can heterodimerize with 
ERα at EREs, ERβ2/ ERβcx not only is unable to bind to EREs but also appears to 
inhibit ERα binding to EREs (Omoto et al., 2003). Hence some of these isoforms 
have the potential to be potent inhibitors of full-length ERβ, but also of ERα, 
providing evidence for the potential role of ERβ as a negative regulator of ERα. In 
this respect, there is evidence showing that ERβ expression is reduced in breast 
tumours; this decrease in ERβ mRNA levels has been suggested to be associated 
with breast tumorigenesis and the reduction in expression being associated with 
methylation of the ERβ gene (Zhao et al., 2003).  
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Despite these findings, the potential role of ERβ in breast cancer progression 
remains highly controversial. Levels of ERβ protein expression have been shown to 
decrease during the progression of normal breast through to invasive carcinoma 
(Roger et al., 2001; Skliris et al., 2003). Further, immunohistochemical studies have 
suggested that a high ratio of ERα:ERβ protein levels is characteristic of benign 
breast lesions which progress to breast cancers (Fuqua et al., 2003; Shaaban et al., 
2005; Skliris et al., 2003). Antibody-based studies on clinical samples have shown 
that ERα-positive breast tumours which express ERβ respond better to tamoxifen 
treatment and therefore have a better rate of survival, although ERβ expression had 
little effect on the outcome of untreated patients (Hopp et al., 2004; Mann et al., 
2001). This has led to suggestions that ERβ expression acts as a predictive marker 
for tamoxifen response in breast cancer (Hopp et al., 2004; Mann et al., 2001; 
Nakopoulou et al., 2004).  
However, studies analysing RNA levels correlate ERβ expression with markers 
of poor progression (Iwao et al., 2000; Speirs et al., 1999a; Speirs et al., 1999b). 
Such discrepancies may be due to the fact that when RNA is measured from either 
breast tissue sections or chunks of tissue, the RNA represents a pool of all the 
different cell types present in the biopsy, including normal epithelial cells expressing 
ERβ and the contaminating normal epithelium may have a significant influence (Saji 
et al., 2005), whilst immunohistochemical detection although allowing ERß levels in 
breast cancer cells to be directly measured, are less quantitative, and may detect 
some isoforms only, depending on the antibody used (Fuqua et al., 2003; Speirs et 
al., 2002). Further investigation is clearly required before a clear role for ERβ in 
breast cancer can be established. 
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1.4.2 Estrogen receptor alpha 
As mentioned previously, the unliganded ERα is present in the nucleus, (King 
and Greene, 1984) and functions primarily as a transcription factor by regulating 
gene expression at the mRNA level in response to binding ligand (O'Malley et al., 
1968).  Genomic functions of ERα describe those that involve the receptor acting as 
a transcription factor by interacting with DNA to either activate or repress gene 
expression. Classically, these genomic functions of ERα require direct interaction of 
ERα with DNA via ERE sequences in promoter regions of estrogen-regulated genes 
(Klein-Hitpass et al., 1988). Initial studies used cloning of cDNAs induced by estrogen 
treatment of breast cancer cells to identify a number of ERα-regulated genes, 
including pS2/TFF1 (trefoil factor 1) (Brown et al., 1984; Jakowlew et al., 1984) and 
cathepsin D (Elangovan and Moulton, 1980). Expression microarrays have allowed 
further identification of ERα-regulated genes by the analysis of alterations in gene 
expression after ligand treatment on a genome-wide scale. This technique has been 
used to show that 70% of estrogen-regulated genes are in fact down-regulated, 
including genes involved in transcriptional repression, antiproliferation and 
proapoptotic genes. Conversely, up-regulated genes included positive proliferation 
regulators, multiple growth factors, genes involved in cell cycle progression and 
regulatory factor-receptor loops (Frasor et al., 2003), highlighting the role of ERα in 
cell-cycle progression.  
The identification of c-Myc (Dubik et al., 1987; Dubik and Shiu, 1988) and 
cyclin D1 (Altucci et al., 1996) as estrogen-regulated genes, highlighted another 
mechanism of ERα gene activation by indirect tethering of ERα to DNA through 
protein-protein interactions. These indirect protein-protein interactions of ERα at 
‘non-classical’ response sites which do not contain ERE sequences require ERα 
interactions with other transcriptional elements including AP1 (c-fos/c-jun), NF-κB, 
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cAMP-like elements, and Sp-1 DNA binding motifs (Dubik and Shiu, 1992; Kushner et 
al., 2000a; Kushner et al., 2000b; Sabbah et al., 1999; Safe, 2001).  
 
1.5 Non-classical ERα response sites 
In addition to regulating gene expression by binding to ERE sequences in 
promoters of estrogen-regulated genes, as exemplified by the pS2 gene, ERα can 
also regulate gene expression by recruitment to gene promoters through interaction 
with other transcription factors, such as AP1, and Sp1.  
Estrogen has been shown in human breast cancer cells to transiently 
upregulate EGFR mRNA and protein (Yarden et al., 1996); this induction appears to 
be due to the recruitment of ERα on the EGFR gene via protein-protein interactions 
with Sp1 (Salvatori et al., 2003). Many genes, including IGF-1 and c-Myc (Dubik and 
Shiu, 1992; Umayahara et al., 1994), are regulated by ERα recruitment to AP1-
responsive elements through interaction with AP1. Estrogen-bound ERα increases 
the activity of AP1 by binding to the coactivators CBP and GRIP1 which are recruited 
by AP1 via ERα (Kushner et al., 2000b). The ERα-DBD is required for recruitment of 
ERα to the AP1 site and the A/B region and LBD are required for transcription 
activation (Cheung et al., 2005). 
Sequencing of the human and mouse genomes have allowed computational 
analysis techniques to identify 660 genes encoding potential EREs which are 
conserved between the two genomes and are within 15 kb of a mRNA start site 
(Bourdeau et al., 2004). Recently however, chromatin immunoaffinity purification 
microarray (ChIP-chip) has been used to identify actual ER binding sites (Carroll et 
al., 2005; Carroll et al., 2006). As little as 4% of ER binding sites were mapped to 
the 1 kb promoter-proximal region, with the rest found to be located in distal cis-
regulatory enhancer regions, some being located more than 150 kb from the target 
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gene transcription start site. In addition to identifying many EREs in genes for which 
the mechanisms by which ERα regulates their expression was unclear, these studies 
also demonstrated that the EREs in many estrogen-responsive genes map close to 
Forkhead transcription factor binding sites, and require the Forkhead transcription 
factor FoxA1 binding at Forkhead factor binding sites near the EREs for the estrogen-
stimulated expression of estrogen-regulated target genes (Carroll et al., 2005; 
Laganiere et al., 2005).  
The finding that ERα can regulate genes by directly binding to DNA sequences 
located at considerable distances from the gene promoter puts into doubt some of 
the ideas about indirect recruitment of ERα by other transcription factors such as 
AP1 and SP1. For example, the Myc gene was originally identified as being 
transcriptionally regulated by ERα indirectly binding the promoter region of this gene 
(Dubik and Shiu, 1992), however, Carroll et al have identified an ER-binding site 67 
kb upstream of Myc which showed a greater increase in ERα-binding upon treatment 
with estrogen than the originally identified site within the promoter region (Carroll et 
al., 2006), suggesting that ERα interaction with the promoter region is not the 
primary ERα binding site. Cyclin D1 gene expression is estrogen-regulated and ERα-
binding sites within the proximal promoter of cyclin D1 have been mapped to a cAMP 
response element (CRE), an AP1 site and a Sp1 site (Altucci et al., 1996; Castro-
Rivera et al., 2001; Sabbah et al., 1999). Recent data has suggested that the ERα-
binding site at the cyclin D1 gene in breast cancer cells is removed from the 
previously described sites and depends on a cell-type-specific enhancer, enh2, 
downstream of the cyclin D1 coding region (Eeckhoute et al., 2006). Estrogen 
stimulation of breast cancer requires cell-specific ERα-mediated stimulation of cyclin 
D1 expression which promotes cell cycle progression. ERα interactions are 
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dependent on FoxA1 which interacts directly with enh2 and other recruited 
transcription factors.  
Further research into ERα binding sites needs to be carried out to ascertain 
which of the previously identified non-classical estrogen regulated genes actually 
bind ERα at the promoter regions indirectly, or if they are largely controlled by ERα 
binding directly at distal enhancer sites. 
 
1.6 Non-genomic actions of ERα 
In addition to regulating gene expression, either through direct binding to EREs 
or by indirect recruitment to gene promoters, ERα can regulate cellular processs 
through non-genomic functions for which ERα does not act as a transcription factor. 
These non-genomic actions of ERα tend to involve the non-reproductive actions of 
estrogen, such as influences on the central nervous system, cardiovascular system 
and the adult skeleton and include processes which control the release of calcium, 
secretion of prolactin, generation of phosphatidylinositol 3,4,5-triphosphate (PIP3), 
nitric oxide and activation of mitogen-activated protein kinases (MAPK). These are 
very rapid effects which are dependent on the cell type and are not sensitive to 
inhibitors of transcription, although the resulting signalling cascades lead to 
downstream events that modulate selected gene transcription. These effects appear 
to require ERα and are mediated by ERα localization at the cell membrane (Marquez 
et al., 2006; Rai et al., 2005; Wessler et al., 2006). 
Growth factor receptors are found to concentrate together with other 
components of the ras-MAPK signalling pathway in specific domains of the plasma 
membrane, termed lipid rafts (Pietras, 2003). Lipid rafts are moving platforms 
formed by the association of glycosphingolipids, cholesterol and specific proteins 
(Simons and Ikonen, 1997). ERα has been shown to associate with growth factor 
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receptors at the plasma membrane via caveolae-like lipid rafts which contain 
additional integral membrane proteins that interact with several other lipid-modified 
proteins involved in signal transduction, including G-proteins and protein kinase C 
(PKC) (Marquez et al., 2006).  
 The two signalling cascades which can be activated by growth factor receptor 
activation, Src-Shc-Ras-Raf-MAPK and phosphatidylinositol 3-kinase (PI3K)/Akt, are 
closely interconnected and it has been shown that the formation of a ternary 
complex of ERα, Src and PI3K, leads to simultaneous activation of both pathways, 
triggering the S-phase entry of the cell (Castoria et al., 2001). The ErbB family of 
growth factor receptors are receptor tyrosine kinases which possess an intrinsic 
protein kinase activity and include EGFR/ErbB1, ErbB2/HER2/Neu, ErbB3/HER3 and 
ErbB4/HER4 (Stoica et al., 2003). Ligand binding activates the growth factor 
receptors which recruit PI3K to the plasma membrane. PI3K is one of the key 
enzymes responsible for phosphoinositide metabolism and subsequent production of 
PIP3 which binds Akt (Lee et al., 2005b). Akt is then activated through 
phosphorylation at the plasma membrane (Campbell et al., 2001) and promotes cell 
survival by mediating the activities of a number of transcription factors in the 
nucleus. Inhibitors of PI3K and dominant-negative Akt have been shown to block the 
effect of estrogen on ERα activity by 70-80% and 55-63% respectively and it has 
been suggested that Akt interacts directly with ERα via the pleckstrin homology (PH) 
domain of Akt. Constitutively active Akt appears to mimic the effects of estrogen in 
the absence of ligand and the effects of Akt are not blocked by tamoxifen  (Stoica et 
al., 2003).  
Estrogen rapidly activates the PI3K/Akt pathway by triggering the binding of 
ERα to the p85 regulatory subunit of PI3K (Castoria et al., 2001; Lee et al., 2005b; 
Simoncini et al., 2000). Estrogen-induced expression of the early response gene c-
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Fos in MCF7 cells is thought to occur by activation of extracellular signal-regulated 
kinases (ERKs) mediated by estrogen-induced activation of the raf-MAPK signalling 
pathway (Almeida et al., 2006). Estrogen can also promote intracellular calcium 
mobilization and the generation of PIP3 in the nucleus by binding to and activating 
the G protein GPCR30 in the endoplasmic reticulum. Heterotrimeric G proteins are 
activated conventionally by members of a family of G-protein coupled receptors 
(GPCRs). Activated G protein subunits are competent to modulate the activity of 
downstream effectors (Revankar et al., 2005). The membrane-associated sub-
population of ERα has been shown to interact directly with Gα-protein subunits 
causing activation and this has been suggested to be the mechanism behind ERα 
activation of endothelial nitric oxide synthase in cultured endothelium (Kumar et al., 
2007; Wyckoff et al., 2001).  
Activation of ERα-mediated non-genomic pathways is dependent on the 
structure of the ligand, with different estrogenic compounds causing activation or 
inhibition of kinase activity (Li et al., 2006). Wessler et al. have recently identified 
two substances which can cause activation of Akt and ERK through non-genomic 
actions of ERα whilst displaying weak activation of genomic ERα activities and 
suggest that these pathway-selective ERα ligands may form the basis for novel 
hormone replacement strategies exhibiting lesser side effects than the existing 
treatments which include the onset of osteoporosis and breast cancer (Wessler et al., 
2006). The relative importance of the non-genomic and genomic actions of ERα 
remains unclear, however, and the pathway-specific ER ligands should help to clarify 
this position. Notwithstanding, the genomic actions of ERα are likely to be 
particularly important for mediating estrogen action in most cell types, particularly in 
breast cancer cells, since gene expression microarray and global ChIP strategies 
 51 
have shown that ERα directly regulates the expression of hundreds to thousands of 
genes in target cells.   
 
1.7 Regulation of ERα activity by Phosphorylation 
Classically, ERα, like other NRs is activated upon binding to its cognate ligand. 
There is considerable evidence, however, that ERα activity can be regulated by post-
translational modification, including acetylation, glycosylation and phosphorylation 
(Cheng and Hart, 2000; Kim et al., 2006; Lannigan, 2003). In particular, 
phosphorylation of ERα can result in its activation in the absence of ligand. Evidence 
for this mode of ERα regulation was first described in vivo, when it was shown that 
following ovariectomy, estrogen-dependent uterine proliferation could be rescued by 
administration of EGF and that co-administration of the anti-estrogen ICI 164, 384 
could inhibit the EGF rescue, indicating that the EGF-mediated uterine proliferation in 
ovariectomised mice was ER-dependent. Further, EGF could not rescue uterine 
proliferation in ERα knockout mice. TGFα and IGF-1 can similarly stimulate uterine 
proliferation in an ER-dependent manner in ovariectomised mice and rats (Curtis et 
al., 1996; Ignar-Trowbridge et al., 1992; Nelson et al., 1991). Other studies have 
revealed that in addition to growth factors, dopamine and other activators of protein 
kinase A stimulate ERα activity in the absence of ligand (Aronica and 
Katzenellenbogen, 1993; Bunone et al., 1996; Chen et al., 1999b; Ignar-Trowbridge 
et al., 1993; Pietras et al., 1995; Power et al., 1991). Together, these findings led to 
a considerable effort in determining the sites of phosphorylation and mechanisms by 
which ERα phosphorylation can regulate its activity, and led to the proposal that 
ligand-independent activation of ERα by phosphorylation could contribute to 
resistance to anti-estrogen and estrogen withdrawal therapies in breast cancer 
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patients and is considered the most important post translational modification of ERα 
(Ali and Coombes, 2002; Lannigan, 2003; Likhite et al., 2006).  
 
1.7.1 Serine 104/106/118 
Deletional analysis and phosphopeptide mapping studies identified serines 104, 
106 and 118 within the A/B region of ERα as major sites of phosphorylation (Figure 
1.5) and their mutation has been shown to reduce transactivation by ERα (Ali et al., 
1993; Chen et al., 2000; Chen et al., 2002; Joel et al., 1995; Kato et al., 1995; Le 
Goff et al., 1994).    
Using mutational studies it has also been shown that S104 and S106 are 
phosphorylated in vitro by cyclin A-cdk2 in a ligand-independent manner, enhancing 
the transcriptional activity of ERα (Rogatsky et al., 1999). S104 and S106 can also be 
phosphorylated by ERK1/2 MAPK (Thomas et al., 2008), whilst their phosphorylation 
by GSK3α has also been described (Medunjanin et al., 2005). Studies carried out in 
cells, using radioactively labelled ERα transiently transfected into COS1 cells have 
shown that Cdk7 mediates ligand-dependent phosphorylation of S118 (Chen et al., 
2000; Chen et al., 2002). Estrogen treatment stimulates ERα phosphorylation and 
co-transfection of Cdk7 significantly increases this. Mutation of S118 prevented Cdk7 
mediated phosphorylation of ERα showing that S118 is the sole target for Cdk7. 
Cdk7 is part of the Cdk-activating kinase (CAK) complex of TFIIH and S118 
phosphorylation occurs in a ligand-dependent manner which involves TFIIH 
interacting with the AF2 via the TFIIH subunits, p62 and XPD. This ligand-dependent 
phosphorylation of S118 by Cdk7 stimulated ERα activity in the presence of estrogen, 
as well as in the presence of tamoxifen. These findings were confirmed following 
expression of ERα in Drosophila cells (Ito et al., 2004). However, cell-based studies 
using Cdk7 inhibitors, DRB and roscovitine, showed that Cdk7 inhibition did not 
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Figure 1.5 Phosphorylation sites of ERα 
Phosphorylation within the AF1 domain has been shown to enhance 
transactivation by ERα, phosphorylation within the DBD has been shown to inhibit 
dimerization and phosphorylation within the LBD/AF2 region has been shown to 
increase estrogen sensitivity, whilst phosphorylation of Y537 appears to regulate 
coactivator recruitment.  
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inhibit estrogen-induced phosphorylation of S118 suggesting that Cdk7 does not 
contribute to S118 phosphorylation in the cell lines used (MCF7, ZR-75-1 and T47D) 
(Weitsman et al., 2006), although recent studies from our laboratory show that S118 
phosphorylation is inhibited by a specific Cdk7 inhibitor (Heathcote et al., 
unpublished). In the study by Weitsman et al. (2006), however, inhibition of IKKα 
using BAY-11-7082 inhibited phosphorylation of S118, suggesting that estrogen-
stimulated phophorylation of S118 may be mediated by IKKα (Weitsman et al., 
2006). 
In addition to its phosphorylation by Cdk7, S118 is phosphorylated in a 
ligand-independent manner by activation of the MAPK signalling pathway and 
phosphorylation by p42/p44 MAPK enables ligand-independent activation of ERα 
whilst enhancing ligand-dependent activation (Kato et al., 1995). Activation of 
p42/p44 MAPK in response to cell treatment with EGF and PMA has been used to 
show induction of S118 phosphorylation (Bunone et al., 1996; Chen et al., 2002; Joel 
et al., 1998b), whilst post-operative treatment of patients with the EGFR inhibitor 
Gefitnib inhibited MAPK activation and reduced S118 phosphorylation (Polychronis et 
al., 2005). However, immunohistochemical staining of primary breast cancer biopsies 
shows that high-level S118 phosphorylation is an indicator of a better prognosis and 
likelihood of response to tamoxifen (Murphy et al., 2004a; Murphy et al., 2004b; 
Sarwar et al., 2006). However, S118 phosphorylation was increased in biopsies taken 
from patients who relapsed following tamoxifen treatment, when compared with the 
pre-treatment biopsy (Sarwar et al., 2006), whilst low-level S118 phosphorylation, 
when coupled with high phosphorylation at S167 has been shown to be associated 
with improved survival (Yamashita et al., 2008), suggesting that S118 
phosphorylation may indeed play a role in endocrine resistance. 
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1.7.2 Serine 167 
Growth factors, including epidermal growth factor (EGF), insulin-like growth 
factor-1 (IGF1) and heregulin-β1 (HRG-β1), can modulate the genomic activities of 
ERα via the PI3K/Akt pathway (Stoica et al., 2003). PI3K and Akt are capable of 
activating ERα in the absence of estrogen by the phosphorylation of ERα at serine 
167. This is thought to modulate coactivator and corepressor interactions of AF1, 
causing an increase in ERα activity in a promoter-specific fashion (Campbell et al., 
2001). S167 is also phosphorylated in response to the activation of the MAPK 
pathway by p90ribosomal S6 kinase (p90RSK), a kinase downstream of MAPK (Joel 
et al., 1998a). However, PI3K-mediated stimulation of Akt also stimulates activation 
of Rsk. The relative contributions of Akt and p90RSK to S167 phosphorylation are 
unclear as yet but it is likely that both p90RSK and Akt regulate ERα activity with 
possible differences depending on cell type and extracellular signals (Lannigan, 
2003). Investigation of S167 phosphorylation by immunohistochemistry showed that 
in patients with ERα-positive breast cancer, phospho-S167 positivity is associated 
with a better prognosis and likelihood of response to hormonal therapies (Jiang et 
al., 2007). In this study, S167 positivity was associated with phosphorylated 
(activated) p90RSK and with phosphorylated Akt. The association with phospho-
p90RSK was considerably stronger than that with phospho-Akt and phospho-p90RSK 
was also associated with a better prognosis, whereas phospho-Akt was associated 
with worse outcome, suggesting that phosphorylation of S167 by p90RSK is more 
important in breast cancer cells. Evidence for S167 phosphorylation as a positive 
prognostic factor has also been provided by another study (as described above), 
which indicated that low-levl S118 phoshproylation and high-level S167 
phosphorylation are predictive of a better outcome in breast cancer patients 
(Yamashita et al., 2008). 
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1.7.3 Serine 236 
S236 is located within the DBD and has been shown to be phosphorylated by 
protein kinase A (PKA) in vitro, preventing receptor dimerisation and consequently 
DNA binding by ERα, although these effects were abrogated in the presence of 
ligand. However, over-expression of PKA was shown to cause phosphorylation in a 
ligand-independent fashion (Chen et al., 1999b). The authors showed that in the 
absence of ligand ERα dimerisation is mediated by the DBD and that phosphorylation 
of S236 by PKA inhibits DBD dimerisation, but that estrogen and tamoxifen binding 
by the receptor allows dimerisation through the LBD, and consequent DNA binding 
by ERα. Indeed, the anti-estrogen ICI 164,384, could not rescue the inhibition of 
DNA binding upon S236 phosphorylation, presumably since ICI 164,384 also inhibits 
LBD dimerisation (Metzger et al., 1995). However, Likhite et al. (2006) showed that 
phosphorylation of S236 increases the affinity of the receptor for estrogen without 
altering the affinity for the anti-estrogen tamoxifen and did not show any alterations 
in DNA binding or receptor dimerization (Likhite et al., 2006). They postulate that 
these differences may be due to receptor phosphorylation enhancing interactions 
with coregulators that modulate dimerization or DNA interactions. 
 
1.7.4 Serine 305 
S305 is located at the junction of the hinge region and the LBD and 
phosphorylation of this site by PKA in vitro has been linked to tamoxifen resistance 
(Likhite et al., 2006; Michalides et al., 2004; Zwart et al., 2007). Phosphorylation of 
S305 increases transcriptional activity and has been implicated in preventing 
acetylation of lysine 303 (Cui et al., 2004). Lys303 is often mutated to arginine in 
breast cancer and this mutation has been associated with hypersensitivity to 
estrogen (Fuqua et al., 2000).  
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Active p21-activated kinase 1 (Pak1), an effector of activated Rho GTPases 
Cdc42 and Rac1 (Manser et al., 1994), has also been reported to phosphorylate ERα 
at S305 in the absence of ligand, increasing the activity of ERα (Wang et al., 2002) 
and causing an inhibition of antiestrogenic effects of tamoxifen on ERα in tamoxifen 
sensitive cell lines (Rayala et al., 2006).  
 
1.7.5 Threonine 311 
Threonine 311 is located in the amino-terminus of the ERα LBD. MEKK1 
activation of p38 MAPK was shown to be required for estrogen-mediated activation 
of ERα in endometrial and ovarian cancer cell lines (Lee et al., 2000) and subsequent 
studies showed that activation of p38 MAPK by estrogen resulted in the stimulation 
of threonine 311 phosphorylation, blocking receptor nuclear export and promoting 
interaction with coactivators (Lee and Bai, 2002). Mutation of T311 to alanine 
prevented ERα activation by estrogen by inhibiting binding of the receptor to the 
coactivators SRC1 and SRC2/TIF2, although the T311A mutant was still able to bind 
estrogen. Treatment of endometrial cancer cells with tamoxifen increased the activity 
of p38 MAPK (Lee and Bai, 2002), suggesting a link between p38-mediated 
phosphorylation of ERα and tamoxifen resistance. Indeed, patient studies have 
shown a link between an increase in active p38 MAPK levels, poor prognosis and 
tamoxifen resistance in breast cancer (Dowsett et al., 2005; Esteva et al., 2004; 
Gutierrez et al., 2005). However, there is also evidence to suggest that activation of 
p38 MAPK stimulates ERα degradation (Buck et al., 2004; Zhang and Shapiro, 2000), 
highlighting potential cell-specificity of these mechanisms. 
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1.7.6 Tyrosine 537 
There is a great deal of controversy over the phosphorylation of Y537, located 
in the LBD. Tyrosine phosphorylation has been shown to occur in breast cancer cells 
over-expressing the HER2 growth factor receptor (Pietras et al., 1995) and in vitro 
studies have shown that phosphorylation of Y537 by Src (Likhite et al., 2006) blocks 
receptor dimerization (Arnold et al., 1997).  Mutagenesis studies have been used to 
show that this residue is important in the modulation of ligand binding and that its 
mutation can lead to constitutive activation of ERα (Weis et al., 1996; White et al., 
1997). Phosphorylation of Y537 has been shown to cause an increase in the affinity 
of ERα for estrogen, a decrease in the affinity for tamoxifen and a decrease in 
affinity for DNA in the presence of both estrogen and tamoxifen (Likhite et al., 
2006). However, phosphorylation has not been observed by a number of other 
groups (Ali et al., 1993; Lahooti et al., 1994). This discrepancy may be due to the 
fact that tyrosine phosphorylation only occurs on a small minority of receptors, is cell 
type-specific or the experimental conditions used were not conducive for the 
detection of tyrosine phosphorylation (Lannigan, 2003; Likhite et al., 2006). 
 
1.8 The development of the human breast  
There are three phases of mammary gland growth in humans, during which 
important developmental events occur; embryonic, adolescent and adult phases. 
Firstly, during prenatal development of the mammary epithelial sprout, formation of 
a bilateral mammary ridge (or milk line) occurs followed by the formation of placodes 
at the site of each future nipple. The placodes penetrate the surrounding fat pad and 
a limited number of branches then sprout to form a rudimentary ductal tree before 
birth (Hens and Wysolmerski, 2005; Howard and Gusterson, 2000). Breast 
development in males is indistinguishable from females until puberty, at which point 
 59 
the female breast undergoes hormone-dependent branching. During this second 
stage, bulbous terminal end buds form at the tips of the ducts and penetrate further 
into the fat pad as the ducts elongate. New primary ducts form by the division and 
sprouting of the terminal end buds until the entire fat pad is filled by an extensive 
system of branched ducts (Hinck and Silberstein, 2005). These terminal end bud 
structures eventually disappear from the mature gland as differentiation proceeds 
and the gland will stay in this form, with minor changes depending on the stage of 
the menstrual cycle. During the third phase, the gland undergoes a critical period of 
development during pregnancy where the gland prepares for functional lactation 
(Fenton, 2006).   
The three phases of mammary branching are differentially regulated. 
Adolescent branching requires estrogen and ERα, adult side-branching requires 
progesterone and its receptor and embryonic branching is hormone independent 
(Bocchinfuso et al., 2000). Growth hormone (GH) is a critical pituitary hormone in 
mammary gland development. GH is already present before the pubertal surge in 
ovarian estrogens and acts via its receptor, GHR, on mammary stromal cells to elicit 
the expression of insulin-like growth factor 1 (IGF-1). IGF-1 then stimulates terminal 
end bud formation and epithelial branching in a paracrine manner and ovarian 
estrogens act together with GH and IGF-1 to stimulate branching (Sternlicht, 2006). 
It has been discovered that EGFR ligands rescue ductal development in ERα deficient 
mice, suggesting that EGFR promotes mammary branching downstream of ERα 
(Kenney et al., 2003). The EGFR-dependent activation of matrix metalloproteinase 2 
(MMP-2) and MMP14 have a key role in lung branching morphogenesis (Kheradmand 
et al., 2002). Similarly, MMP-2 has been shown to regulate mammary ductal 
elongation in vivo and MMP-14 promotes ductal development by activating MMP-2 
and collaborating with it to degrade type I collagen (Wiseman et al., 2003).  
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The same general processes that take place during normal mammary 
development, such as proliferation and invasion, also occur in malignant disease and 
most of the pathways that influence ductal branching have been linked with the 
development or progression of cancer (Sternlicht, 2006).  
 
1.9 The involvement of ER in breast cancer 
Breast cancer is the leading cancer in women in the Western World with one in 
nine women developing the disease at some point during their lives (Kelsey and 
Berkowitz, 1988). Approximately 70-80% of breast cancers express ERα and 
estrogen is the main stimulant in the development and growth of these tumours (Ali 
and Coombes, 2002; Anderson et al., 2002; EBCTCG, 1998; Johnston and Dowsett, 
2003). 
It is estimated that between 7-10% of normal breast epithelial cells express 
ERα, with levels fluctuating during the menstrual cycle (Markopoulos et al., 1988; 
Petersen et al., 1987; Ricketts et al., 1991). Levels of ERβ are much higher with 80-
85% of normal breast cells expressing the receptor and levels do not fluctuate 
(Critchley et al., 2002; Palmieri et al., 2002). The ERα expressing cells do not 
proliferate but appear to stimulate the proliferation of surrounding ERα-negative 
epithelial cells (Clarke et al., 1997; Russo et al., 1999). The mechanisms which 
enable ERα-positive cells to be converted from non-dividing cells to proliferating 
under the control of estrogen is unclear (Ali and Coombes, 2002). It has been 
hypothesised that aberrant signalling of ER could lead to abnormal cellular 
proliferation and survival, potentially resulting in the development and progression of 
breast cancer (Herynk and Fuqua, 2004).  
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1.10    Treatment of breast cancer 
As early as the late 1800s, it was recognised that surgical removal of the 
ovaries (oophorectomy) of premenopausal women with metastatic breast cancer 
caused tumour regression in approximately one third of patients (Beaston, 1896; 
Boyd, 1900). Before 1950, cancer therapy mainly concentrated on the surgical 
removal of tumours. Radiation therapy introduced in the 1960’s was able to control 
local and regional disease in a non-invasive manner, however, like surgery, could not 
eradicate metastatic cancer (Chabner and Roberts, 2005). Chemotherapy, where 
cytotoxic drugs such as methotrexate are used to kill cancer cells, was introduced in 
the early 1950’s and has the advantage over surgery and radiation therapy of being 
able to infiltrate the whole body and therefore come into contact with any metastatic 
cancer cells. Trials carried out using a combination of drugs, cyclophosphamide, 
methotrexate and fluorouracil, proved that adjuvant chemotherapy after complete 
surgical removal of breast tumours significantly extended survival (Bonadonna et al., 
1976). 
Targeted chemotherapeutic drugs have now been developed including 
imatinib mesylate (Glivec) which inhibits the kinase BCR-ABL, the tyrosine kinase KIT 
and the platelet derived growth factor receptor-β (PDGFRβ) and is used in the 
treatment of chronic myeloid leukemia (CML), gastrointestinal stromal tumours and 
hypereosinophilic syndrome. However, treatment leads to a rapid outgrowth of drug-
resistant cells (Chabner and Roberts, 2005). Trastuzumab, more commonly known 
under the trade name Herceptin, is a monoclonal antibody which recognises the 
epidermal growth factor receptor HER2/neu and this receptor is overexpressed in 
between 20-30% of early-stage breast cancers (Bange et al., 2001). Trastuzumab is 
used to treat advanced and early-stage breast cancers which over-express 
HER2/neu; however, the benefit of the drug as an adjuvant treatment to prevent 
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recurrence is controversial with no clear consensus, partly due to the detrimental 
effects on cardiac function that long-term trastuzumab treatment causes (Madarnas 
et al., 2008; Romond et al., 2005). Lapatinib, also known as Tykerb (USA) and 
Tyverb (Europe), is also a monoclonal antibody which inhibits both EGFR and 
HER2/neu and has recently been licensed to treat advanced breast cancer which is 
no longer responsive to Trastuzumab, in conjunction with the chemotherapeutic 
drug, capecitabine (Xeloda) (Geyer et al., 2006). 
    
1.10.1 Endocrine therapies 
At present treatment of patients who present with localised disease involves 
surgical removal of the tumour (lumpectomy) or removal of the whole breast 
(mastectomy), which is usually followed by adjuvant therapy, such as endocrine 
treatments, in order to treat any possible micrometastases (Ali and Coombes, 2002). 
Endocrine therapies aim to disrupt the ER signalling pathway, either by reducing 
levels of circulating estrogen (such as aromatase inhibitors and LHRH agonists) or by 
competing with estrogen for binding to ER and thereby inhibiting the actions of the 
ER (such as selective estrogen receptor modulators (SERMs) and pure antiestrogens) 
(Howell and Dowsett, 2004). Only patients with ERα-positive disease respond to 
endocrine therapies (Osborne, 1998), which nevertheless makes these very 
important for the adjuvant treatment of breast cancer, since 70-80% of primary 
breast cancers are ERα positive (Ali and Coombes, 2002). 
 
1.10.1.1 LHRH agonists 
Estrogen is synthesized primarily in the ovaries of pre-menopausal women 
and requires the aromatase complex. Estrogen biosynthesis is subject to feedback 
 63 
regulation through hormonal signals released from the pituitary gland of the brain 
(Ali and Coombes, 2002; Buluwela et al., 2004). Luteinising hormone (LH) and 
follicle-stimulating hormone (FSH) act together to control levels of estrogen and the 
release of both hormones is regulated by luteinising hormone releasing hormone 
(LHRH). LHRH agonists such as goserelin (Zoladex), buserelin, leuprolide and 
triptorelin cause the inhibition of LH and FSH by a negative feedback loop which 
causes LHRH-receptor down regulation, therefore leading to a reduction in levels of 
estrogen. In pre-menopausal women LHRH agonists are used as a form of medical 
castration (Klijn et al., 2001). However, their use is limited as estrogen synthesis in 
tissues other than the ovary is not affected and it has been suggested that they be 
used in conjunction with tamoxifen or aromatase inhibitors to treat pre-menopausal 
breast cancer patients (Klijn et al., 2001).  
 
1.10.1.2 Aromatase inhibitors 
Aromatase inhibitors (AIs) as a treatment for breast cancer was first 
investigated in the 1970s. In post-menopausal women the majority of estrogen is 
produced by converting androstenedione and testosterone secreted by the adrenal 
gland in a reaction catalysed by the aromatase complex which occurs at peripheral 
sites such as adipose tissue, liver and muscle (Buzdar and Howell, 2001). Two-thirds 
of breast carcinomas contain aromatase which is a cytochrome P450 enzyme 
complex (Osawa et al., 1987) and produces biologically significant amounts of 
estrogen local to the tumour (Santen et al., 1994). AIs block this vital enzyme 
therefore reducing levels of circulating estrogen. However, this is most effective only 
in post menopausal women due to the fact that pre-menopausal women are still 
capable of secreting estrogen from the ovaries (Howell and Dowsett, 2004). First 
generation AIs, such as the adrenotoxic antiepileptic drug aminoglutethimide, aimed 
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to achieve ‘medical adrenalectomy’ (Cash et al., 1967; Griffiths et al., 1973; Santen 
et al., 1974), although its clinical relevance was revealed to be due to inhibition of 
peripheral aromatisation (Santen et al., 1978). Second generation AIs included non-
steroidal as well as steroidal inhibitors but these did not show any improved 
therapeutic outcome over conventional treatment (Buzdar et al., 1996b; Falkson and 
Falkson, 1996; Thurlimann et al., 1996). Third generation AIs including anastrazole, 
letrazole and exemestane however, show superior response and time to progression 
rates compared to first and second generation AIs (Buzdar et al., 1996a; 
Dombernowsky et al., 1998; Kaufmann et al., 2000) and achieved total body 
aromatase inhibition by 98% or more (Geisler et al., 2002; Geisler et al., 1998; 
Geisler et al., 1996).  
 
1.10.1.3 Selective Estrogen Receptor Modulators (SERMs) 
Tamoxifen is a non-steroidal drug which competes against estrogen for 
binding to the ER and inhibits receptor activation through the ligand-dependent AF2 
domain. The drug was first developed in the 1960’s as an antifertility drug (Harper 
and Walpole, 1966) and although this failed, the potential to develop the drug as a 
targeted breast cancer treatment was identified and by the 1980’s tamoxifen had 
become the first line endocrine treatment for all stages of ER-positive breast cancer 
(Jordan, 2003). Five years of adjuvant tamoxifen treatment has been shown to 
provide a 50% reduction in recurrence and 25% reduction in mortality (EBCTCG, 
1998). 
Both estrogen and tamoxifen binding to ERα cause its dimerization and high 
affinity binding to EREs, however, the bulky side chain of tamoxifen prevents H12 
from adopting the agonist bound position which allows coactivator interaction 
(Brzozowski et al., 1997). The tamoxifen-ER complex preferentially binds 
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corepressors that maintain the inactive state of ERα (Lavinsky et al., 1998). Although 
tamoxifen blocks receptor activity through the AF2, the drug has agonist activity in 
some tissues such as the uterus and bone, and is therefore known as a ‘selective 
estrogen receptor modulator’. This allows other activities of ERα to proceed as 
normal, such as, maintenance of bone density and reduced circulating levels of 
cholesterol (Jordan, 2004; Jordan et al., 2003). Tamoxifen and estrogen cause 
conformational changes that allow interaction of ERα with a range of coactivators 
and corepressors and it is thought that the relative levels and/or activities of each 
are likely to determine whether the ligand bound has estrogenic or anti-estrogenic 
properties (Howell and Dowsett, 2004). Early studies indicated that tamoxifen has 
partial agonist activity due to its inhibition of AF2, but activation of AF1 (Berry et al., 
1990; Metzger et al., 1992; Tzukerman et al., 1994). However, the picture is 
probably more complex, likely being dependent, as stated above, on the relative 
levels of coactivators and corepressors in different target tissues (Shang and Brown, 
2002). Cross-signalling growth factor transduction pathways also impact on the 
activity of the anti-estrogen-ER complex (Johnston and Dowsett, 2003). 
Unfortunately, although the agonist activity of tamoxifen is desirable in some tissues, 
in other tissues this agonist activity is problematic, hence the intrinsic activity of the 
tamoxifen-ER complex results in an increase in the incidence of endometrial cancer 
in the lining of the uterus (Jordan et al., 2003). 
 
1.10.1.4 Combined SERM and aromatase inhibitor treatments 
Whilst tamoxifen has contributed to the significant falls in breast cancer 
mortality, it is clear that a significant proportion of patients receiving tamoxifen who 
initially present with localised disease and all of the patients who present with 
metastatic disease relapse (Ali and Coombes, 2002). A number of clinical trials have 
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therefore been set up to evaluate the use of antiestrogens and aromatase inhibitors, 
either to compare the treatments or to evaluate the combination or sequencing of 
the treatments.  
The ATAC-trial (arimidex (anastrazole), tamoxifen, alone or in combination) 
compared anastrozole with tamoxifen for 5 years in 9366 postmenopausal women 
with localised breast cancer. The first report revealed improvement in relapse-free 
survival for anastrazole compared to tamoxifen and the two drugs taken in 
combination did not show any improvement compared to tamoxifen alone (Baum et 
al., 2002). The final report after a median follow-up of 68 months concluded that in 
ERα-positive post menopausal breast cancer patients, anastrozole significantly 
prolonged disease-free survival, time-to-recurrence and significantly reduced distant 
metastases and contralateral breast cancers. Anastrozole was also associated with 
fewer side-effects than tamoxifen, especially gynaecological problems and vascular 
events, but arthralgia and fractures were increased. No difference regarding overall 
survival was recorded (Howell et al., 2005a).  
 The MA-17 trial investigated the benefit of extending adjuvant therapy 
beyond 5 years but with use of an alternative drug after tamoxifen. This was based 
on the finding that five years of postoperative tamoxifen therapy prolongs disease-
free and overall survival, whereas treatment with tamoxifen for a longer period does 
not provide any additional benefit, whilst increasing the risk of endometrial cancer 
and other side effects. The trial was conducted to test the effectiveness of five years 
of letrozole therapy in postmenopausal women with breast cancer who have 
completed five years of tamoxifen therapy. A total of 5187 women were enrolled and 
after the median follow-up at 2.4 years, the independent data and safety monitoring 
committee recommended termination of the trial and communication of the results to 
the participants as, compared with placebo, letrozole therapy after the completion of 
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standard tamoxifen treatment significantly improved disease-free survival (Goss et 
al., 2003). 
  The effects of exemestane treatment after 2-3 years of tamoxifen treatment 
were compared to continuing tamoxifen treatment for 5 years in the IES-trial 
(Intergroup Exemestane Study). A total of 4742 patients enrolled and the 
exemestane group compared with the tamoxifen group showed an absolute benefit 
in terms of disease-free survival of 4.7 percent at three years after randomization. 
Overall survival was not significantly different in the two groups, however, 
exemestane therapy after two to three years of tamoxifen therapy significantly 
improved disease-free survival compared with the standard five years of tamoxifen 
treatment (Coombes et al., 2004). 
 
1.10.1.5 Pure estrogen receptor inhibitors 
Fulvestrant (ICI 182,780) is a steroidal antiestrogen that inhibits the activities 
of both AF1 and AF2 and is therefore known as a pure antiestrogen. Fulvestrant 
(also known as Faslodex) competes with estrogen for binding to ERα (Wakeling et 
al., 1991), prevents ERα binding DNA by disrupting ERα dimerization (Fawell et al., 
1990b; Parker, 1993) and promotes nuclear export of the receptor causing 
accumulation in the cytoplasm (Dauvois et al., 1993). The pure antiestrogen also 
reduces the half-life of the protein, resulting in a rapid loss of cellular ERα (Dauvois 
et al., 1992).  
Since Fulvestrant is a complete antagonist of ER, treatment is not associated 
with the side effects of SERM’s, such as tamoxifen which causes ERα activation via 
AF1, linked to an increase in cases of endometrial cancer in patients undergoing 
tamoxifen treatment for breast cancer (Fisher et al., 1994; Wakeling et al., 1991). 
Fulvestrant has been shown to inhibit agonistic effects of estrogen in endometrial 
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tissue in postmenopausal women (Addo et al., 2002) and shows a significant 
reduction in estrogenic activity in breast cancer cells compared to tamoxifen when 
used to treat postmenopausal women with previously untreated primary breast 
cancer (Robertson et al., 2001).  
In vivo studies have shown that fulvestrant treatment abrogated the growth 
of tamoxifen-resistant MCF7 xenografts generated in nude mice (Osborne et al., 
1994), suggesting a use for fulvestrant treatment of tamoxifen-resistant tumours. 
This was shown to be the case in two large Phase III trials (Howell et al., 2002; 
Osborne et al., 2002) which showed that fulvestrant treatment of advanced breast 
cancer in postmenopausal women whose disease had progressed on prior endocrine 
therapy was as effective as anastrozole. Combined analysis of the trials after a 
median follow-up of 15.1 months showed no statistically significant difference 
between fulvestrant and anastrazole treatment, although a median follow-up of 22.1 
months showed that the duration of response rate of fulvestrant was 30% greater 
than that for anastrazole (Robertson et al., 2003). However, a median-follow up of 
27 months showed that the two treatments were near-identical in terms of median 
time to death (Howell et al., 2005b).  
These studies, and other smaller Phase II studies (Ingle et al., 2006; 
Mlineritsch et al., 2007; Perey et al., 2007), show the potential of fulvestrant in the 
treatment of postmenopausal women with advanced breast cancer who have 
progressed on prior endocrine therapies. Other Phase III trials are underway to 
evaluate the benefit of fulvestrant treatment in such settings (Evaluation of 
‘Faslodex’ versus Exemestane Clinical Trial, Study Of ‘Faslodex’, Exemestane, and 
‘Arimidex’ Trial, Southwest Oncology Group (SWOG) SO226 Trial) (Howell, 2006). 
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1.11 Resistance to endocrine therapies 
Around 50% of patients with ERα-positive disease do not respond to tamoxifen 
treatment (de novo resistance) and a large proportion of patients who present with 
primary breast cancer and all those with metastatic disease who do initially respond 
to tamoxifen, eventually relapse (acquired resistance) (Likhite et al., 2006). ERα 
continues to play an important role in many tamoxifen-resistant cases as 
demonstrated by the finding that the aromatase inhibitor anastrazole and the 
complete ERα inhibitor, fulvestrant, provide tumour regression in many resistant 
cases (Morris and Wakeling, 2002). This suggests a mechanism of resistance 
whereby the activation of ERα is altered in some way and it has been hypothesised 
that resistance to hormonal therapies could result from growth factor-induced 
activation of protein kinases, resulting in phosphorylation and consequent ligand-
independent activation of ERα (Stoica et al., 2003). Other possible mechanisms for 
endocrine resistance include loss or mutation of ERα, changes in signalling pathways, 
coregulator control of ERα activity or growth factor production/sensitivity, or 
pharmacological changes in the antiestrogen itself, including altered uptake and 
retention or metabolism of the antiestrogen (Katzenellenbogen et al., 1997). 
 
1.11.1 Tamoxifen resistance due to mutations in the ERα gene 
 There have been very few reported mutations within the ERα gene that might 
suggest that mutation of the receptor is linked to resistance towards tamoxifen, with 
mutation being detected in only 1% of breast cancers (Roodi et al., 1995).  
 The somatic mutation of ERα lysine 303 to arginine has been identified in 
34% of hyperplastic breast lesions (Fuqua et al., 2000). K303 is situated at the 
border of the hinge and LBD and the K303R mutant shows an enhanced binding to 
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the SRC1 coactivator at low levels of estrogen with a subsequent increased 
sensitivity to estrogen compared with wild-type ERα in vitro. This is suggestive of a 
potential mechanism which could promote or accelerate the development of cancer 
from premalignant breast lesions (Fuqua et al., 2000). Acetylation of K303 by the 
coactivator p300 has been suggested to reduce hormone sensitivity of ERα (Wang et 
al., 2001), therefore the K303N mutation may cause hormone hypersensitivity due to 
the inhibition of this regulatory mechanism. However, the rate of occurrence of this 
mutant in breast cancer is under dispute with a study of 635 newly diagnosed 
invasive beast tumours carried out in North America only recording a 5.7% rate of 
occurrence (Conway et al., 2005), a study carried out by Herynk et al (Herynk et al., 
2007) recording a 50% rate of occurrence in invasive breast tumours and Zhang et 
al. recording no instances of the mutant in a study carried out with Japanese women 
(Zhang et al., 2003). This difference could be due to variability in the mutantion 
detection methods used, or could be due to the different ethnic make-up of the 
groups tested. 
 A mutation which substitutes tyrosine 537 in the LBD for asparagine has been 
shown to be equally active in the absence of ligand, presence of estrogen or the 
presence of tamoxifen (Zhang et al., 1997), whilst a number of other substitutions at 
this residue have been made experimentally. Many of these substitutions also 
demonstrate ligand-independent coactivator recruitment and transcriptional activity 
(Weiss et al; White et al). As mentioned above (section 1.7.5), Y537 was identified 
as being phosphorylated by members of the c-src family of tyrosine kinases, with 
phosphorylation causing an increase in the affinity of ERα for estrogen, a decrease in 
the affinity for tamoxifen and a decrease in affinity for DNA in the presence of both 
estrogen and tamoxifen (Likhite et al., 2006).  
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Deletion of a nucleotide in codon 432 that introduces a stop codon at residue 
437 of ERα has been identified in a metastatic lesion of a patient but not in the 
primary tumour (Karnik et al., 1994), suggesting a possible role in tamoxifen 
resistance and metastatic spread, although there have been no other reports of this 
mutation occurring in a clinical situation (Herynk and Fuqua, 2004).  
 Expression of ERα splice variants with various deletions of the eight exons, 
singly and in combination, have been noted in breast cancer cells and normal breast 
tissue (Leygue et al., 1996a; Leygue et al., 1996b; Murphy et al., 1996; Pfeffer et al., 
1995; Poola et al., 2000; Zhang et al., 1996). The ERα exon 5 deletion mutant (ERα 
Δ5) is probably one of the most interesting due to the lack of most of the LBD but 
retention of the AF1 and DBD (Fuqua et al., 1991), enabling constitutive activity of 
the receptor when transfected into some (Lemieux and Fuqua, 1996), but not other 
(Rea and Parker, 1996), breast cancer cell lines. This suggests that the variant may 
possess tamoxifen-resistant growth characteristics when expressed in breast cancers, 
although assessment of clinical samples has not shown any link between ERα Δ5 and 
tamoxifen resistance (Daffada et al., 1995; Madsen et al., 1997; Zhang et al., 1996). 
As with many mRNA splice variants, expression of wild-type ERα is greater than that 
of the splice variant in the majority of cases (Zhang et al., 1996) and the role of 
expressed splice variants is unclear at present. 
 
1.11.2 Tamoxifen resistance due to posttranslational modifications 
Activation of ERα via growth factor signalling pathways is thought to be a 
major factor in acquired resistance to endocrine therapies. Cooperative interactions 
between estrogen and growth factor receptor signalling pathways involved in ERα 
phosphorylation have been identified in breast tumour cells, and signalling pathways 
which activate MAPK, notably EGFR/HER1 and HER2/neu, appear to play critical roles 
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in the development of tamoxifen resistance (Marquez et al., 2006). Approximately 
25-30% of breast cancers over-express HER2/neu and 50% over-express 
EGFR/HER1; both of these instances correlate with poor prognosis and resistance to 
endocrine therapy (Pietras, 2003; Stoica et al., 2003). Antiestrogen binding to ERα is 
thought to increase the transcription of HER2/neu gene by releasing ERα 
coactivators which then go on to activate the HER2/neu promoter (Jordan, 2003).  
S118 phosphorylation has been linked to tamoxifen resistant growth partly 
due to the fact S118 phosphorylation enhances ligand-independent activity in breast 
cancer cell lines (Bunone et al., 1996; Joel et al., 1998b; Kato et al., 1995). MAPK 
has been shown to phosphorylate S118 in a ligand-independent manner in vitro 
(Bunone et al., 1996; Kato et al., 1995) and many in vitro studies have shown that 
an increase in MAPK activity due to increased expression of upstream activators 
leads to increased ERα activity in the presence of antiestrogens in breast cancer cell 
lines (Feng et al., 2001; Hutcheson et al., 2003; Knowlden et al., 2003; McClelland et 
al., 2001). Clinical studies have also shown an increased activity of MAPK in 
malignant breast tumour cells compared to normal breast tissue (Sivaraman et al., 
1997). A significant relationship between elevated levels of activated MAPK and a 
reduced period of antiestrogen response (Gee et al., 2001), as well as relapse after 
antiestrogen treatment (Mueller et al., 2000), has also been reported.  
However, although increased levels of active MAPK have been shown to be 
significantly associated with ERα phosphorylated at S118 in vitro and in breast 
cancer tumour samples (Britton et al., 2006; Bunone et al., 1996; Joel et al., 1998b; 
Murphy et al., 2004a; Sarwar et al., 2006), phosphorylated S118, which is thought to 
lead to tamoxifen-resistant growth and has been shown to be present in 62% of 
ERα-positive tumours (Murphy et al., 2004b), has also shown to be associated with 
lower grade tumours (Murphy et al., 2004a; Sarwar et al., 2006) and longer disease 
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free survival (Bergqvist et al., 2006; Murphy et al., 2004b) – characteristics 
suggestive of phosphorylated S118 being a good prognostic factor. This is supported 
by in vitro evidence that ERα phosphorylated at S118 interacts with the promoters of 
several estrogen regulated genes in MCF7 cells following estrogen treatment, 
suggesting that phospho-S118 is a marker of functional, intact ligand-dependent ERα 
signalling (Weitsman et al., 2006).  
Studies have reported an increase in levels of both phosphorylated S118 and 
activated MAPK in tamoxifen-resistant cell lines (Sarwar et al., 2006; Vendrell et al., 
2005). However, although an increase in phosphorylated S118 and activated MAPK 
was seen in tumour biopsies taken from tamoxifen-resistant breast cancer patients, 
comparison of pre- and post-tamoxifen resistant biopsies showed increased levels of 
S118 phosphorylation in post-tamoxifen resistant biopsies, this was not linked to an 
increase in activated MAPK compared to the pre-tamoxifen resistant biopsies (Sarwar 
et al., 2006). This suggests that increased activity and over-expression of growth 
factor receptors is not linked to an increase in phosphorylated S118 and that other 
signalling pathways are involved in this increase, perhaps via Cdk7 or IKKα 
mechanisms.  
However, Gee et al. (2005) have detected phosphorylated S118 in tamoxifen-
responsive as well as de novo and acquired tamoxifen-resistant breast tumour cells 
(Gee et al., 2005), whilst another study described above showed improved outcome 
for patients with tumours having low-level S118 phosphorylation (Yamashita et al., 
2008), suggesting that S118 phosphorylation status is not linked to a better 
prognosis. Strong correlations between ERα, active p38 MAPK and active ERK in 
tamoxifen-resistant tumours compared to pre-treatment biopsies have also been 
reported, although this study did not assess levels of phosphorylated S118 (Gutierrez 
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et al., 2005). The contradictions in these findings highlight the need for more study 
into this potential mechanism of tamoxifen-resistance in breast cancer.  
As mentioned previously (section 1.7.4), Pak1 can phosphorylate ERα at 
serine 305 (Rayala et al., 2006). Pak1 is a serine-threonine kinase involved in 
regulating the actin cytoskeleton dynamic and its expression has been shown to be 
deregulated in human cancers leading to increased invasivness of tumours (Adam et 
al., 1998; Balasenthil et al., 2004; Bokoch, 2003; Kumar et al., 2006; Stofega et al., 
2004). Increased expression of Pak1 at the mRNA and protein level has been shown 
in up to 50% of breast cancer tumours (Balasenthil et al., 2004; Vadlamudi et al., 
2000). Active Pak1 has been reported to phosphorylate ERα at S305 in the absence 
of ligand, increasing activity of ERα, (Wang et al., 2002) and causing an inhibition of 
antiestrogenic effects of tamoxifen on ERα in tamoxifen sensitive cell lines (Rayala et 
al., 2006). High nuclear Pak1 expression in primary breast tumours from 
premenopausal women has been linked with features of aggressive types of breast 
cancer and tamoxifen-resistance (Holm et al., 2006). Rayala et al. (2006) show that 
tamoxifen induces Pak1 expression and interaction with ERα in tamoxifen resistant 
breast cancer cell lines, but not tamoxifen sensitive lines, suggesting tamoxifen 
induced Pak1 expression may be linked with maintaining a tamoxifen-resistant cell 
phenotype. They also show evidence that phosphorylation of S305 by Pak1 leads to 
S118 phosphorylation.  
 
1.11.3 Breast cancer cell growth in a reduced estrogen environment 
A key step in the progression of breast cancer is the conversion of cells from 
an estrogen-dependent to an estrogen-independent state; however, the molecular 
mechanisms involved in this switch are poorly understood. Reduction of estrogen 
levels by surgical oophorectomy in pre-menopausal women with hormone-dependent 
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breast cancers causes tumour regression, however, after 12-18 months tumours 
begin to re-grow even in the reduced estrogen environment (Santen et al., 1990). 
Subsequent treatment with AIs to reduce estrogen levels further can promote 
tumour regression again, however, resistance to AIs eventually develops. Resistance 
to AIs typically develops more slowly than that to SERMs and is thought to be due to 
ERα overcoming the estrogen deprived conditions via mechanisms such as elevated 
levels of growth factor and estrogen receptors and increased transduction via the 
MAPK and PI3K pathways (Likhite et al., 2006; Martin et al., 2005; Santen et al., 
2001). 
 An in vitro model of long term estrogen deprivation (LTED), whereby breast 
cancer cell lines are cultured in the absence of estrogen for 6-24 months, has been 
used to investigate mechanisms of ERα hypersensitivity towards estrogen. MAPK has 
been implicated in the development of these mechanisms, with basal levels of MAPK 
being increased in LTED cell lines and inhibition of the enzyme significantly reducing 
hypersensitivity to estrogen (Jeng et al., 2000; Yue et al., 2002; Yue et al., 2003). 
However, MAPK inhibition does not cause complete abrogation of estrogen 
hypersensitivity; LTED cell lines also show increased activity of the PI3K signalling 
pathway, including increased Akt activity (Santen et al., 2005a; Santen et al., 
2005b). Non-genomic activities of estrogen via membrane-localised ERα and 
mediated by the adapter protein Shc, are thought to be in part responsible for the 
activation of these signalling pathways (Song et al., 2002; Zhang et al., 2002b). In 
support of this theory are studies showing that sub-physiological concentrations of 
estrogen are capable of stimulating maximal activation of MAPK in LTED cell lines 
(Santen et al., 2005a) and that association between Shc and ERα is markedly 
enhanced in these lines compared to wild-type cell lines with estrogen stimulating 
Shc activation (Song et al., 2002).  
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Growth of LTED cell lines is inhibited by treatment with the pure anti-
estrogen ICI 182,780 (Martin et al., 2005) showing that the cell lines require ERα 
activity for growth. S118 phosphorylation of ERα has also been noted in LTED cell 
lines, although this was shown not to be due to MAPK-mediated phosphorylation 
pathways but rather stimulated by estrogen, highlighting the continued ligand-
dependency of this cell line (Martin et al., 2005). Estrogen stimulates ERα 
transcriptional activation and also the down-regulation of ERα expression (Nawaz et 
al., 1999a; Saceda et al., 1988). Conversely, reduction in estrogen levels causes an 
increase in ERα levels which is a phenotype of many breast tumours and reported in 
LTED cell lines where it is thought to contribute towards estrogen hypersensitivity 
(Chan et al., 2002; Fowler et al., 2004; Gaskell et al., 1989; Santen et al., 2001; 
Thorpe et al., 1993). Induced high levels of ERα expression in breast cancer cell lines 
have been shown to promote gene activation in the absence of ligand in an AF1-
dependent manner (Fowler et al., 2004). This concentration-dependent activation of 
ERα is independent of AF1 phosphorylation and p160 coactivators (Fowler et al., 
2004; Fowler et al., 2006) and is thought to come about due to interaction of 
unliganded ERα directly with the basal transcription machinery through interactions 
which are usually too weak to promote transcriptional activation under normal levels 
of ERα expression (Fowler et al., 2006).  
 
1.11.4 Anti-estrogen-induced gene expression 
As mentioned previously, estrogen-induced activation of ERα stimulates 
transcriptional activities of ERα which include the activation of genes but also the 
repression of many genes (Frasor et al., 2003). Microarray studies have also been 
used to profile the effect of antiestrogens on gene expression in breast cancer cells 
and these studies have shown that not only do different antiestrogens have different 
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gene expression profiles, but they also have an antagonistic effect on the repressive 
actions of estrogen (Frasor et al., 2004). Many of the genes repressed by estrogen 
are anti-proliferative and pro-apoptotic with anti-estrogen treatment promoting 
transcription of these genes, expression of which would aide the antiproliferative 
effect of endocrine treatments. However, a number of estrogen-regulated genes 
which are down regulated are involved with cell growth and proliferation, including 
EGFR (Frasor et al., 2004; Gee et al., 2003; Wilson and Chrysogelos, 2002; Yarden 
et al., 2001). Tamoxifen-induced expression of EGFR has been shown to cause 
activation of MAPK and Akt at levels high enough to maintain S118 phosphorylation 
of ERα. The increased expression of EGFR over time during tamoxifen treatment is 
thought to contribute towards tamoxifen-resistant growth due to induced activation 
of ERα and subsequent expression of estrogen-regulated growth factors, such as 
amphiregulin, which can then activate EGFR and stimulate cell growth by this 
alternative signalling pathway (Britton et al., 2006; Gee et al., 2003; Knowlden et al., 
2003; Yarden et al., 2001).  
 Tamoxifen has also been shown to regulate a set of genes not regulated by 
either estrogen or other SERMs (Frasor et al., 2006). Whilst microarray studies 
showed that a number of these genes have potential tumour suppressor roles, such 
as SOCS1 and PTPRG, the expression of two genes (YWHAZ and LOC441453) were 
found to correlate with a reduced disease-free survival in breast cancer patients 
(Frasor et al., 2006). Little is known about LOC441453, however, YWHAZ (also 
known as 14-3-3ξ) is a scaffold protein belonging to the highly conserved 14-3-3 
family of proteins which regulate the cell cycle and prevent apoptosis. YWHAZ is 
thought to play a central role in insulin receptor and EGFR signalling and in cell cycle 
regulation by stabilizing and activating key signalling proteins, such as Akt and c-raf 
(Ogihara et al., 1997; Oksvold et al., 2004). Frasor et al. (2006) suggest that the 
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expression of these two genes in breast tumours could indicate a more aggressive 
form of cancer since increased expression of YWHAZ could lead to increased 
signalling of cell cycle progression pathways. In support of this is clinical evidence 
showing that YWHAZ expression is associated with a poor outcome following 
tamoxifen treatment (van 't Veer et al., 2002). 
 The expression of genes in breast cancer cells will obviously impact on how 
cell growth is affected by endocrine treatments. Analysis of any alterations in gene 
expression due to different treatments could provide a way of predicting the 
outcomes of treatment and may provide novel targets for future treatments that 
could be administered in conjunction with other endocrine therapies to prevent 
recurrence of tumour growth or even formation of resistance to endocrine therapies. 
 
1.11.5  Transcriptional Coregulators and resistance 
Denner et al. demonstrated that treatments which enhance activity of kinases 
or inhibit phosphatase activities cause SR activation through increasing the activity of 
coactivators (Denner et al., 1990). These authors showed that cells transfected with 
chicken PR and a PR-responsive reporter gene, when treated with 8-bromo-cyclic 
adenosine monophosphate (8-Br-cAMP), a stimulator of protein kinase A (PKA), 
showed hormone-independent, but cPR-dependent, activation of the reporter. 
Subsequent studies revealed that 8-Br cAMP caused activation of p42/p44 MAPK and 
increased phosphorylation of SRC1 which contributed to the ligand-independent 
activation (Rowan et al., 2000). Subsequent studies have shown that activation of 
ERα coactivators is capable of causing ligand-independent activation of the receptor 
and is a potential mechanism of endocrine-resistant growth in breast cancer cells. 
Many breast cancers exhibit increased expression of growth factors and their 
receptors, which is linked to poor prognosis and development of resistance to 
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endocrine therapies (Benz et al., 1992; Gutierrez et al., 2005; Klijn et al., 1992; 
Meng et al., 2004b; Pietras et al., 1995; Sainsbury et al., 1985; Shou et al., 2004). 
Indeed, tyrosine kinase inhibitors used in conjunction with tamoxifen have been 
shown to restore antagonistic activities of tamoxifen as they inhibit these signalling 
pathways (Chu et al., 2005; Kurokawa et al., 2000; Shou et al., 2004; Witters et al., 
2002). Activation of growth factor signalling pathways has been shown to affect the 
activity of a number of ERα coactivators resulting in an increase in ERα activity in 
breast cancer, some instances of which will be discussed below. 
The coactivator AIB1/SRC3 is overexpressed in over 50% of breast cancers 
and is thought to play an important role in breast cancer pathogenesis (Anzick et al., 
1997; Torres-Arzayus et al., 2004; Zhou et al., 2003). It has been suggested that the 
ability of growth factors to modulate estrogen action may be mediated through 
MAPK activation of AIB1/SCR3 (Font de Mora and Brown, 2000). As mentioned 
above, estrogen/ERα can rapidly stimulate MAPK activity (section 1.6). One apparent 
target of estrogen-stimulated MAPK activity appears to be AIB1/SRC3, with MAPK 
phosphorylation of AIB1 stimulating its transcriptional activity (Font de Mora and 
Brown, 2000; Marquez et al., 2006; Zheng et al., 2005). AIB1 is capable of shuttling 
between the nucleus and the cytoplasm and the phosphorylation status of AIB1 has 
also been linked to an increased dwell-time in the nucleus (Qutob et al., 2002; Wu et 
al., 2002a). It has been suggested that constitutively active HER2 signalling, an 
activator of MAPK, would result in elevated AIB1 phosphorylation and activity, hence 
increasing ERα activity (Amazit et al., 2007; Shou et al., 2004). Furthermore, 
overexpression of AIB1 in transgenic mice causes the formation of malignant 
mammary tumours (Torres-Arzayus et al., 2004) and correlation between high AIB1 
and HER2 expression levels and poor response to tamoxifen has been reported in 
breast cancer patients (Kirkegaard et al., 2007; Osborne et al., 2003).  
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As mentioned previously, the activity of AF1 is regulated by phosphorylation, 
which promotes the recruitment of coactivators to the ERα via the LBD/AF2 and 
interactions with AF1 (Webb et al., 1998). Moreover, the ATP-dependent RNA 
helicase p68 has been identified as an ERα-specific coactivator. The interaction of 
p68 is enhanced by MAPK-mediated phosphorylation of ERα at S118. Only the 
activity of AF1 and not AF2 is potentiated by p68 and the coactivator activity of p68 
has been shown to be specific to ERα, even whilst ERα is bound by tamoxifen 
(Endoh et al., 1999). The RNA helicase activity of p68 (Hirling et al., 1989) is not 
required for the coactivator function of p68 and is instead due to p68 acting as a 
bridge between AF1 and other coactivators, including CBP (Endoh et al., 1999) and 
SRC1/TIF2 (Watanabe et al., 2001). Increased expression of p68 in breast cancer 
cell lines has been shown to cause tamoxifen-induced activation of ERα via AF1 
(Fujita et al., 2003), suggesting a potential mechanism for activation of tumour cell 
growth in the presence of tamoxifen. 
More than 80% of breast tumours exhibit an increased activity of the non-
receptor Src tyrosine kinase compared with normal breast tissue (Verbeek et al., 
1996). Src activation leads to the activation of signal transduction cascades including 
the MAP kinase subgroups ERKs via Raf/MEK/ERK kinase cascades and c-Jun N-
terminal kinases (JNKs) via MEKK/JNKK/JNK. Feng et al. (Feng et al., 2001) have 
shown that S118 phosphorylation of ERα via Src activation of the Raf-MEK-ERK 
signalling cascade enhances ERα AF1 activity (Kato et al., 1995). They have also 
shown that Src activation of the MEKK/JNKK/JNK signalling cascade pathway 
enhances ERα action in a S118-independent manner due to Src-mediated enhanced 
activity of the CBP and GRIP1/SRC2 coactivators which can bind directly to and 
activate the AF1 (Feng et al., 2001; Weitsman et al., 2006).  GRIP1 also contains an 
EGF-regulated transcriptional activation function which is activated due to 
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phosphorylation by p38 MAPK and promotes interaction with CBP (Frigo et al., 2006; 
Lopez et al., 2001). Levels of GRIP1 are seen to be increased in a proportion of 
breast tumours (Kurebayashi et al., 2000). 
Phosphorylation of the corepressor SMRT by MEKK1, a downstream mediator 
of the MAPK signalling pathway, disrupts interaction of the corepressor with 
transcription factors such as ERα (Hong et al., 1998; Lavinsky et al., 1998; Wagner 
et al., 1998) and also promotes nuclear export of the corepressor (Hong and 
Privalsky, 2000). Activation of MEKK1 does not however affect interactions of the 
closely related corepressor NCoR with transcription factors (Jonas and Privalsky, 
2004; Jonas et al., 2007). SMRT and NCoR are expressed as different splice variants 
which have different affinities for transcription factors and are expressed at varying 
levels in different tissues (Downes et al., 1996; Goodson et al., 2005; Malartre et al., 
2004). SMRT splice variants respond differently to phosphorylation by the MAPK 
signalling pathway with some showing more sensitivity and a greater inhibitory 
response (Jonas et al., 2007). Potentially therefore, expression in breast cancer cells 
of SMRT splice variants with a greater response to MAPK signalling, could cause an 
increase in the activity of ERα. 
Proline-, glutamic acid-, leucine-rich protein 1/modulator of the non-genomic 
activities of ER (PELP1/MNAR) has been identified as a coactivator of ERα and has 
similar characteristics to the p160 family of SR coactivators in that it contains an 
LXXLL motif and has a molecular weight of 160kDa (Vadlamudi et al., 2001; Wong et 
al., 2002). Although PELP1/MNAR acts as a coactivator for ERα, it has been reported 
to act as a corepressor for a range of other transcription factors (Choi et al., 2004). 
PELP1 demonstrates no intrinsic transcriptional activity, suggesting that it acts in a 
similar way by recruiting cofactors to the liganded ERα (Vadlamudi et al., 2001). 
MNAR, which was subsequently shown to be the same protein as PELP1 (Balasenthil 
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and Vadlamudi, 2003), was identified as a ligand-dependent ERα-interacting protein 
which stabilises the interaction between ERα and Src family of tyrosine kinases at the 
cell membrane, leading to activation of the MAPK signalling pathway (Barletta et al., 
2004; Wong et al., 2002). PELP1/MNAR has also been implicated in the estrogen-
regulated activation of the PI3K/Akt signalling pathway, with studies showing that 
PELP1/MNAR mediates an estrogen-dependent association of ERα and the p85 
regulatory subunit of PI3K, which is dependent of the phosphorylation of 
MNAR/PELP1 by activated c-Src and leads to activation of the PI3K/Akt signalling 
pathway (Greger et al., 2007). Overexpression of PELP1/MNAR causes an increase in 
the transcriptional activity of ERα (Vadlamudi et al., 2001; Wong et al., 2002) and 
PELP1/MNAR expression has been reported to be increased in breast tumours 
compared to normal breast tissue (Vadlamudi et al., 2001), with higher levels of 
expression correlating to higher grade node-positive invasive tumours (Rajhans et 
al., 2007). The retinoblastoma protein (pRb) is involved in cell cycle progression and 
causes cell cycle arrest in the G1 phase by inhibiting the expression of genes 
required for progression into the S phase (Weinberg, 1995). Continuation of the cell 
cycle requires inhibition of pRb by phosphorylation of the protein, predominantly 
controlled by the cyclinD/CDK4 and cyclinE/CDK2 enzymes (Harbour and Dean, 
2000). PELP1/MNAR has been shown to interact with pRb, increasing 
phosphorylation and therefore inhibition of pRb, allowing cell cycle progression 
(Balasenthil and Vadlamudi, 2003). A role for PELP1/MNAR in estrogen-mediated cell 
migration, cytoskeletal changes and anchorage-independent cell growth has been 
reported, suggesting that PELP1/MNAR is an oncogene, the expression of which is 
deregulated during cancer progression (Rajhans et al., 2007). 
Alterations to different components of the cyclin/CDK/p16Ink4A/pRb pathway 
through overexpression, mutation, and epigenetic gene silencing are a very common 
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characteristic of human cancers (Malumbres and Barbacid, 2001). The activation of 
CDKs by the binding of cyclins controls the progression of the cell cycle; cyclin D1 is 
considered a weak oncogene and its overexpression has been shown to result in 
estrogen-independent growth of breast cancer cells in vitro (Bindels et al., 2002) and 
development of mammary carcinoma in mouse models (Wang et al., 1994). The 
cyclin D1 gene is amplified in approximately 15% of breast cancers (Jirstrom et al., 
2005; Ormandy et al., 2003) and the protein is overexpressed in 30–50% of breast 
cancers (Alle et al., 1998; Buckley et al., 1993; Gillett et al., 1994; Hui et al., 1996). 
Expression of cyclin D1 is regulated by estrogen (Altucci et al., 1996; Castro-Rivera 
et al., 2001; Eeckhoute et al., 2006; Sabbah et al., 1999) and dysregulation of PKA 
has been linked to an increase in cyclin D1 protein half-life (Nadella and Kirschner, 
2005). Therefore, overexpression of cyclin D1 in breast cancer cells is likely due to 
increased activity of ERα and possibly PKA. Antiestrogen treatment has indeed been 
shown to cause cell cycle arrest in the G1 phase and inhibit cell proliferation due to 
reduced cyclin D1/CDK4 activity (Sutherland et al., 1983; Watts et al., 1995). 
Although cyclin D1 overexpression is associated with a better outcome for breast 
cancer patients (Gillett et al., 1996; Jirstrom et al., 2003; Nielsen et al., 1997; Pelosio 
et al., 1996), possibly due to its ability to repress the antiapoptotic transcription 
factor signal transducer and activator of transcription 3 (STAT3) (Bienvenu et al., 
2001; Ishii et al., 2006; Quintanilla-Martinez et al., 2003), its overexpression is also 
linked to tamoxifen resistance due to its ability to mimic estrogenic effects on cell 
cycle progression (Bindels et al., 2002; Hui et al., 2002; Kilker et al., 2004; Prall et 
al., 1998; Wilcken et al., 1997). Cyclin D1 also acts as a coactivator for ERα 
independently of CDKs and potentiates the activity of ERα in the presence of 
estrogen whilst causing ligand-independent activation of ERα, which is not inhibited 
by antiestrogens, by recruiting SRC1 to the receptor (Neuman et al., 1997; Zwijsen 
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et al., 1998; Zwijsen et al., 1997). Treatment with tamoxifen abolishes cyclin D1-
mediated repression of STAT3 and growth suppression by inducing a redistribution of 
cyclin D1 from STAT3 to ERα, which results in the activation of both STAT3 and ERα 
(Ishii et al., 2008). This may well be an important mechanism involved in the 
transition from tamoxifen-responsive to tamoxifen-resistant breast cancer cell 
growth. 
Taken together, there is considerable evidence that crosstalk between 
estrogen signalling through ERα and cell surface receptors, other signal transduction 
pathways, impacting on phosphorylation of transcriptional coregulators is likely to be 
an important feature of breast cancer progression and response to endocrine 
treatments.  
 
1.12 Aim of study 
Antagonistic actions of tamoxifen in breast cancer cells occur due to inhibition of 
the AF2 domain of ERα. Activation of the AF1 domain, not normally involved with 
receptor activation in breast cells, is likely to play an important role in enabling 
tamoxifen-resistant breast cancer cell growth. Serine residues 104, 106 and 118 
have previously been identified as phosphorylation sites within the AF1 that are 
phosphorylated in a ligand-independent manner by MAPK, a downstream mediator of 
growth factor signalling pathways. Increased expression and activity of growth 
factors and receptors, such as EGFR and HER2, occur in a large number of breast 
cancers and overexpression of HER2 in ERα positive breast cancers is linked to a 
poor a prognosis and tamoxifen-resistant tumour growth. During normal ERα 
activity, estrogen binding induces recruitment of coactivator proteins via the AF2 to 
the estrogen regulated gene which initiates transcription by coordinating binding of 
the basal transcription machinery. In breast cancer cells which are sensitive to 
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tamoxifen, this recruitment of coactivators and therefore activation of transcription, 
is inhibited by tamoxifen binding to ERα. However, over time, resistance to this 
mechanism of receptor inhibition occurs. We hypothesise that phosphorylation of 
residues S104, S106 and S118 within the AF1 cause ligand-independent activation of 
ERα in the presence of tamoxifen by recruiting coactivators to the AF1. However, as 
outlined above, phosphorylation of coactivators and corepressors may also be 
important for the crosstalk between cell surface receptors such as EGFR and HER2, 
and ERα. In order to investigate the importance of AF1 phosphorylation sites, 
therefore, the estrogen-responsive and ERα-positive MCF7 breast cancer cell line was 
stably transfected with ERα in which S104, S106 and S118 were substituted by 
alanine or glutamic acid residues. This would allow the importance of these 
phosphorylation sites for mediating estrogen responses to be determined directly. 
Stable lines expressing ERα and ERα AF1 phosphorylation site mutants were 
characterised for their growth response to estrogen withdrawal and to anti-
estrogens, as was expression of estrogen-regulated genes, in order to test the 
importance of these phosphorylation sites in MCF7 cells. The results of these studies 
are presented in the following chapters. 
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2 MATERIALS AND METHODS 
 
2.1 Materials 
2.1.1 General chemicals and reagents 
All chemicals were supplied by BDH Laboratory Supplies/Merck (Poole, UK), 
Sigma-Aldrich (Dorset, UK) or Fisher Scientific (Leics, UK), unless otherwise stated. 
Molecular biology grade reagents were used, unless otherwise stated.  
 
2.1.2 General stock solutions 
Standard solutions listed in table 2.1 were made by dissolving the appropriate 
quantity of reagent in distilled, de-ionised water (ddH2O) then autoclaved and stored 
at room temperature, unless otherwise stated. 
 
Table 2.1 General stock solutions 
 
10X TBE 89mM Tris base, 89mM Boric acid, 2mM 
Na-EDTA, pH 8.0 
 
TE Buffer 10mM Tris-HCl pH7.5, 1mM Na-EDTA,  
pH 8.0 
 
Sodium ethylene diamine tetra-acetate 
(Na EDTA) 
 
0.5M Na-EDTA, pH 8.0. 
10% lauryl sodium dodecyl sulphate  
(SDS) 
 
10% w/v SDS, pH 7.0. Filter sterilised. 
Not autoclaved. 
10X phosphate buffered saline (PBS) 136mM NaCl, 3mM KCl, 8mM Na2HPO4, 
1.5mM KH2PO4 
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2.1.3 Cell culture consumables and reagents 
Tissue culture plastics were supplied by Corning/Appleton Woods 
(Birmingham, UK) and Triple Red Laboratory Technology (Bucks, UK). A NuAIRE DH 
Autoflow CO2 Air-Jacketed Incubator (NuAIRE, Oxon, UK) maintained at 5% CO2 was 
used to incubate cell cultures and cell manipulation was carried out in a NuAIRE class 
II, ducted laminar flow safety cabinet (NuAIRE, Oxon, UK). Dulbecco’s Modified 
Eagle’s Medium (DMEM) was supplied by Invitrogen (Paisley, UK). 0.02% Na EDTA 
solution, 10x trypsin solution and 5mg penicillin/streptomycin/L-glutamine (P/S/G) 
solution was supplied by Sigma-Aldrich (Dorset, UK). Phenol red free DMEM and fetal 
calf serum (FCS) were purchased from GIBCO (GibcoBRL Life Technologies, Paisley, 
UK). Dextran-coated charcoal-treated FCS (DSS), prepared to remove steroids, 
including estrogens from the FCS, was purchased from Globepharm (Surrey, UK). 
17β-estradiol (E2), 4-hydroxytamoxifen (OHT), epidermal growth factor (EGF) and 
insulin were obtained from Sigma-Aldrich (Dorset, UK). ICI 182,780 (ICI) and U0126 
were obtained from Tocris Biosciences (Avonmouth, UK). Hygromycin B was supplied 
by Invitrogen (Paisley, UK) and G418 was purchased from Sigma-Aldrich (Dorset, 
UK). Dimethyl sulphoxide (DMSO) was supplied by GIBCO (GibcoBRL Life 
Technologies, Paisley, UK). 
 
2.1.4 Molecular size markers 
The molecular weights of protein bands resolved using SDS-polyacrylamide 
gel electrophoresis (SDS-PAGE) techniques were estimated by comparison with the 
Full Range Rainbow marker (MW 250, 160, 105, 75, 50, 35, 30, 25, 15, 10 kDa) 
supplied by Amersham Life Sicence (Bucks, UK). The sizes of DNA fragments were 
estimated by comparison with GeneRuler 1kb DNA ladder (250-10,000 base pairs) 
supplied by Fermentas Life Sciences (York, UK). The sizes of RNA were estimated by 
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comparison with GeneRuler Low Range DNA ladder (25-700 base pairs) purchased 
from Fermentas Life Sciences (York, UK). 
 
2.1.5 Sundries 
Polypropylene microfuge tubes were supplied by Corning/Appleton Woods Ltd 
(Birmingham, UK). Thin-walled 0.2ml PCR tubes were supplied by Advanced 
Biotechnologies Ltd (Surrey, UK). Whatman 3MM filter paper was obtained from 
Whatman International Ltd (Kent, UK). Hybond-ECL nitrocellulose blotting membrane 
and Hyperfilm-ECL autoradiography film was supplied by Amersham Biosciences 
(Bucks, UK).  
 
2.1.6 Laboratory equipment 
Centrifugation steps for volumes under 1.5mls were carried out using a 
Sorvall®pico table top centrifuge. An Innova 2000 platform shaker (New Brunswick 
Scientific, USA) was used for all shaking steps carried out, unless otherwise stated. 
 
2.2 Methods 
2.2.1 Routine tissue culture 
The MCF-7 breast cancer cell line and derived lines were maintained at 37oC 
with 5% CO2 in DMEM supplemented with 10% FCS, 100μg/ml P/S/G, 10-8M 
estrogen and 0.1μg/ml doxycycline (DOX), which is a more stable analogue of 
tetracycline. Where appropriate, the medium was supplemented with the selection 
antibiotics Hygromycin B and G418, both at a concentration of 1μg/ml, during 
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routine maintenance of the cells, which were omitted one week before recruitment 
into and during experiments carried out using the cells.  
Cultures were grown to ~80% confluencey then washed in sterile phosphate 
buffered saline (PBS) and treated with trypsin (1x trypsin in 0.02% Na EDTA) to 
release adherent cells from the plastic. Culture medium was then added to dilute the 
trypsin 1:3 and cells were passaged 1:5. Cultures were routinely maintained in T150 
flasks. 
Aliquots of cells were regularly frozen by pelletting 5 x 106 cells in the growth 
phase of the logarithmic growth curve by centrifugation for 5 minutes an 1300 rpm 
and re-suspending the pellet in 1ml of freezing-down medium (10% DMSO, 90% 
FCS). Cells were transferred to 2ml cryovials and stored at -80°C for 48 hours before 
being placed in liquid nitrogen for long-term storage. 
 
2.2.2 Preparation of cell lysates using hot lysis buffer 
Cell lysates for protein analysis were generally prepared using the hot lysis 
buffer technique. Cells were washed twice with PBS warmed to 37°C and excess PBS 
removed by aspiration. 0.1ml of 2x SDS-PAGE sample buffer (125mM Tris-HCl, 
pH6.4, 4% v/v SDS, 20% v/v glycerol, 400mM DTT, 0.002% bromophenol blue) 
heated to 100°C was added per 1x106 cells. The cells were collected by scraping off 
the plates using a rubber policeman and transferred to a microfuge tube and 
incubated at 100°C for 10 minutes before cooling on ice, aliquoting and storing at -
80°C. 
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2.2.3 DNA Manipulations 
2.2.3.1 Cell transformation using competent TG2 cells 
Competent E.coli TG2 strain was prepared using the Hanahan method 
(Hanahan 1983). A starter culture was prepared by inoculating 5ml of SOB Medium 
(0.5% w/v yeast extract, 2% w/v tryptone, 10mM NaCl, 2.5mM KCl, 20mM MgSO4) 
with a single bacterial colony and incubating overnight at 37°C with shaking. 3ml of 
the starter culture was added to 300ml of SOB medium and incubated at 37°C until 
the OD at 600nm reached between 0.4-0.6. The culture was placed on ice for 15 
minutes then centrifuged at 2500rpm at 4°C for 15 minutes. The resulting pellet was 
resuspended in 90ml of RF1 buffer (100mM RbCl; 50mM MnCl2.4H2O; 30mM KOAc, 
pH 7.0; 10mM CaCl2.2H2O; 15% glycerol; pH 5.8) and incubated on ice for 15 
minutes before centrifugation at 2500rpm at 4°C for 15 minutes. The pellet was 
resuspended in 21ml of RF2 buffer (10mM MOPS, pH6.8; 10mM RbCl; 75mM 
CaCl2.2H2O; 15% glycerol) and incubated on ice for 15 minutes. 50μl of the 
competent cells were transformed by incubating with 100ng of either pxpERE or 
pxpRL-TK DNA on ice for 30 minutes. Transformation mixtures were then incubated 
at 42oC for 2 minutes followed by incubation on ice for 3 minutes. 500μl of LB broth 
was added to the transformation mixtures and the culture incubated at 37oC with 
shaking (150rpm) for 60 minutes using a G2 (New Brunswick Scientific, NJ, USA) 
incubator. The culture was then centrifuged at 6000rpm for 3 minutes and the pellet 
was then resuspended in 50μl of fresh LB broth and spread on selective LB agar 
plates and incubated at 37oC overnight.  
LB broth was prepared by suspending 25.0g LB broth (MILLER) 
granules (Merck, DE, USA) (10g bacto-tryptone; 5g bacto yeast; 10g NaCl, 
pH7.0) in 1L of ddH2O and autoclaving the solution. Selective LB agar plates 
 91 
were made by suspending 37.0g LB agar (MILLER) (Merck, DE, USA) in 1L of 
ddH2O (10.0g/L peptone from casein, 5.0g/L yeast extract, 10.0g/L NaCl, 
12.0g/L Agar-agar) and autoclaving the solution. After cooling, ampicillin was 
added to a final concentration of 50μg/ml.  
 
2.2.3.2  Large scale plasmid preparation (maxi prep) 
An individual bacterial colony from TG2 cells transformed with the plasmid of 
interest was used to inoculate 1ml of selective LB broth and incubated for 8 hours at 
37oC with shaking (150rpm). This starter culture was then diluted 1:500 into a large 
conical flask containing 500ml of selective LB broth containing 50μg/ml ampicillin and 
incubated over night at 37°C with shaking at 150 rpm. 
Plasmid DNAs were prepared from the bacterial cell culture using the Qiagen-
tip500 Plasmid Maxi Purification Kit (Qiagen, DE) following the handbook 
instructions.  For buffers used see table 2.2. The bacterial cells were harvested by 
centrifugation at 6000rpm for 15 minutes at 4°C using a Sorvall RC6 centrifuge. The 
bacterial pellet was resuspended in 10ml of resuspension buffer (Buffer P1), then 
lysed by adding 10ml of lysis buffer (Buffer P2) and incubated at room temperature 
for 5 minutes. The lysis buffer activity was neutralized by adding 10ml of Buffer P3, 
followed by incubation on ice for 20 minutes. The lysed cells were centrifuged at 
13,000 rpm for 30 minutes at 4°C using a Sorvall RC6 to remove cell debris. The 
Qiagen-tip 500 was prepared by applying 10ml of equilibration buffer (Buffer QBT), 
allowing emptying by gravity flow. A 3-layer thick piece of muslin was placed over 
the Qiagen-tip 500 before adding the supernatant from the Buffer P3 step, to filter 
cell debris. The tip was washed twice with 30ml of wash buffer (Buffer QC) before 
the DNA was eluted with 15ml of Buffer QF. The DNA was precipitated by adding 
 92 
10.5ml of isopropanol to the eluted DNA and centrifuged at 11,000rpm for 30 
minutes at 4°C using a Sorvall RC6. The DNA pellet was further cleaned by carrying 
out phenol chloroform extraction and ethanol precipitation.  
 
Table 2.2 Qiagen DNA maxi preparation buffers 
Buffer P1 50 mM Tris-HCl, pH 8.0; 10mM EDTA; 100μg/ml Rnase A 
 
Buffer P2 200 mM NaOH, 1% SDS (w/v) 
 
Buffer P3 3.0 M potassium acetate, pH5.5 
 
Buffer QBT 750 mM NaCl; 50 mM MOPS, pH7.0; 15% isopropanol (v/v); 0.15% 
Triton X-100 (v/v) 
 
Buffer QC 1.0 M NaCl; 50 mM MOPS, pH7.0; 15% isopropanol (v/v) 
 
Buffer QF 1.25 M NaCl; 50 mM Tris-Cl, pH8.5; 15% isopropanol (v/v) 
 
TE Buffer 10mM Tris, pH8; 1mM EDTA 
 
 
2.2.3.3  Phenol-chloroform extraction 
The DNA pellet obtained from the QIAGEN column purification was 
resuspended in 100μl of TE buffer. The DNA concentration was then 
measured using a spectrophotometer (NanoDrop ND-1000, Labtech 
International UK) and 100μg of DNA was diluted in TE buffer to give a volume 
of 200μl. 100μl of phenol-chloroform was added to the DNA, vortexed and 
then centrifuged at 13,000rpm for 5 minutes. The top layer was transferred to 
a fresh microfuge tube and 1/10 volume of ice-cold 3M sodium acetate (pH 
5.2) was added and then vortexed. 2-3 volumes of ice-cold 100% ethanol 
was added and samples were placed at -70oC for 30 minutes. Samples were 
then centrifuged for 10 minutes at 13000rpm. The supernatant was removed 
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and 500μl of 70% ethanol was added to the cell pellet before centrifugation 
at 13,000rpm for 10 minutes. The supernatant was then removed and the 
DNA pellet allowed to air dry on the bench at room temperature for 20 
minutes. The DNA pellet was re-suspended in 100μl TE buffer by incubation 
at 4oC over night and DNA concentration determined, as above. 
 
2.2.3.4  DNA sequencing 
DNA sequencing was carried out using the dideoxy chain termination method 
carried out by Genomics Core Laboratory, MRC Clinical Sciences, Imperial College. 
3.2pmol of forward and reverse primers (Table 2.3) were added to 9μg of DNA and 
diluted to a final volume of 10μl with sterile water. 
 
Table 2.3 Primer sequences for luciferase plasmid DNA sequencing 
Primer Sequence 
Renilla-F1 5’ –CCA GGT CCA CTT CGC ATA TT- 3’ 
Renilla R1 5’ –ACC ACT GCG GAC CAG TTA TA- 3’ 
Renilla F2 5’ –ATG GGA TGA ATG GCC TGA TA- 3’
Renilla R2 5’ –ACC AGA TTT GCC TGA TTT GC- 3’ 
 
 
2.2.3.5  Restriction enzyme digestion 
0.5-1 µg of DNA was digested in a volume of 20 µl, with restriction enzymes 
in the recommended digestion buffer (New England Biolabs, USA) and at the 
recommended temperature, over 1-2 hours, at which point 2μl of 6x loading dye 
(10 mM Tris-HCl, pH 7.6; 0.03% bromophenol blue; 0.03% xylene cyanol FF; 60% 
 94 
glycerol; 60 mM EDTA) (Fermentas Life Sciences (York, UK)) was added before 
analysis by agarose gel electrophoresis as described in section 2.2.4.3.1.  
 
2.2.4 MCF-7 cell transfection 
MCF-7 cells were grown in DMEM without phenol red supplemented with 
P/S/G, 5% DSS plus or minus 0.1μg/ml DOX for 72 hours. Cells were trypsinised as 
described in section 2.2.1, then plated in 24-well plates, 8 x104 cells per well, in 
0.5mls DMEM without phenol red supplemented with P/S/G, 5% DSS plus or minus 
0.1μg/ml DOX. After 24 hrs the cells were transfected using FuGENE6 (Roche Applied 
Science, Indianapolis, USA)) which works by forming micelles around the DNA 
allowing fusion and transportation across the cell membrane. For this 0.1μg pxpERE, 
0.1μg RL-TK, 0.5μg BSM were mixed and the volume made to a total of 50μl, per 
well. 2 µl of FuGENE6 was added to 48 µl of DMEM lacking phenol red. After a 5 
minute incubation the DNA mix was added drop-wise to the FuGENE6 in DMEM 
lacking phenol red. They were then incubated together for 15 minutes at room 
temperature. 
Media on the 24 well plates was replaced with fresh media containing plus or 
minus Dox and 30 minutes later the cells were transfected per well with 100μl of the 
FuGENE6/DNA mix added drop-wise. Cells were then incubated for 5 hrs at 37oC 
before replacing the media with fresh media containing the ligands 17β-estradiol (E2; 
10-8M), 4-hydroxytamoxifen (OHT; 10-7M) and ICI 182, 780 (ICI; 10-7M) in the 
presence and absence of Dox. Since the ligands were dissolved in ethanol, an equal 
volume of ethanol was added to the no ligand controls. The luciferase activity was 
then measured after 24 hours, using the Dual-Luciferase Reporter Assay system 
(Pomega, USA). The cells were washed with 0.5ml of ice cold PBS then lysed by 
adding 80μl passive lysis buffer (Promega, USA) and incubated at room temperature 
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with gentle shaking for 15 minutes. 50μl of the cell lysate was added to a 96 well 
OptiPlate (PerkinElmer, UK) and 50μl of the DualGlo firefly reagent was added to the 
cells in order to initiate firefly bioilluminescence which was measured using a 
TopCount NXT Microplate Scintillation & Luminescence Counter (Parkard Biosciences, 
USA). 50μl of the DualGlo Stop reagent was then added and the Renilla luciferase 
activity was measured as an internal control which was used to normalise the firefly 
luciferase readings. 
 
2.2.5  Sulphorhodamine B (SRB) Growth Assay 
Cells were grown with or without Dox for 96 hours, then plated at 3 x103 cells 
per well in a 96 well plate in 150μl of DMEM without phenol red, supplemented with 
5% DSS and P/S/G in the presence or absence of Dox. Cells were plated with 6 
replicates and 200μl of PBS was added to all wells around the edge of the plate to 
reduce evaporation of media from wells being utilised in the experiment. After cells 
were plated, 50μl of media containing ligand at 4x the required final concentration 
was added to each well, such that the final concentration of E2 was 10-8M and that 
of OHT and ICI was 10-7M. Ethanol was as added to the no ligand controls. 
Epidermal growth factor (EGF) (Sigma-Aldrich, Dorset, UK) was reconstituted in 
DMEM without phenol red containing 5% DSS and used over the range of 
concentrations 1ng/ml, 10ng/ml and 100ng/ml.  Insulin (Sigma-Aldrich, Dorset, UK) 
was reconstituted in 10mM HCl and used over the range of concentrations 0.1μg/ml, 
1μg/ml and 10μg/ml. An equal volume of a 10mM HCl solution was added to cells 
not treated with insulin. The MEK inhibitor, U0126 (Tocris Biosciences, UK), was 
reconstituted in DMSO and used at a final concentration of 10μM. An equal volume 
of DMSO was added to cells not treated with U0126 as a control. 
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SRB staining of cells was carried out using the Skehan method (Skehan et al., 
1990). Cells were fixed by adding 100μl per well of ice-cold 40% trichloroacetic acid 
(TCA) gently so as not to disrupt the cells and incubating at room temperature for 1 
hour. Plates were then washed 5 times in running tap water at an angle to allow the 
wells to fill indirectly. Cells were stained by adding 100μl per well of 0.4% (w/v) SRB 
(Sigma Aldrich, Dorset, UK) in 1% acetic acid and incubating at room temperature 
for 30 minutes. Plates were washed 5 times in 1% acetic acid and allowed to air dry 
overnight at room temperature. Dye was solubilised by adding 100μl per well of 
10mM Tris-base and agitating the plate rapidly using a PMS-1000 shaker (Grant 
Instruments, UK) for 10 minutes. Absorbance was read using a spectrophotometer 
(Anthos 2001, Anthos Labtech Instruments, Austria) at a wavelength of 492nm.  
 
2.2.6 RNA analysis 
2.2.6.1 RNA Extraction  
Cells were seeded 7.5 x105 in 10cm plates with 10mls of DMEM without 
phenol red, supplemented with 5% DSS and P/S/G, plus and minus Dox. Cells were 
harvested 96 hours later, with E2 (10-8 M) being added 8 or 16 hours prior to 
harvesting. RNA was extracted using the Qiagen RNeasy Mini Kit. Details of all 
buffers was withheld by the the manufacturer. Cells were washed twice with PBS and 
lysed in 600μl of Buffer RLT. The lysate added to a QIAshredder spin column and 
centrifuged for 2 minutes at full 10,000 rpm at room temperature. An equal volume 
of 70% ethanol was added, then after mixing was transferred 700μl at a time to an 
RNeasy spin column and centrifuged for 15 seconds at 10,000rpm. The flow through 
was discarded and the column washed with 350μl of Buffer RW1 by centrifuging for 
15 seconds at 10,000rpm. DNase digestion was carried out using the RNase-free 
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DNase set (Qiagen, USA). The DNase I was reconstituted in ddH2O (3 Kunitz units 
per μl) and 10μl diluted with 70μl of Buffer RDD. The 80μl of diluted DNase I was 
added directly onto the spin column membrane and incubated at room temperature 
for 15 minutes. The column was then washed with 350μl of Buffer RW1 and 
centrifuged for 15 seconds at 10,000rpm. The spin column was washed twice with 
500μl of Buffer RPE and centrifuged for 15 seconds at 10,000rpm. The column was 
centrifuged for 15 seconds at 10,000rpm with no buffer added to remove any 
residual buffer before RNA was eluted by adding 50μl of RNA-free H2O, incubating at 
room temperature for 5 minutes then centrifuging for 1 minute at 10,000rpm. RNA 
concentration was measured at 260 and 280 nm, using a spectrophotometer (Nano 
Drop ND-1000, Labtech International, UK), aliquoted and stored at -80°C. 
 
2.2.6.2 Reverse Transcription for cDNA preparation 
Complementary DNA (cDNA) was made by the reverse transcription 
technique using the reverse transcriptase RevertAid™ M-MuLV (Fermentas Life 
Sciences, York, UK). 2μg of RNA was made up to a total volume of 12μl with ddH2O 
in a sterile tube. The master mixture was prepared on ice as follows for each sample 
of RNA; 2μl of 10mM dNTPs (Fermentas Life Sciences, York, UK), 1μl (200ng) of 
random primers (pd(N)6, Pharmacia, USA) , 4μl of 5x RT Buffer (Fermentas Life 
Sciences, York, UK) (250mM Tris-HCl, pH8.3; 250mM KCl; 20nM MgCl2; 50mM DTT) 
and 1μl (200u) of RevertAid™ M-MuLV. 8μl of the master mixture was added to the 
12μl of diluted RNA to give a total volume of 20μl. The reaction mixture was 
incubated at 42°C for 60 minutes then the reaction stopped by heating at 95°C for 5 
minutes using a GeneAmp® PCRSystem 9700 (PE Applied Biosystems, UK). The 
cDNA was diluted 1:5 with ddH2O and stored at -20°C. 
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2.2.6.3 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) 
RT-PCR was carried out using Pre-Aliquoted ReddyMix™ PCR Master Mix, 25μl 
reaction (ABgene, UK). The primers used are shown in table 2.6. A master mix of 
primers was prepared using 2.5μl of each of the forward and reverse PCR primers 
and 5.5μl of ddH2O per reaction. 2μl of cDNA, prepared as in the last section, was 
added per reaction to the ReddyMix™ PCR Master Mix tube and 10.5μl of the primer 
master mix was then added per reaction. The reaction mix was incubated at 95°C for 
5 minutes to denature the cDNA. A cycle of heating at 94°C for denaturing to take 
place, cooling to 55°C to allow the oligonucleotide primers to anneal to the target 
sequences and then heating to 72°C for DNA synthesis to take place was carried out. 
The reaction was held at each temperature for 1 minute and the number of cycles 
carried out was dependent on the gene of interest and stored a 4°C. 
 
Table 2.4 RT-PCR primers 
Primer Sequence  Accession number 
GAPDH-F TCCCATCACCATCTTCCA NM_002046 
GAPDH-R CATCACGCCACAGTTTCC NM_002046 
ER-alpha-F CAGATGGTCAGTGCCTTGTTGG X03635 
ER-alpha-R CCAAGAGCAAGTTAGGAGCAAACAG X03635 
pS2-F TTGGAGCAGAGAGGAGGCAATG X00474 
pS2-R TTAGGATAGAAGCACCAGGGGACC X00474 
PR-F CCAGAGCCCACAAATACAGCTTC AF016381 
PR-R GCCAGCCTGACAGCACTTTCTAAG AF016381 
Cathepsin D-F CATTCCCGAGGTGCTCAAGAAC NM 001909 
Cathepsin D-R TCTTCACGTAGGTGCTGGACTTG NM 001909 
GREB1-F AAGGAGGGCTGGAAACAAAT BC054502 
GREB1-R CATTGTGGCCATTGTCATCT BC054502 
 
 
 99 
2.2.6.3.1  Agarose Gel Electrophoresis 
PCR products were analysed by agarose gel electrophoresis. Samples were 
resolved on a 1% (w/v) agarose gel prepared in TBE and containing 0.25μl/ml 
ethidium bromide, run at 100V for 1 hour and electrophoresis was carried out in 
horizontal submersion gel tanks (Thistle Scientific, UK) in 1x TBE buffer at 150 volts 
for 30 minutes. Agarose gels were visualized using an UV transilluminator. 
 
2.2.6.4 Real-time (Quantitative) RT-PCR 
Real-time or quantitative RT-PCR (qRT-PCR) was carried out using the 
TaqMan® Gene Expression Assays (Applied Biosystems, USA). This uses TaqMan® 
Fast Universal PCR Master Mix (2x) No AmpErase UNG (Applied Biosystems, USA) 
which contains a hot-start DNA polymerase. The probes used are shown in table 2.8. 
A master mix of probes was prepared on ice using 10μl of the TaqMan® Fast 
Universal PCR Master Mix (2x) No AmpErase UNG, 1μl of the probe and 7μl of ddH2O 
per reaction. 18μl of the probe master mix was then added per well into a MicroAmp 
Fast Optical 96-well Reaction Plate (0.1ml) (Applied Biosystems, USA) and 2μl of 
cDNA was added per reaction. The plate was sealed with a MicroAmp Optical 
Adhesive Film and centrifuged at 1200rpm for 1 minute at 4°C. The assay was 
carried out using an Applied Biosystems 7900HT Fast Real-Time PCR machine. The 
reaction was heated at 95°C for 20 seconds and then a thermal cycle of 95°C for 1 
second followed by 60°C for 20 seconds was carried out for 40 cycles.  
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Table 2.5 qRT-PCR primers 
Shown are the ABI Taqman assay numbers. These were purchased from ABI (CA, 
USA). Primer sequences are withheld by the manufacturer.  
 
ERα Hs00174860_m1 ESR1 
pS2 Hs00170216_m1 TFF1 
Cathepsin D Hs00157201_m1 CTSD 
GREB1 Hs00536409_m1 GREB1 
PR Hs00172183_m1 PGR 
GAPDH Hs99999905_m1 GAPDH 
 
2.2.7  Microarray 
The HumanWG-6 v2 Illumina Expression BeadChip (Illumina, USA) microarray 
platform was used to carry out whole-genome expression analysis comparing the cell 
lines. This technology probes for 48,804 transcripts using 79-mer oligonucleotides, 
combining a 50-mer gene-specific probe and a unique 29-mer “address” sequence, 
that are covalently attached to silica beads (Figure 2.1). These 3 micron beads are 
randomly assembled and bound within microwells on planar silica slides. The 29-mer 
address sequences present on each bead are the targets for a hybridization-based 
decoding procedure to map the array, identifying the location of each bead. 
Subsequent hybridization of the chip with labelled cRNA, derived by cDNA synthesis 
and single round in vitro transcription amplification of cellular total RNA using the 
Illumina RNA amplification Kit, can be quantified and correlated with the location of 
each gene-specific bead, using the Illumina Bead Array reader. Subsequent analysis 
of the generated data was performed using GeneSpring 7 software (Agilent 
Technologies, Cheshire, UK).  
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Figure 2.1 Illumina gene expression probe design 
The oligonucleotides attached to beads in Illumina gene expression arrays contain a 
29-base address used in the manufacturing/decoding process and a 50-base gene-
specific probe. Each address and probe sequence combination has been selected 
bioinformatically, followed by a functional screen in the laboratory to ensure that no 
cross-hybridization is observed. Gene-specific probe design is accomplished through 
a multi-step bioinformatics algorithm that scores potential probes by considering the 
uniqueness compared with other genes, the sequence complexity, self-
complementarity for hairpin structure prediction, melting temperature for 
hybridization uniformity and the distance from the 3’ end of the transcript. Probe 
design also takes into account exon structure, enabling design of probes that target 
specific splice isoforms. For simplicity, this bead only shows one oligomer attached; 
actual beads have thousands of copies of the same sequence attached. (Taken from 
Illumina Gene Expression Profiling Technical Bulletin) 
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2.2.8  Immunoaffinity Purification 
FLAG- and HA- double-tagged ERα was purified using FLAG and HA 
immunoprecipitation kits from Sigma Aldrich (Dorset, UK), as described below.  
 
2.2.8.1 Harvesting cells 
Cells were grown in DMEM with phenol red, supplemented with 10% FCS and 
P/S/G in the presence of E2 (10-8M) with or without Dox for 72 hours. Cells 
were trypsinised as described in section 2.2.7 then plated at 7.5 x105 cells per 
10cm plate in DMEM without phenol red, supplemented with 5% DSS and 
P/S/G in the presence or absence of E2 (10-8M) with or without Dox and cultured 
for a further 72 hours at 37°C, 5% CO2.  
Cells were harvested at 4°C by one of three methods; using Sigma lysis 
buffer supplied with the kit, using high salt lysis buffer (HSLB) with 500mM NaCl or 
using modified HSLB with 150mM NaCl (Table 2.9). Protein concentration was 
ascertained by Bradford assay as described in section 2.2.5.2. An input sample was 
made by adding an equal volume of 2x Laemmli buffer (Table 2.9) to the lysate 
regardless of lysis buffer used to harvest cells. 
 
2.2.8.1.1 Harvesting cells using Sigma lysis buffer  
Cells were washed twice in ice cold PBS and 125μl of Sigma lysis buffer 
was added per 1 x106 cells, at 4°C with gentle rocking for 15 minutes, 
according to the Sigma instruction manual. Cells were scraped from the plate 
using a rubber policeman and lysates were collected in 1.5ml microfuge 
tubes. Samples were spun at 13,000rpm for 10 minutes at 4°C to remove any 
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remaining debris and the supernatant was placed in a fresh microfuge tube 
before storing at -80°C. 
 
Table 2.6 Immunoaffinitiy purification buffers  
Sigma lysis buffer 50 mM Tris, pH 7.4; 150mM NaCl; 1mM EDTA; 1% Triton® 
X-100; supplemented with 1x proteinase inhibitors (Roche) 
HSLB 
(500 mM NaCl) 
10mM Tris, pH 7.4; 500mM NaCl; 1mM EDTA; 0.1% NP40; 
1x proteinase inhibitors (Roche); 1mM PMSF 
Modified HSLB 
(no NaCl) 
10mM Tris pH 7.4, 1mM EDTA, 0.1% NP40; 1x proteinase 
inhibitors (Roche); 1mM PMSF 
2x Laemmli Buffer 1M Tris, pH6.8; 15% glycerol; 2% v/v SDS; 50% v/v  ddH2O; 
0.1% w/v bromophenol blue; 400mM DTT 
Elution buffer 0.1M Glycine, pH3.5 
Wash buffer 50mM Tris-HCl, pH7.4; 150mM NaCl 
 
 
2.2.8.1.2  Harvesting cells using HSLB 
Cells were washed twice in ice cold PBS then harvested by scraping with a 
rubber policeman in 500μl ice cold HSLB containing 500mM NaCl. Lysates were 
incubated on ice for 10 minutes then sonication was carried out for 5 seconds at 
25% using a Soniprep 150 (MSE, UK). Samples were spun at 13,000rpm for 10 
minutes at 4°C to remove any remaining debris and the supernatant was placed in a 
fresh microfuge tube before storing at -80°C. 
 
2.2.8.1.3  Harvesting cells using modified HSLB 
Cells were washed twice in ice-cold PBS then harvested by scrapping with a 
rubber policeman in 1ml ice cold PBS and spinning at 6,000rpm, 4°C for 10 minutes. 
The pellet was resuspended in 150μl HSLB with 500mM NaCl and sonication was 
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carried out for 5 seconds at 25% using a Soniprep 150 (MSE, UK). The samples were 
then spun at 13,000 rpm for 10 minutes at 4°C to remove any remaining debris. The 
supernatant was placed in a fresh microfuge tube and 350μl modified HSLB (Table 
2.9) was added to dilute the NaCl to a final concentration of 150mM. Lysates were 
then stored at -80°C. 
 
2.2.8.2 Determining protein concentration by Bradford assay 
Protein concentrations were determined using the Bradford assay. Bio-Rad 
Protein Assay Dye Reagent Concentrate (Bio-Rad Laboratories, DE) was diluted 1:5 
with ddH2O and 200μl of the diluted reagent added per well of a 96 well plate. 
Known concentrations of BSA were used to produce a standard curve and known 
volumes of lysates were compared to this to determine protein concentration of the 
lysates. All measurements were performed in triplicate and absorbance was read 
using a spectrophotometer (Anthos 2001, Anthos Labtech Instruments, Austria) at 
wavelength 620nm. 
 
2.2.8.3 Anti-FLAG Immunoaffinity Purification 
The Sigma FLAG Tagged Protein Immunoprecipitation Kit was used to purify 
FLAG-ERα-HA from whole cell lysates. 20μl of anti-FLAG M2-agarose affinity gel was 
used per mg of protein. The gel was washed 5 times with 1x wash buffer (Table 2.9) 
at a volume equal to 20 times the volume of gel and centrifuged at 13,000rpm for 1 
minute at 4°C and then the supernatant was removed. Between 1-10mg of whole 
cell lysate was then added to the gel and incubated overnight at 4°C with gentle 
rocking. The gel was centrifuged at 13,000rpm for 1 minute at 4°C and supernatant 
removed before washing 3 times in 1x wash buffer as before. The bound proteins 
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were eluted using peptide elution, acid elution or by the addition of Laemmli buffer, 
as described below. 
 
2.2.8.3.1  Elution of FLAG-tagged protein with 3x FLAG peptide 
A 5μg/μl solution of 3x FLAG peptide (N-Met-Asp-Tyr-Lys-Asp-His-Asp-Gly-
Asp-Tyr-Lys-Asp-His-Asp-Ile-Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys-C) was prepared as 
stated in the manufacturers manual by dissolving in 1x wash buffer (Table 2.9). A 
working concentration of 150ng/μl was produced by diluting 3μl of this stock peptide 
with 100μl of 1x wash buffer. The FLAG-tagged protein was eluted from the beads 
by adding 50μl of the working stock 3x FLAG peptide solution and incubating for 30 
minutes at 4°C with gentle rocking. The gel was then centrifuged at 13,000rpm for 2 
minutes at 4°C. The supernatant was transferred to a fresh microfuge tube and 
stored at -20°C. 
 
2.2.8.3.2  Elution of FLAG-tagged protein by acid elution 
FLAG-tagged proteins were eluted from the gel by adding 100μl of elution 
buffer (Table 2.9) and incubating at room temperature for 5 minutes with gentle 
rocking. The sample was then centrifuged at 13,000rpm for 5 minutes and the 
supernatant transferred to a fresh microfuge tube containing 10μl of 10x wash buffer 
then stored at -20°C. 
 
2.2.8.3.3  Elution of FLAG-tagged protein with Laemmli Buffer 
FLAG-tagged proteins were eluted from the gel by adding 50μl of 2x Laemmli 
Buffer to each sample and boiling for 3 minutes. The samples were then centrifuged 
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at 13,000rpm for 1 minute at room temperature and the supernatants transferred to 
a fresh microfuge tube then stored at -20°C. 
 
2.2.8.4 Anti-HA Immunoaffinity Purification 
The Sigma Anti-HA Immunoprecipitation Kit was used to purify FLAG-ERα-HA 
from whole cell lysates by the HA tag. 20μl of anti-HA-agarose affinity gel was used 
per mg of protein.  Between 1-10mg of whole cell lysate was added to the gel and 
incubated over night at 4°C with gentle rocking. A minimum total volume of 600μl 
was achieved by adding 1x wash buffer if required. The gel was then washed 5 times 
in 700μl of 1x wash buffer by centrifugation at 13,000rpm for 1 minute at 4°C. The 
HA-tagged protein was eluted by the addition of Laemmli buffer as above, or with 
peptide elution (below). 
 
2.2.8.4.1  Elution of HA-tagged protein with HA peptide 
The HA peptide (Sigma, US) was prepared in ddH2O at a stock concentration 
of 1mg/ml. A working concentration of 150ng/μl was produced by diluting 15μl of 
this stock peptide with 85μl of ddH2O. The HA-tagged protein was eluted from the 
beads by adding 50μl of the working concentration HA peptide solution and 
incubating for 30 minutes at 4°C with gentle rocking. The gel was then centrifuged at 
13,000rpm for 2 minutes at 4°C. The supernatant was transferred to a fresh 
microfuge tube and stored at -20°C. 
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2.2.8.5 Double Immunoaffinity Purification 
Proteins eluted using the 3xFLAG peptide elution method were further 
purified by loading the eluate onto anti-HA-agarose affinity gel. Proteins were eluted 
from anti-FLAG M2-Agarose affinity gel as described in section 2.2.5.3.1; however, 
100μl of 150ng/μl 3x FLAG peptide was used instead of 50μl. After the initial elution 
was carried out and the supernatant removed, the process was repeated again with 
100μl of 150ng/μl 3x FLAG peptide and the total volume from both elutions (200μl) 
was loaded onto 40μl of anti-HA-agarose affinity gel. A final volume of 600μl was 
achieved by adding 400μl of 1x wash buffer. Incubation and wash steps were then 
carried out as described in section 2.2.5.4. Proteins were eluted by the HA peptide 
elution method as detailed in section 2.2.5.4.1.  
 
2.2.9   Protein Analysis 
2.2.9.1 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Samples were denatured in sample buffer containing SDS according to the 
method of protein extraction required. After boiling the samples at 95°C for 5 
minutes, they were loaded onto 8x7cm SDS-polyacrylamide gels, the percentage of 
which was determined by the size of the protein of interest (see Table 2.10 for gel 
composition). A discontinuous buffer system was used which consists of a non-
restrictive large pore gel (stacking gel) which is layered on top of a separating gel 
(resolving gel). Electrophoresis was performed with running buffer (Table 2.11) at 60 
volts for 45 minutes and then 100 volts for approximately 150 minutes using Mighty 
Small II gel apparatus (Amersham Biosciences, UK). 
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Table 2.7 Components of SDS-PAGE Gels  
 7% Resolving 
Gel 
10% 
Resolving Gel 
15% 
resolving gel 
Stacking 
Gel 
Lower Buffer (4x) 5ml 5ml 5ml - 
Upper Buffer (10x) - - - 0.5ml 
Bis-acrylamide (30% 
stock solution) 
4.7ml 6.7ml 10.7ml 0.5ml 
ddH2O 10.3ml 8.3ml 5.3ml 4ml 
10% (w/v) APS 200μl 200μl 200μl 50μl 
TEMED 20μl 20μl 20μl 5μl 
 
Table 2.8 SDS-PAGE and Western Buffers 
10x Running buffer 0.25M Tris base, 1.0M glycine, 35mM SDS 
50x Electrotransfer buffer 0.25M Tris base, 1.0M glycine 
1x Electrotransfer buffer 1x Electrotransfer buffer, 20% v/v methanol, diluted 
in ddH2O 
Washing buffer 0.1% v/v Tween 20 in PBS  
Blocking buffer 5% w/v Marvel dried skimmed milk dissolved in 
washing buffer 
 
2.2.9.2 Western Blotting 
Proteins were resolved by SDS-PAGE and then transferred from the gel to 
Hybond-ECL nitrocellulose membrane (Amersham Biosciences, UK) by 
electrophoresis. The resolving gel and membrane were set up as in figure 2.2. The 
proteins are drawn from the gel onto the membrane by the negative to positive flow 
of current. Gel electrotransfer was carried out using the Bio-Rad Mini Trans-Blot Cell 
at 100 volts for 90 minutes with electrotransfer buffer (Table 2.11). The 
nitrocellulose membrane was then incubated in 10ml of blocking buffer (Table 2.11) 
for 30 minutes at room temperature with gentle rocking before the primary antibody 
was added. The membrane was incubated overnight at 4°C with gentle rocking in 
10ml of primary antibody which was diluted in blocking buffer as shown in table 
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2.12. Membranes were then washed four times, over a period of one hour, using 
washing buffer (Table 2.11) at room temperature with gentle rocking. The 
membrane was then incubated with horse radish peroxidise (HRP)-conjugated goat 
 
Figure 2.2 Preparing membrane and gel for electrophoresis 
 
 
anti-rabbit or anti-mouse immunoglubulins, as appropriate. The membrane was 
incubated for 1 hour at room temperature with gentle shaking in 10ml of secondary 
antibody diluted in blocking buffer (see table 2.13 for dilutions). Membranes were 
then washed as before over a period of one hour. Following washes, the membranes 
were incubated with SuperSignal® West Pico Enhanced Chemiluminescent (ECL) 
Substrate (Pierce, US). The HRP enzyme complex catalyzes the conversion of the 
ECL substrate into a sensitized reagent which on further oxidation by the addition of 
hydrogen peroxide produces an excited carbonyl which emits light as it decays from 
a triplet to a singlet carbonyl. Signals were detected by exposing high performance 
autoradiography film (Amersham, UK) to the membrane. The film was developed 
using a Konica SRX-101A X Ray Developer. 
 
 
 
 
Sponge
3MM filter paper 
Nitrocellulose membrane 
Gel 
Positive charge
Negative charge
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Table 2.9 Primary antibody information 
Antibody Antigen Dilution Antigen raised in Company 
ER6F11 Estrogen 
Receptor α 
1:2000 Mouse monoclonal Nova Castra
HA (3F10) HA-peptide 1:500 HRP-conjugated Roche 
AC-15 β-Actin 1:20,000 Mouse monoclonal AbCam 
CTD-19 Cathepsin D 1:1000 Mouse monoclonal AbCam 
FL-84 pS2 1:400 Rabbit polyclonal Santa Cruz 
C-19 Progesterone 
receptor 
1: 200 Rabbit polyclonal Santa Cruz 
 
Table 2.10 Secondary antibody information 
Antibody Dilution Antigen raised in Company 
α mouse HRP 
conjugated 
1:2000 Goat polyclonal  DAKO 
α rabbit HRP 
conjugated 
1:2000 Goat polyclonal DAKO 
 
2.2.9.3 SYPRO Ruby Gel Stain 
After SDS-PAGE, the resolving gel was placed in a clean plastic dish (Sterelin, 
Barloworld Scientific UK) where it was washed in 25ml of fixing solution (10% 
methanol, 7% acetic acid) for 30 minutes with rocking at room temperature. After 
this time, the fixing solution was removed and 50ml SYPRO Ruby protein gel stain 
(Bio-Rad, DE) added. After gentle agitation for 120 minutes, the gel stain was 
removed and the gel washed in 25ml of fixing solution for 30 minutes. Gel imaging 
was then carried out using a Typhoon 8600 Variable Mode Imager (Amersham 
Pharmacia Biotech, UK). 
 
2.2.9.4 Silver Stain 
Silver staining of the resolving gel was carried out using the ProteoSilverTM 
Plus Silver Stain kit (Sigma, USA) following the manufacturers instructions. All steps 
were carried out at room temperature with shaking at 60rpm. The resolving gel was 
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placed in a clean 10cm square Petri dish (Sterelin, Barloworld Scientific UK) and fixed 
by incubating in 25ml of fixing solution (50% ethanol, 10% acetic acid) for 40 
minutes. The gel was then washed in 25ml of a 30% ethanol solution for 10 minutes 
followed by a 10 minute wash with 25ml of ddH2O. The gel was then treated with 
25ml of the Sensitizer Solution for 10 minutes then washed twice for 10 minutes 
each with 25ml of ddH2O. The gel was equilibrated with 25ml of the Silver Solution 
for 10 minutes then washed for 1 minute with 25ml of ddH2O before being 
developed by treating the gel with 25ml of the Developer Solution for up to 7 
minutes until the desired staining intensity was achieved. The developing reaction 
was stopped by adding 2.5ml of ProteoSilver Stop Solution to the Developer Solution 
and incubating for 5 minutes. 
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3 RESULTS 
3.1 Characterising MCF7-TO cell lines 
The MCF7 human breast cancer-derived cell line is the most commonly used 
model system for estrogen-responsive breast cancer. MCF7 cells grow in an 
estrogen-dependent manner, with their growth being inhibited by anti-estrogens or 
by estrogen withdrawal. They express ERα and demonstrate estrogen and anti-
estrogen regulation of the expression of estrogen-responsive genes. Previous studies 
from the laboratory have used a MCF7-derived line (MCF7-TO) (BD Biosciences, UK), 
which stably expresses TetR-VP16, allowing tetracycline regulation of the expression 
of genes of interest (Buluwela et al., 2005). The MCF7-TO cells continue to express 
ERα, express estrogen-responsive genes in an estrogen and anti-estrogen-regulated 
manner, grow in a ligand-dependent manner and form estrogen-dependent tumours 
in xenografts (Buluwela et al., 2005), and in this context they are indistinguishable 
from the parental MCF7 cells. MCF7-TO cells were stably transduced with pRevTRE-
ERα, (MCF7-TO-ERα) encoding HA and FLAG epitope tag sequences at the 5’ and 3’ 
ends respectively, to facilitate immunoaffinity purification of ERα and associated 
proteins. For this, HA-ERα-FLAG was cloned into the retroviral plasmid pRevTRE, 
which encodes a tetracycline responsive promoter to provide tetracycline regulation 
of the gene of interest and the hygromycin B resistance gene, to allow for selection 
of stable transformants. Stable MCF7-TO lines were also generated to express HA- 
and FLAG-tagged ERα in which serines 104, 106 and 118 have been substituted by 
alanine residues (MCF7-TO-ERα(AAA)) to prevent phosphorylation at these sites. 
Finally, stable lines were generated, in which serines 104, 106 and 118 have been 
substituted by glutamic acid (MCF7-TO-ERα(EEE)). Serine residues are often 
replaced by glutamic or aspartic acids, to “mimic” phosphorylation, and have  
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Figure 3.1 Expression levels of ERα in MCF7-TO-ERα clones 
Whole cell lysates were made for the (a) MCF7-TO-ERα cell line (clones WT01-
WT15), (b) MCF7-TO-ERα(EEE) cell line (clones E01-E15) and (c) MCF7-TO-
ERα(AAA) cell line (clones A01-A15) using the hot lysis method 96hr after Dox 
removal. Lysates were immunoblotted using HA-hrp (top blot) which identifies 
the HA tag of the HA-ERα-FLAG construct, and ER6F11 (bottom blot) which 
identifies both endogenous and exogenous ERα. 
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previously been described for ERα (Ali et al., 1993; Chen et al., 2002; Thomas et al., 
2008). As these lines express the gene of interest following removal of tetracycline, 
routine culturing was performed in the presence of doxycycline (Dox), a more stable 
form of tetracycline, to prevent expression of HA-ERα-FLAG, HA-ERα(EEE)-FLAG and 
HA-ERα(AAA)-FLAG and any possible long-term changes that high levels of ERα 
expression might cause. These lines were generated prior to my arrival (R. Thomas 
et al., unpublished) but had not been characterised beyond preliminary confirmation 
of the expression of the transgene in a few of the cloned lines. For further 
experiments, it was therefore necessary to characterise the clones for expression of 
the epitope-tagged ERα. 
Lysates prepared from fifteen hygromycin B-resistant clones arising from 
each of the retroviral transductions with pRevTRE-ERα, pRevTRE-ERα(EEE) and 
pRevTRE-ERα(AAA) 120 hours after removal of Dox from the medium, were 
immunoblotted for ERα and HA-ERα-FLAG. Immunoblotting using an antibody for the 
HA tag, showed that nine of the clones selected following transduction for HA-ERα-
FLAG (named WT01-WT15), expressed a polypeptide of the expected size, which 
was confirmed by immunoblotting using the ERα-specific antibody (ER6F11) (Fig. 
3.1a). As seen in the ERα immunoblot, HA-ERα-FLAG migrates slightly more slowly 
than endogenous ERα, presumably due to the HA and FLAG tags. Ten of the MCF7-
TO-ERα(EEE) clones (named E01-E15) expressed HA-ERα(EEE)-FLAG, the 
polypeptide migrating more slowly than endogenous ERα (Fig. 3.1b). Four of the the 
MCF7-TO-ERα(AAA) clones (named A01-A15) expressed HA-ERα(AAA)-FLAG (Fig. 
3.1c).  Clones that expressed the “transgene” were next tested for Dox regulation of 
HA-ERα-FLAG, HA-ERα(EEE)-FLAG and HA-ERα(AAA)-FLAG expression, by 
immunoblotting of lysates prepared in the absence or presence of Dox (Fig. 3.2). All 
of the positive clones demonstrated Dox regulation with little or no transgene 
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expression being detected in the presence of Dox (Fig. 3.2). Based on these data, 
three clones were selected for further investigation based on the level of HA- and 
FLAG-tagged ERα expression compared to the expression level of endogenous ERα; 
one clone from each cell line that demonstrated high, one medium and one 
demonstrating low levels of HA-ERα-FLAG expression compared to endogenous ERα, 
were selected for further study, in order to determine if the level of HA-ERα-FLAG 
expression influenced the ligand response of the cells. For the MCF7-TO-ERα cell line 
(Fig. 3.2a) clone WT02 was chosen as expressing high, clone WT06 (intermediate 
expression) and clone WT11 (low level expression) of HA-ERα-FLAG. For the MCF7-
TO-ERα(EEE) cell line (Fig. 3.2b) clone E04 was chosen as expressing high, clone 
E06 as expressing medium and clone E01 as expressing low levels of HA-ERα(EEE)-
FLAG. For the MCF7-TO-ERα(AAA) cell line (Fig. 3.2c) clone A12 was chosen as 
expressing high, clone A10 as expressing medium and clone A04 as expressing low 
levels of HA-ERα(AAA)- FLAG. All subsequent studies were performed using these 
nine lines, together with MCF7-TO cells as controls. 
A time course experiment was next carried out to assess transgene 
expression over time and to identify when maximal levels of transgene expression 
are observed (Fig. 3.3). This was carried out in order to determine how long clones 
should be grown in the absence of Dox to achieve stable levels of HA-ERα-FLAG 
protein. From the time course, expression generally reached near maximal 96 hours 
following removal of Dox, although higher levels were achieved at 144 hours (Fig 3.3 
a-c). A longer time course showed levelling out of expression at 168 hours (Fig. 3.3 
d). However, as there was substantial expression at 96 hours, this time-point was 
used for subsequent studies as it provided the most appropriate staging for the 
ligand experiments. 
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Figure 3.2. Western blotting of MCF7-TO-ERα clones demonstrates Dox 
regulation of transgene expression  
Whole cell lysates of (a) MCF7-TO-ERα, (b) MCF7-TO-ERα(EEE) and (c) MCF7-TO-
ERα(AAA) clones were made using the hot lysis method 120 hours after Dox removal.  
Lysates were probed using antibodies for HA and ERα (ER6F11). Clones displaying low, 
medium and high levels of HA-ERα-FLAG expression compared to endogenous ERα 
were chosen as listed in (d). 
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Figure 3.3 Time course of HA-ERα-FLAG induction after removal of Dox  
The expression of HA and FLAG tagged ERα in the presence of estrogen for three 
clones from each cell line was determined at 24, 48, 72, 96, 120 and 144 hours 
after Dox removal. (a) MCF7-TO-ERα clone WT11 represented low, WT06 
medium and WT02 high levels of HA-ERα-FLAG expression. (b) MCF7-TO-
ERα(EEE) clone E01 represented low, E06 medium and E04 high levels of HA-
ERα(EEE)-FLAG expression. (c) MCF7-TO-ERα(AAA) clone A01 represented low, 
A10 medium and A12 high levels of HA-ERα(AAA)-FLAG expression. Low, medium 
and high clones are denoted by L, M and H respectively. (d) The time course was 
extended up to 216 hours for MCF7-TO-ERα(WT02), MCF7-TO-ERα(EEE)(E06) 
and MCF7-TO-ERα(AAA)(A04). 
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3.2 Reporter Gene Assay Shows Dox-Regulated Increased Stimulation of 
ERα Activity in Stable Lines 
In order to determine how over-expression of ERα, or the expression of 
ERα(EEE) and ERα(AAA) alters the estrogen-responses in the MCF7-TO lines, 
reporter gene assays were carried out following transient transfection with an 
estrogen-responsive firefly luciferase reporter gene encoding three EREs (pXpERE3) 
and the RLTK renilla luciferase reporter gene DNA (Promega, UK) as a control for 
transfection efficiency. Receptor activity was measured after treatment with vehicle 
(ethanol) (Fig.3.4a), 17β-estradiol (E2) (10-8M) (Fig3.4b), 4-hydroxytamoxifen (OHT) 
(10-7M) (Fig.3.4c) and ICI 182, 780 (ICI) (10-7M) (Fig3.4d) for 24 hours (section 
2.1.1.2). These concentrations were chosen to mimic physiological concentrations of 
the individual drug. The reporter gene activities for each of the three chosen clones 
for MCF7-TO-ERα (WT11, WT06, WT02), MCF7-TO-ERα(EEE) (E01, E06, E04) and 
MCF7-TO-ERα(AAA) (A04, A10, A12) were measured in triplicate and the average 
shown in figure 3.4. In the parental (MCF7-TO) cells, reporter gene activity was 
stimulated by E2, and to a lower extent by the partial ERα inhibitor, OHT. There was 
no significant difference in reporter gene activity in the presence or absence of Dox 
for the MCF7-TO cell line under any of the conditions tested, indicating that Dox does 
not influence ERα activity in MCF7-TO cells.  
In the presence of Dox, each cell line displayed a similar profile to MCF7-TO 
parental cells, displaying an estrogen-stimulated increase in activity (Fig.3.4b) which 
was reduced in the presence of OHT (Fig.3.4c) and reduced further in the presence 
of ICI (Fig.3.4d), to levels similar as that in the absence of ligand (Fig.3.4a). In the 
presence of Dox, each clone would be expected to express similar levels of ERα to 
the MCF7-TO parental cell line and as such show similar levels of ERα activity. 
However, all the clones showed slightly varying levels of ERα activity under all 
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Figure 3.4 Transactivation activity of HA-ERα-FLAG constructs 
Luciferase reporter gene assays were used to measure ERα activity in the presence of vehicle 
(EtOH) (a), E2 (10¯8 M) (b), OHT (10¯7 M) (c) and ICI (10¯7 M) (d). 0.1μg pxpERE, 0.1μg RL-
TK and 0.5μg BSM was used per well to transfect 8x104 cells per well using FuGENE6. The 
data represent the average activities of 3 replicates for each clone; (in order of low to high 
expression) MCF7-TO-ERα clones WT11, WT06, WT02, MCF7-TO-ERα(EEE) clones E02, E06, 
E04 and MCF7-TO-ERα(AAA) clones A04, A10, A12. The error bars represent the standard 
errors of the mean. Statistical differences with p values ≤ 0.01 denoted by * and p values ≤ 
0.001 denoted by ** 
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conditions in the presence of Dox compared with each other and MCF7-TO. WT11, 
E06, E04 and A12 consistently showed higher levels of activity compared to MCF7-
TO under all conditions suggesting a higher level of endogenous ERα expression in 
these clones and may be indicative of some transgene expression in the presence of 
Dox.  
In the absence of ligand (fig. 3.4a), removal of Dox and subsequent 
expression of ERα, ERα(EEE) and ERα(AAA) caused a significant increase in reporter 
gene activity compared to in the presence of Dox, except for MCF7-TO-ERα clone 
WT11. Interestingly, clones expressing the lowest levels of HA and FLAG tagged ERα 
(WT11, E01 and A04) showed the smallest increase in reporter gene activity in the 
absence of Dox compared to in the presence of Dox whereas those expressing the 
highest levels of HA and FLAG tagged ERα (WT02, E04 and A12) showed the largest 
increase. In a similar way, E2 -stimulated reporter gene activity was increased in the 
absence of Dox compared to in the presence of Dox – the level of increase 
correlating to the level of ERα expression in each clone with WT11, E01 and A04 
showing the smallest increase and WT02, W04 and A12 showing the largest increase 
(fig. 3.4b). Since this occurred for all cell lines regardless of the ERα mutant 
expressed, this suggests that ERα over-expression is sufficient for increased levels of 
reporter gene activity in the presence and absence of E2, with ERα phosphorylation 
not contributing greatly to this effect.  
OHT treatment (Fig.3.4c) caused an inhibition of ERα activity for all the cell 
lines compared to the acitivty measured in the presence of E2 in the presence and 
absence of Dox. In the absence of Dox, MCF7-TO-ERα clones showed no significant 
difference in activity compared to in the presence of Dox, MCF7-TO-ERα(EEE) clones 
showed a significant increase in activity and MCF7-TO-ERα(AAA) clones showed a 
significant decrease in activity compared to in the presence of Dox during OHT 
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treatment. This suggests that whereas the phosphorylation status of these AF1 sites 
did not have an effect on ERα activity in the presence or absence of E2, 
phosphorylation may be significant in the presence of OHT as an increase in ERα 
acitivity shown by clones expressing glutamic acid residues at these sites appears to 
be inhibited due to the expression of alanine residues.   
 
3.3 Expression analysis of Estrogen-Regulated genes by immunoblotting 
Cells were treated with estrogen in the presence and absence of Dox to 
investigate how over-expression of ERα and the phosphorylation site mutants affects 
the expression of endogenous estrogen-regulated genes. The cells were grown in the 
presence or absence of Dox for 120 hours before the addition of E2 (10-7M) and cell 
lysates were prepared a further 24 hours later (Fig. 3.5). Immunoblotting for ß-actin 
was used as a control for protein loading.  
The MCF7-TO cell line (Fig. 3.5a) shows endogenous ERα expression which is 
not altered by Dox treatment, and no expression of HA-ERα-FLAG, as expected. The 
cell lines expressing epitope-tagged forms of ERα (Fig. 3.5b-d) show Dox regulation 
of the tagged protein as seen by the HA blots and the upper band of the ERα blots 
where tagged ERα, ERα(EEE) and ERα(AAA) are not present in the presence of Dox. 
There appears to be low level expression of HA-ERα-FLAG in the MCF7-TO-ERα clone 
WT06 (Fig. 3.5b) in the presence of Dox, indicating ‘leaky’ expression of HA-ERα-
FLAG in this clone.  
 Cathepsin D is a well-characterised estrogen-regulated gene. In agreement 
with previous findings, cathepsin D expression was stimulated by E2 both in the 
presence and absence of Dox in all cell lines (Fig. 3.5a-d). In cell lines expressing 
tagged forms of ERα (Fig. 3.5b-d) an increase in the levels of cathepsin D can be 
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Figure 3.5 Expression of estrogen-regulated genes in the presence and 
absence of HA-ERα-FLAG constructs and estrogen 
Cells were grown in the presence or absence of Dox for 96 hrs before treatment with 
vehicle (ethanol) or E2 (10-7M) for 24 hrs. Cells were then harvested and western blot 
analysis carried out for estrogen regulated genes pS2 and cathepsin D, the HA tag, 
ERα and β-Actin as a loading control. The three clones from each cell line are in the 
order from left to right of high to low levels of phospho-mutant ERα expression. 
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seen in the absence of Dox compared to the presence of Dox with and without E2 
treatment.  
Levels of the estrogen-regulated gene, pS2, were also stimulated by E2 in all 
the cell lines in the presence and absence of Dox (Fig. 3.5a-d). MCF7-TO showed no 
expression of pS2 in the absence of ligand in either the presence or absence of Dox, 
although lower levels of pS2 overall were found in this line (Fig.3.5a). All MCF7-TO-
ERα, MCF7-TO-ERα(EEE) and MCF7-TO-ERα(AAA) clones showed ligand-
independent pS2 expression which was increased in response to E2 in the presence 
and absence of Dox (Fig. 3.5b-d) and both ligand-independent and estrogen-
dependent pS2 expression was increased in the absence of Dox compared to in the 
presence of Dox. 
Levels of pS2 expression remained similar in the presence and absence of 
Dox for the MCF7-TO cell line. However, MCF7-TO-ERα(EEE) clones (Fig. 3.5c) 
displayed a larger increase in ligand-independent pS2 expression compared to MCF7-
TO-ERα (Fig. 3.5b) and MCF7-TO-ERα(AAA) (Fig. 3.5d) clones in the absence of Dox 
compared to in the presence of Dox. MCF7-TO-ERα(AAA) clone A10 showed 
abnormally high levels of pS2 expression compared to the other clones within the 
MCF7-TO-ERα(AAA) cell line. 
These data show that over-expression of ERα leads to an increase in 
expression of cathepsin D and pS2, both in the presence and absence of E2. 
However, expression of ERα(EEE) (Fig. 3.5c) appears to cause an increase in ligand-
independent expression of pS2 greater than that seen by cell lines expressing WT 
ERα or ERα(AAA). This suggests that phosphorylated AF1 residues may cause an 
increase in ligand-independent expression of some E2-regulated genes.  
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3.4 Determination of the expression of estrogen responsive genes using 
RT-PCR and real-time PCR 
In order to determine if the altered expression of pS2 and cathepsin D was 
also observed at the transcriptional level, total RNA was isolated from cells after 8 
hours and 16 hours following estrogen treatment. Reverse transcriptase PCR (RT- 
PCR) and real-time (quantitative) RT-PCR (qRT-PCR) were used to examine 
expression of a number of estrogen-regulated genes; pS2, cathepsin D, PR and 
GREB1, as well as ERα, with GAPDH serving as control. For these experiments, the 
cell line that appeared to express HA-ERα-FLAG (line WT06) at levels similar to those 
of endogenous ERα, as determined by immunoblotting, was used. On this basis, the 
E06 and A10 lines were used to represent MCF7-TO-ERα(EEE) and MCF7-TO-
ERα(AAA), respectively.  
qRT-PCR was carried out using validated primer sets from ABI on a Taqman 
7900HT machine. Expression for each gene is depicted relative to expression levels 
of GAPDH and is shown as fold expression relative to expression level in the absence 
of E2 and the presence of Dox for MCF7-TO cells (Figure 3.6). Both real-time RT-PCR 
(Fig. 3.6e) and RT-PCR (Fig. 3.7) showed that, as expected, ERα mRNA levels were 
elevated in the MCF7-TO-ERα, MCF7-TO-ERα(EEE) and MCF7-TO-ERα(AAA) lines, 
compared to MCF7-TO cells in the absence, but not in the presence of Dox, as the 
PCR primers were designed against the ERα coding sequences and hence would 
detect both the endogenous and “transgene” ERα. This increase in ERα expression in 
the absence of Dox for the MCF7-TO-ERα, MCF7-TO-ERα(EEE) and MCF7-TO-
ERα(AAA) lines was also seen at the protein level (Fig. 3.5). However, whilst levels of 
ERα expression were similar in the MCF7-TO-ERα and MCF7-TO-ERα(EEE) lines, 
levels of ERα expression in the MCF7-TO-ERα(AAA) line were considerably higher in 
the absence of Dox, compared to the other lines as analysed by real-time RT-PCR 
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Figure 3.6 Expression of estrogen-regulated genes in response to 
estrogen and HA-ERα-FLAG constructs 
Cells were treated with ethanol or E2 (10-8M) in the presence and absence of DOX. 
Cells were harvested after 8 hours of estrogen treatment and total RNA extracted. 
Real-time PCR was performed in triplicate for three clones of each cell line MCF7-
TO-ERα (WT), MCF7-TO-ERα(EEE) (EEE) and MCF7-TO-ERα(AAA) (AAA) using 
Taqman gene expression primers for the estrogen-regulated genes PR (a), pS2 (b), 
cathepsin D (c), GREB1 (d) and ERα (e). Averages are shown for each cell line plus 
MCF7-TO as a control. Readings were corrected against GAPDH and fold difference 
is shown relative to MCF7-TO +Dox -E2.  
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Figure 3.7 Expression of estrogen-regulated genes in response to 
estrogen in individual HA-ERα-FLAG construct cell lines 
Cell lines expressing similar levels of exogenous ERα compared to endogenoue 
ERα were treated with ethanol or E2 (10-8M) in the presence and absence of Dox. 
Cells were harvested after 16 hours of E2 treatment and total RNA extracted. RT-
PCR was performed using primers for the estrogen-regulated genes progesterone 
receptor (PR), GREB1, pS2, cathepsin D (CathD), ERα and GAPDH as a loading 
control. RNA extracted from COS cells transfected with ERα grown in the 
presence and absence of E2 was used as a positive control. 
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 (Fig. 3.6e). This high-level expression at the RNA level was not observed at the 
protein level (Fig. 3.5) or by RT-PCR (Fig. 3.7).    
Expression of all four estrogen-regulated genes was stimulated by E2 in the 
MCF7-TO cell line at 8 and 16 hours after addition of E2 as shown by real-time RT-
PCR and RT-PCR (Fig. 3.6 and Fig. 3.7). In MCF7-TO cells, the expression of pS2, 
cathepsin D and GREB1 were stimulated similarly in the presence or absence of Dox, 
in agreement with the immunoblotting data. Further, despite the apparent increase 
in levels of pS2 and cathepsin D protein seen in the absence of Dox in the MCF7-TO-
ERα, MCF7-TO-ERα(EEE) and MCF7-TO-ERα(AAA) cell lines, there was only a small, 
and statistically insignifcant increase in expression of these genes, as analysed by 
semi-quantitative RT-PCR (Fig. 3.6) and real-time RT-PCR (Fig. 3.7), with 8 or 16 
hours E2 treatment.  
 Although PR gene expression was stimulated by estrogen in all of the lines in 
the absence or presence of Dox, a greater level of PR expression was observed in 
the MCF7-TO cells than in the transgene lines as shown by both qRT-PCR (Fig. 3.6a) 
and RT-PCR (Fig. 3.7). Moreover, qRT-PCR analysis of PR expression showed an 8-
fold induction in response to estrogen in the presence of Dox for the MCF7-TO cell 
line, however, this was reduced to a 3-fold induction in the absence of Dox (Fig. 
3.6a). This is surprising as the MCF7-TO cell line is not expected to show any 
reaction to Dox. However, this effect of Dox was not seen by RT-PCR analysis of PR 
(Fig. 3.7) or for any of the other genes examined.  
Together, these data suggest that overexpression of ERα leads to only a 
small effect on expression of the pS2, cathepsin D and GREB1 genes over 8 or 16 
hours treatment with E2, although immunoblotting for pS2 and cathepsin D proteins 
suggests that the increased expression is sufficient for the increase in levels of these 
proteins, as judged by immunoblotting.   
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3.5 Whole-genome analysis of MCF7-TO cell lines by microarray 
In order to investigate if expression of WT ERα, ERα(EEE) or ERα(AAA) 
affected the expression of specific genes, whole-genome expression analysis was 
carried out in triplicate for one representative clone from each of the ERα variants, 
WT06, E01 and A10, and the parental MCF7-TO was used as a control. WT06 and 
A10 were used as these clones expressed moderate levels of exogenous ERα. E06 
should have been used for the MCF7-TO-ERα(EEE) cell line for this purpose but 
results in figure 3.5 showed the clone had infact the highest level of ERα(EEE) 
expression compared to E04 (high expresser) and E01 (low expresser) and it was 
decided that clone E01 expressed more suitable levels. Total RNA was extracted from 
cells after 8 hours of E2 (10-8M) treatment in the presence and absence of Dox, 
using Qiagen RNA prep kit, as described in section 2.2.4.1.  
Raw microarray data was subjected to quality control and normalisation 
criteria. Firstly, data from probes with very low signal were removed from the 
analysis as background noise could potentially give rise to false positives. As part of 
the default normalisation procedures, probes which had a normalised value of less 
than 0.1 were set to 0.1, further offsetting false-positive detection in this low 
expression area. Standard normalisation to the 50th percentile, as recommended for 
Illumina data by Agilent (Genespring), was applied to all data sets, aiding the 
comparison of data from slide to slide and sample to sample. Normalised data from 
all samples were subjected to cluster analysis to generate a dendogram relating 
treatment groups (Figure 3.8). Firstly the cluster analysis divided the four cell lines 
into two groups, namely: (i) MCF7-TO and MCF7-TO-ERα (WT06) and (ii) MCF7-TO-
ERα(AAA) (A10) and MCF7-TO-ERα(EEE) (E01). With the exception of one of the 
three MCF7-TO samples treated with Dox and lacking E2, cluster (i) separates the 
two lines, MCF7-TO and WT06. Similarly, cluster (ii) divides cleanly into in the A10 
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Figure 3.8 Global clustering of normalised data 
Shown is the tree cluster analysis of the normalised microarray data for MCF7-TO-
ERα (WT06) (green), MCF7-TO-ERα(EEE) (E06) (red), MCF7-TO-ERα(AAA) (A10) 
(blue) and the control cell line MCF7-TO (black). The cells were cultured in the 
presence or absence of Dox for 96 hours. RNA was prepared 8 hours following the 
addition of E2 (10-8M). Microarrays analysis was carried out using 3 replicate RNA 
preparations for each condition.  
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and E01 lines. With the exception of the A10 line, clustering could distinguish E2 
treated samples from the no ligand controls. In the case of the A10 line, the no 
ligand and Dox-treated replicate samples cluster together, as do the E2 treated 
samples in the absence of Dox. These are the samples that would express ERα(AAA). 
However, the samples treated with Dox and E2 fail to form a tight cluster and show 
relationship with the other treatments. Overall, this suggests the possibility that E2 
regulation in this line is distinct from that seen in the other lines examined. It is also 
noted that in the case of the E01 line, one of the no ligand samples does not cluster 
with the bioreplicates for this treatment and is as closely related to any other 
treatment. Taken together, the cluster analysis shows that there is a high degree of 
correlation between related samples, apart from clone A10 where correlation was 
less defined.  
For analysis of differentially expressed genes, replicates were combined to 
give a mean and standard error for the expression of each gene within a particular 
experimental condition. One-way ANOVA analysis was performed on the log scale 
data of a pair of experimental conditions (eg. MCF7-TO in the absence of ligand (NL) 
versus MCF7-TO treated with E2) using a parametric test, assuming variances were 
equal (student's t-test). Variances were assumed to be equal as all data are based 
on the same parental cell line (MCF7-TO), and therefore the number of genes whose 
expression is changed in different clones and treatments are expected to be only a 
small proportion of all genes. Differentially expressed genes were considered 
statistically significant at p <= 0.01. These genes were then filtered according to fold 
change between the two experimental conditions and lists of genes that were up or 
down regulated by 1.5- or 2- fold were generated. 
The cluster analysis showed that the MCF7-TO and WT06 lines were most 
similar to each other, whilst the E2 regulation is unclear for the ERα(AAA) line A10.  
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Figure 3.9 Venn diagrams showing the selection of estrogen-regulated genes 
Normalised microarray data was analysed to identify the number of estrogen-regulated 
genes in the presence and absence of Dox for the MCF7-TO cell line (a) and MCF7-TO-
ERα(EEE) E01 cell line (b). Genes up or down regulated by E2 greater than 1.5-fold 
(p>0.01) in the presence of Dox are shown in the top left section, those regulated in 
the absence of Dox (i.e. during transgene expression) are shown in the top right 
section. Genes up or down regulated by Dox greater than 1.5-fold (p>0.01) are shown 
in the bottom section 
 132 
Therefore, the first analysis carried out compared expression profiles of the 
MCF7-TO line with the ERα(EEE) line (E01). Comparison of genes in the presence 
and absence of E2 identified 128 genes which showed up or down estrogen-
regulation greater than 1.5-fold in the MCF7-TO cell line in the presence of Dox and 
182 in the absence of Dox (Figure 3.9a); 70 genes were estrogen-regulated in the 
presence and absence of Dox. By comparing estrogen-regulated genes with those 
regulated by at least 1.5-fold in the presence and absence of Dox alone, a further 49 
genes which displayed estrogen-regulation were also shown to be Dox regulated. 
The same analysis was  
carried out for the E01 cell line (Figure 3.9b) which identified 451 genes that were up 
or down regulated by at least 1.5-fold in response to E2 in the presence of Dox and 
254 genes in the absence of Dox; 208 genes showed estrogen-regulation in the 
presence and absence of Dox.  
Full lists of estrogen regulated genes for the MCF7-TO and MCF7-TO-
ERα(EEE) cell line are shown in appendix 1 and 2. Classical estrogen-regulated genes 
were shown to be up-regulated in these cell lines. Cathepsin D, pS2 and GREB1 
expression were up-regulated 1.6, 1.2 and 1.8 -fold in the parental cell line in the 
presence of Dox and 2.4, 1.3 and 1.6 -fold in the absence of Dox, respectively. E01 
showed a 1.9, 1.2 and 1.5 –fold induction of these genes in the presence of Dox and 
1.8, 1.2 and 1.7 –fold induction in the absence of Dox, respectively. MCF7-TO-
ERα(EEE) showed similar control of these estrogen regulated genes to the parental 
cell line and expression of ERα(EEE) did not alter the estrogen-induction of these 
genes. 
Further analysis was carried out to identify genes which were regulated due 
to the expression of ERα(EEE) in the absence of E2 (Fig. 3.10). This would 
theortically identify any genes specifically regulated by ERα in the absence of E2 due 
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Figure 3.10 Venn Diagram identifying genes regulated due to expression 
of ERα(EEE) in an E2-independent manner 
Genes which are up or down regulated 1.5-fold (p<0.01) in the absence of Dox 
(i.e. when ERα(EEE) is expressed) in the E01 clone, but not in MCF7-TO, are 
shown in the top left circle. Genes which are up- or down-regulated 1.5-fold 
(p<0.01) due to the expression of ERα(EEE) are shown in the top right circle. 
Genes which are up- or down-regulated 1.5-fold (p<0.01) by Dox treatment in the 
MCF7-TO cell are shown in the bottom circle. Genes which are specifically 
regulated due to expression of ERα(EEE) in the absence of estrogen and shown in 
the yellow segment. 
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to phosphorylation of ERα.  Firstly, all genes regulated by Dox treatment were 
identified by comparing MCF7-TO gene expression in the presence and absence of 
Dox. Genes which were regulated by ERα(EEE) expression were identified by 
comparing MCF7-TO-ERα(EEE) gene regulation in the presence and absence of Dox. 
This identified 235 genes which were up or down regulated by at least 1.5-fold due 
to the expression of ERα(EEE), of which, 51 were also seen to be Dox regulated in 
the parental cell line. These 51 genes that were Dox regulated in the parental cell 
line were of no interest and discarded from further analysis. In order to identify 
which of the remaining 184 genes regulated by ERα(EEE) expression were specific to 
the MCF7-TO-ERα(EEE) cell line, genes regulated in the absence of Dox for E01 and 
MCF7-TO were compared. This identified 534 genes that were up or down regulated 
by at least 2-fold in the MCF7-TO-ERα(EEE) cell line and not the parental cell line. Of 
these, 148 also showed Dox regulation in the parental cell line of at least 1.5-fold 
and were discarded from further analysis. Only 60 of the genes regulated in the 
absence of Dox specifically in the MCF7-TO-ERα(EEE) cell line were also up or down 
regulated 1.5-fold in response to Dox – the remaining 326 genes showed regulation 
in the E01 and not the MCF7-TO cell line in the absence of Dox, but were not 
regulated specifically by the expression of ERα(EEE). The 60 genes regulated in 
response to ERα(EEE) expression alone are detailed in table 3.2. Many of the genes 
identified are involved with the control of cell growth, gene transcription or protein 
degradation; however, four genes were highlighted as being of interest – 
LOC643287, peptidyl-propyl isomerise-like 1 (PPIL1/CYPL1), pp32r1 and insulin-like 
growth factor binding protein 5 (IGFBP5).  
Levels of LOC643287 were increased 2-fold due to expression of ERα(EEE). 
Very little is known about LOC643287, however, LOC643287 has a similar sequence 
to prothymosin α (ProTα). ProTα is a protein involved in mammalian cellular 
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proliferation and has been shown to be increased in breast cancer (Dominguez et al., 
1993; Tsitsiloni et al., 1993). These data suggest that expression of ERα(EEE) causes 
an increase in expression of a gene which is similar to ProTα. Levels of LOC643287 
induction in WT06 and A10 in the absence of Dox compared to the presence of Dox 
were 1.0 and 1.3 –fold, respectively.  
PPIL1 is a member of the cyclophin family of peptidyl-prolyl isomerases which 
carry out cis-trans isomerization of the peptide bond on the N-terminal side of proline 
residues in proteins (Hunter, 1998), and increased expression of PPIL1 has been 
shown to promote growth of colon cancer cells (Obama et al., 2006). Microarray  
studies have also shown an elevation of PPIL1 expression in cervical, pancreatic and 
gastric cancers (Obama et al., 2006). Levels of PPIL1 expression were increased 1.6-
fold in response to ERα(EEE) expression in contrast to WT06 and A10 cell lines which  
  showed a 0.9 and 1.2 -fold change in the absence of Dox compared to the 
presence of Dox, respectively.  
The pp32r1 has been shown to have oncogenic properties in prostatic 
adencarcinoma cells (Kochevar et al., 2004) and over-expression of the gene has 
been linked to transformation and tumourigenesis (Bai et al., 2001). Levels of pp32r1 
expression were increased 1.6-fold in response to ERα(EEE) expression in contrast to 
WT06 and A10 cell lines which showed a 0.9 and 1.0 – fold change in the absence of 
Dox compared to the presence of Dox, respectively.    
This suggests that the increase in expression of these three genes, 
LOC643287, PPIL1 and pp32r1, expression of which could potentially be linked to an 
increase in cancerous cell growth, is not due to the general increase in levels of ERα 
expression in the absence of Dox compared to in the presence of Dox for these cell 
lines, but that ERα(EEE) expression specifically causes an increase in the levels of 
expression. 
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 IGFBP5 has been shown to act as a tumour suppressor by inhibiting angiogenesis 
(Chun et al., 2008), however, levels have been shown to be increased in breast 
carcinoma (Wang et al., 2008). Levels of IGFBP5 expression were decreased 1.6-fold 
in response to ERα(EEE) expression. However, expression levels were also decreased 
in WT06 and A10 cell lines in the absence of Dox compared to the presence of Dox 
by 1.8 and 1.3 –fold, respectively. This suggests that overexpression of ERα in the 
absence of Dox causes a decrease in levels of IGFBP5 expression.   
 
3.6 Effects of HA-ERα-FLAG and ERα mutant expression on MCF7 cell 
growth in the presence of estrogen and anti-estrogens 
MCF7 cell growth requires estrogen and is inhibited by anti-estrogens, such as 
OHT and ICI. Cell growth was determined using the SRB growth assay, in which cells 
were cultured in the absence of ligand, or in the presence of E2 (10-7M), OHT (10-8M) 
and ICI (10-8M), plus and minus Dox, over a period of 12 days (Fig. 3.11). As 
expected, in both the presence and absence of Dox there was no growth of the 
parental (MCF7-TO) cells in the absence of ligand, with growth being stimulated by 
E2, but not stimulated in response to OHT or ICI (Fig. 3.11a). In the presence of 
Dox, the growth curve shows that the cells are in a state of exponential growth up to 
12 days. In the absence of Dox the graph appears to suggest cell growth rate is 
slowing down and beginning to plateau within the 12 day time period although a 
similar optical density, and therefore cell density, is reached. 
The growth of MCF7-TO-ERα (Fig. 3.11b-d), MCF7-TO-ERα(EEE) (Fig. 3.11e-g) 
and MCF7-TO-ERα(AAA) (Fig. 3.11h-j) lines in response to ligands were similar to 
that of MCF7-TO cells in the presence of Dox, with the exception of E06 (the medium 
ERα(EEE) expresser, Fig. 3.11g), where the estrogen-stimulated growth was 
considerably lower than that seen in other lines.  
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Figure 3.11 SRB growth assays in the presence of estrogen and anti-estrogens 
Sulphorhodamine B assays were carried out to assess cell growth, in the presence of vehicle 
(EtOH), E2 (10-8M ), OHT (10-7M) and ICI (10-7M) in the presence and absence of Dox for all 
MCF7-TO-ERα  clones (b, c, d), MCF7-TO-ERα(EEE) clones (e, f, g), MCF7-TO-ERα(AAA) (h, i, 
j) and the parental cell line MCF7TO as a control (a). The order of clones is low, medium and 
high expression of transgenic ERα in each case. 
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Similar to the parental cell line, although E2-stimulated growth is still exponential by 
day 12 in the presence of Dox, in the absence of Dox (i.e. when the transgenes are 
expressed) growth appears to plateau for all the MCF7-TO-ERα, MCF7-TO-ERα(EEE) 
and MCF7-TO-ERα(AAA) clones (except E01). E2-stimulated cell growth in clones 
WT11, E04, A04 and A12 reached a similar cell density by day 12 in the presence 
and absence of Dox whereas E01, E06 and A10 showed slightly higher cell density 
when the transgenes were expressed in the absence of Dox compared to in the 
presence of Dox. WT02 and WT06 showed a reduction in cell density by day 12 n the 
absence of Dox compared to the presence of Dox. How the clones responded to E2 
and Dox was not dependent on either the type or level of phosphorylation mutant 
expressed. Since this plateauing of cell growth also occured for the parental cell line, 
this suggests these differences are due to Dox treatment and not the mutant ERα. 
Similar to the parental cell line, cell growth was not stimulated by either OHT or 
ICI for any of the MCF7-TO-ERα, MCF7-TO-ERα(EEE) or MCF7-TO-ERα(AAA) clones 
in the absence of Dox. This suggests that neither over-expression of ERα or 
expression of ERα phospho-mutants is sufficient to stimulate growth in the presence 
of OHT. Ligand-independent cell growth however, was consistently increased for all 
of the lines expressing tagged forms of ERα (Fig. 3.11 b-j) in the absence of Dox 
compared to in the presence of Dox. The lack of an obvious difference in ligand-
independent growth between cell lines expressing ERα, ERα(EEE) or ERα(AAA) 
suggests that this increase in growth is due to overexpression of ERα induced by the 
expression of WT ERα, ERα(EEE) and ERα(AAA) in the absence of Dox, with the 
phosphorylation site mutantions not contributing to cell growth. 
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3.6.1   Growth of ERα, ERα(EEE) and ERα(AAA) expressing MCF7-TO cells 
in the presence of epidermal growth factor 
Previous studies have shown that S104, S106 and S118 are phosphorylated in 
a ligand-independent manner by p42/p44 MAPK (Chen et al., 2002; Kato et al., 
1995), a downstream kinase of the Raf-MAPK signalling cascade. Activation of 
p42/p44 MAPK in response to cell treatment with EGF and PMA has been used to 
show induction of S118 phosphorylation (Bunone et al. 1996; Joel et al. 1998; Chen 
et al. 2002; Sarwar et al. 2006). In order to determine if mutation of S104, S106 and 
S118 alters the response of MCF7 cells to activation of the MAPK pathway by EGF, 
growth assays were carried out in the presence and absence of EGF using the 
conditions of the previous experiment; in the presence of vehicle (EtOH), E2, OHT 
and ICI, all in the presence and absence of Dox. The growth was measured after 8 
days as this time point provided sufficient ligand-induced growth, with differences 
between the ligands to be evident, without the cells reaching confluence (Figure 
3.12). Graphs show the growth at day eight relative to the cell numbers 24 hours 
after plating.  
In the MCF7-TO parental cell line, Dox treatment did not have a significant 
affect on ligand-independent or estrogen-dependent cell growth, either in the 
presence or absence of EGF. EGF treatment did however cause a significant increase 
in ligand-independent cell growth in the presence and absence of Dox. Estrogen-
dependent cell growth was not significantly affected by EGF treatment (Fig. 3.12a). 
Dox treatment caused a significant decrease in cell growth in the presence of OHT 
and ICI, which was not affected by EGF treatment. This suggests that the cell growth 
of the parental line is increased due to the presence of Dox under these conditions, 
which is unexpected since the parental cell line does not express any Dox-regulated 
proteins.  
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Figure 3.12 Cell growth in the presence of epidermal growth factor 
Sulphorhodamine B assays were carried out to assess cell growth, in the presence of vehicle 
(EtOH), E2 (10-8M ), OHT (10-7M) and ICI (10-7M) in the presence and absence of Dox, with 
and without EGF treatment (10ng/ml) for all MCF7-TO-ERα  clones (b, c, d), MCF7-TO-
ERα(EEE) clones (e, f, g), MCF7-TO-ERα(AAA) (h, i, j) and the parental cell line MCF7TO as 
a control (a). Cell growth is shown at day 8 relative to the plating efficiency measured 24 
hours after plating cells. Standard error is shown based on 6 replicates. Clones are in order 
of lowest to highest mutant ERα expression. Statistical differences between treatments with 
a p value <0.01 are denoted by an *. 
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There was no significant difference in ligand-independent cell growth with or 
without Dox treatment in the MCF7-TO-ERα clones (Fig. 3.12b-c). MCF7-TO-
ERα(EEE) clones E01 (Fig. 3.12e) and E04 (Fig. 3.12g) showed a significant increase 
in ligand-independent cell growth when the transgene was expressed in the absence 
of Dox compared to the presence of Dox; however E06 (Fig. 3.12f) did not show this 
but more importantly, all three MCF7-TO-ERα(AAA) clones (Fig. 3.12h-j) showed a 
significant increase similar to clones E01 and E04. Since two clones from the MCF7-
TO-ERα(EEE) cell line and all three MCF7-TO-ERα(AAA) cell lines showed an increase 
in ligand-independent cell growth due to Dox removal, this suggests that this is due 
to the over expression of ERα in these cell lines and not the phosphorylation status 
of the phospho-mutant.  
Treatment with EGF caused a significant increase in ligand-independent cell 
growth in the absence of Dox for all the clones except clone E06, which showed a 
slight, but not significant increase. The degree of increase did not appear to correlate 
with the levels of Dox-regulated ERα, ERα(EEE) or ERα(AAA) expression as shown 
by Western blotting in figure 3.2.  E01, E04, A04 and A12 also showed a significant 
increase in ligand-independent cell growth in the presence of Dox as well, however, 
in all four cases the increase was more pronounced when the transgenes were 
expressed (-Dox). This suggests that EGF treatment causes an increase in ligand-
independent cell growth in some, but not all, cell lines. Overexpression of ERα 
increases this effect since ligand-independent cell growth was increased due to the 
expression of both ERα(EEE) and ERα(AAA) as well as WT ERα so cannot be said to 
be phospho-specific. 
E2-dependent cell growth was increased significantly due to the expression of 
Dox-regulated ERα in the absence of Dox compared to in the presence of Dox for 
clones E01 (Fig. 3.12e), E04 (Fig. 3.12g), A04 (Fig. 3.12h) and A10 (Fig. 3.12i). A12 
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(Fig. 3.12j) showed a significant decrease in E2-stimulated cell growth after the 
removal of Dox and expression of the transgene. E2-stimulated cell growth was not 
significantly affected by Dox treatment for any of the MCF7-TO-ERα clones (Fig. 
3.12b-d) or E06. Similar to the increase seen in ligand-independent cell growth in the 
absence of Dox, these data suggest the increase in E2-stimulated cell growth is due 
to the over-expression of ERα in these lines and not due to the phosphorylation 
status of ERα. 
EGF treatment caused a significant increase in E2-stimulated cell growth in 
the presence and absence of Dox for clones E01, E04 and A12; however, A04 
showed a significant decrease in cell growth in the absence of Dox due to EGF 
treatment, as did A10 in the presence of Dox where as E06 showed a significant 
increase in the presence of Dox but no significant change in cell growth in the 
absence of Dox due to EGF treatment. The MCF7-TO-ERα clones showed no 
difference in cell growth due to EGF treatment. Overall, these data show that EGF 
treatment had no consistent affect on cell growth and the increases or decreases 
appear to be clone-specific and not related to over-expression of ERα or the 
phosphorylation status of ERα. 
Similar to the control cell line, all MCF7-TO-ERα clones and A12 showed a 
significant decrease in OHT and ICI stimulated cell growth in the absence of Dox 
compared to in the presence of Dox. In general, EGF treatment caused an increase 
in OHT and ICI-stimulated cell growth, but since the changes observed with Dox or 
EGF treatment were consistently seen in the presence of both OHT and ICI, this 
suggests they were not due to the involvement of ERα since ERα activity is totally 
inhibited by ICI treatment (fig. 3.4).  
Similar to the previous findings in figure 3.11, these results show that over-
expression of ERα can cause an increase in ligand-independent cell growth, and for 
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some clones estrogen-dependent cell growth, but this appears to be unrelated to the 
phosphorylation status of the three residues within the AF1 of ERα or to overall 
levels of ERα expression. These results suggest that treatment with EGF causes a 
general increase in ligand-independent cell growth which appears to be enhanced by 
over-expression of ERα, but not phosphorylation, as overexpression of ERα in the 
absence of Dox caused further increases compared to growth in the presence of Dox 
across the clones from MCF7-TO-ERα, MCF7-TO-ERα(EEE) and MCF7-TO-ERα(AAA) 
cell lines. Treatment with EGF also appears to increase E2-stimulated cell growth, 
again, regardless of the phosphorylation status of the AF1 residues, although over-
expression of ERα caused a further increase in this effect in some, but not all cases. 
 
 
3.6.2 Growth of ERα, ERα(EEE) and ERα(AAA) expressing MCF7-TO cells in 
the presence of insulin 
Insulin is a growth factor which, similar to EGF, causes activation of the Ras-
MAPK signalling pathway (Porras et al., 1998). Insulin-like growth factor signalling 
has been implicated in resistance to endocrine treatments (Gee et al., 2005; 
Knowlden et al., 2005). In order to determine if insulin stimulates the ligand-
independent growth of MCF7 and ERα lines, growth assays were carried out as 
performed for EGF above (Fig. 3.13). Since the insulin was prepared in 10mM HCl, 
the cells not treated with insulin were treated with an equal volume of 10mM HCl. 
Graphs depict the growth measured at day 8 relative to that measured 24 hours 
after plating of cells (Fig. 3.13). 
Cell growth of the MCF7-TO cell line was stimulated by treatment with E2 and 
less so with OHT treatment whereas cell growth was not stimulated in the absence 
of ligand and severely inhibited by ICI treatment (Fig. 3.13a). Dox treatment in 
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Figure 3.13 Cell growth in the presence of insulin 
Sulphorhodamine B assays were carried out to assess cell growth, in the presence of vehicle 
(EtOH), E2 (10-8M ), OHT (10-7M) and ICI (10-7M) in the presence and absence of Dox, with 
and without insulin treatment (1μg/ml) for all MCF7-TO-ERα  clones (b, c, d), MCF7-TO-
ERα(EEE) clones (e, f, g), MCF7-TO-ERα(AAA) (h, i, j) and the parental cell line MCF7TO as 
a control (a). Cell growth is shown at day 8 relative to the plating efficiency measured 24 
hours after plating cells. Clones are in order of lowest to highest mutant ERα expression. 
Standard error is shown based on the readings of 6 replicates. Statistical differences 
between treatments with a p value <0.01 are denoted by an *. 
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conjunctin with insulin treatment causd a significant reduction in cell growth in the 
presence of E2, OHT and ICI compared to Dox treatment in the absence of insulin. 
Treatment with insulin caused a significant increase in ligand-independent cell 
growth in the presence and absence of Dox. E2-dependent cell growth was 
decreased significantly by insulin in the presence of Dox from 16- to 12- fold, 
although increased significantly in the absence of Dox from 13.5- to 16.5- fold. Cell 
growth in the presence of OHT and ICI was decreased significantly due to insulin in 
the presence of Dox yet remained similar in the absence of Dox.  
All the MCF7-TO-ERα, MCF7-TO-ERα(EEE) and MCF7-TO-ERα(AAA) clones 
(Fig. 3.13b-j) displayed a significant increase in ligand-independent cell growth due 
to expression of the Dox-regulated ERα in the absence of Dox compared to in the 
presence of Dox. Similar to the control cell line but to a greater extent, ligand-
independent cell growth increased in response to insulin treatment in the presence 
and absence of Dox for all MCF7-TO-ERα, MCF7-TO-ERα(EEE) and MCF7-TO-
ERα(AAA) clones, except A04 which did not show a significant increase in growth in 
the absence of Dox. The level of increase in ligand-independent cell growth induced 
by insulin treatment was similar in the presence and absence of Dox and was not 
influenced by the levels of Dox-regulated ERα expression, although ligand-
independent cell growth was higher in the absence of Dox. This suggests that the 
expression of Dox-regulated ERα causes an increase in ligand-independent cell 
growth which is independent of the phosphorylation status of ERα and this affect is 
increased due to insulin treatment. 
E2-stimulated cell growth was significantly increased due to expression of 
ERα, ERα(EEE)or ERα(AAA) in clones WT11, WT06, E06, E04 and A04, yet 
significantly decreased in clones WT02, E01, A10 and A12. Treatment with insulin in 
the presence of Dox caused a significant increase in E2-stimulated cell growth in all 
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clones, except WT02 which showed a slight but not significant increase, and WT11 
which showed a significant decrease in cell growth similar to the control cell line. 
Treatment with insulin in the absence of Dox caused a significant decrease in E2-
stimulated cell growth for clones WT11, E01, E06 and A04, whereas a significant 
increase in cell growth was shown for clone A12, similar to the control cell line. All 
other clones showed no significant change in E2-stimulated cell growth due to insulin 
treatment in the absence of Dox. These data suggest that insulin has no specific 
effect on E2-induced cell growth. 
Slight increases in cell growth in the presence of OHT and ICI in response to 
insulin were seen in the presence and absence of Dox for all the clones, although cell 
growth remained the lowest under these conditions compared to in the presence or 
absence of E2. 
3.6.3 Cell growth in the presence of the MEK inhibitor U0126 
Tyrosine kinase receptors such as EGFR stimulate the activity of c-raf, which 
in turn activates MAPK kinase (MAPKK, also known as MEK), which is an upstream 
activator of p42/p44 MAPK (Lange-Carter et al., 1993). The U0126 compound inhibits 
the MEK family members MEK1 and MEK2 (Favata et al., 1998). If phosphorylation of 
S104, S106 and S118 by MAPK is important for the growth of MCF7 cells, then 
treatment with U0126 would be expected to inhibit the growth of MCF7-TO (parental 
cells) as well as the growth of lines expressing HA-ERα-FLAG, but should not 
influence the growth of the MCF7-TO-ERα(EEE) or MCF7-TO-ERα(AAA) lines. In 
order to test this possibility, the lines were treated with U0126 (10μM) (Thomas et 
al., 2008) in the presence of vehicle (EtOH), E2, OHT and ICI, plus and minus Dox, 
in order to investigate how inhibition of p42/p44 MAPK activation affected cell 
growth. Cells which were not treated with U0126 were treated with an equal volume 
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Figure 3.14 Cell growth in the presence of MEK inhibitor U0126 
Sulphorhodamine B assays were carried out to assess cell growth, in the presence of 
vehicle (EtOH), E2 (10-8M ), OHT (10-7M) and ICI (10-7M) in the presence and absence 
of Dox, with and without U0126 treatment (10μM) for all MCF7-TO-ERα  clones (b, c, 
d), MCF7-TO-ERα(EEE) clones (e, f, g), MCF7-TO-ERα(AAA) (h, i, j) and the parental 
cell line MCF7TO as a control (a). Cell growth is shown at day 8 relative to the plating 
efficiency measured 24 hours after plating cells. Standard error is shown based on the 
readings of 6 replicates. Clones are in order of lowest to highest mutant ERα 
expression. Statistical differences between treatments with a p value <0.01 are denoted 
by an *.
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of the vehicle DMSO. Graphs depict the growth measured at day 8 relative to that 
measured 24 hours after plating of cells (Fig. 3.14). 
U0126 inhibited the ligand-stimulated growth of MCF7-TO cells (Fig. 3.14a), 
indicating that MAPK activity is important for the growth of MCF7 cells. Growth of the 
ERα lines was similarly inhibited by U0126, regardless of the nature of the residues 
at S104, S106 and S118, suggesting that the action of U0126 is independent of ERα 
phosphorylation status at these sites (Fig. 3.14b-j). Further, the ligand-independent 
growth in the absence of Dox in the MCF7-TO-ERα, MCF7-TO-ERα(EEE) and MCF7-  
TO-ERα(AAA) lines was also inhibited by U0126. Together, these data show that 
MAPK activity is important for the growth of MCF7 cells, and that phosphorylation of 
ERα at these residues is not able to overcome the affects of total MAPK inhibition.  
 
 
3.7 Identification of proteins associated with ERα using immunoaffinity 
purification 
Immunoaffinity purification was used to isolate HA and FLAG tagged ERα 
protein and associated proteins from whole cell lysates. Isolated proteins were 
analysed by SDS-PAGE followed by silver stain and mass spectrometory was then 
carried out on any bands which occurred on the gel. Firstly, the method of producing 
lysates was explored in order to ascertain which lysis buffer produced whole cell 
lysates with intact ERα in the largest quantities. 
 
3.7.1    Testing lysis buffers 
Three lysis buffers were tested to produce cell lysates using the high salt lysis 
method as SDS-containing lysis buffers used for the studies in previous sections 
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Figure 3.15 Western blot showing different cell lysis techniques used 
for immunoaffinity purification  
Lysates of clone WT02 were made using Sigma lysis buffer (lanes 1 and 2), 
modified HSLB (lanes 3 and 4) and HSLB (lanes 5 and 6). For each of the three 
sets of lysates, immunoaffinity purification was carried out using the Sigma FLAG 
Tagged Protein Immunoprecipitation Kit, proteins eluted by sample buffer elution 
and 10% of elute loaded (lanes 2, 4 and 6). Whole cell extracts were generated 
by adding Laemmli buffer and the equivalent of 1% of the volume of whole cell 
lysate added to the immunoaffinity purification column was loaded (lanes 1, 3 and 
5). Levels of HA-ERα-FLAG protein (HA) were determined by immunoblotting. 
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would interfere with the immunoaffinity purification. All tests were done using clone 
WT02 as an example of a clone expressing HA-ERα-FLAG. Preliminary experiments 
showed very poor ERα yield using the Sigma lysis buffer with a salt concentration of 
150mM NaCl provided in the immunoaffinity purification kit used, so this lysis buffer 
was compared to the HSLB routinely used in the lab, which has a salt concentration 
of 500mM NaCl. A modified HSLB technique was also developed which lysed the cells 
at a higher salt concentration of 500mM NaCl, then the lysates were diluted to give a 
final salt concentration of 150mM NaCl, same as the Sigma lysis buffer, before  
loading onto the column. Immnoaffinity purification was carried out using the Sigma 
FLAG Tagged Protein Immunoprecipitation Kit for 1mg of protein from each type of 
cell lysis technique used, as measured by Bradford assay. Figure 3.15 shows the 
results of each cell lysis technique used with the levels of ERα measured in 1% of 
whole cell lysate input compared to the ERα isolated using immunoaffinity 
purification. Lanes A, C and E show the levels of HA-ERα-FLAG measured in the 
whole cell extract from Sigma lysis buffer, modified HSLB and HSLB, respectively. 
Levels of HA-ERα-FLAG measured from whole cell extract inputs produced using 
Sigma lysis buffer (lane A), as shown by immunoblot HA, clearly show a lower level 
of HA-ERα-FLAG protein compared to that measured using the modified HSLB (lane 
C) and HSLB (lane E). All lysates showed lower levels of immunopurified HA-ERα-
FLAG in 10% of eluate compared to that in 1% of input, however, the Sigma lysis 
technique again showed the lowest level of protein. The modified HSLB technique 
and HSLB technique showed very similar levels of HA-ERα-FLAG in the input and 
after immunoaffinity purification, suggesting that the different concentrations of NaCl 
do not adversely affect the immunoaffinity purification. Based on these findings, the 
HSLB technique was used for further experiments due to the simpler technique 
compared to the modified HSLB technique. 
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3.7.2     Testing methods of elution of immunoprecipitated ERα 
Three methods of eluting proteins bound to the immunoaffinity purification 
column are available; elution using Laemmli buffer, peptide elution in which the 
immunoprecipitates are incubated with a molar excess of the peptide corresponding 
to the epitope recognised by the primary antibody and acid elution, in which a low 
pH solution is used to dissociate the antibody-antigen complex. These three methods 
were compared in order to ascertain which provided the best elution method for HA-
ERα-FLAG. Figure 3.16a shows Laemmli buffer elution following immunoaffinity 
purification using the HA tag (lane 2) and using the FLAG tag (lane 3). This shows 
that more HA-ERα-FLAG is removed from the column using the FLAG tag as both the 
upper blot identifying the HA tag and the lower blot identifying total ERα show 
considerably higher levels of HA-ERα-FLAG. Lane 4 shows peptide elution following 
immunoaffinity purification using the FLAG tag and lane 5 shows the same procedure 
using the HA tag. For both the HA and FLAG tags, peptide elution yields considerably 
lower levels of HA-ERα-FLAG compared to that produced using sample buffer elution, 
indicating inefficient competition. Figure 3.13b shows acid elution (lane B) compared 
to elution by the addition of Laemmli buffer (lane D) following immunoaffinity 
purification using the FLAG tag; this method of immunoaffinity purification was used 
over HA tag as it yielded higher levels of HA-ERα-FLAG in figure 3.16a. Laemmli 
buffer elution was carried out on the same immunoaffinity purification column after 
acid elution to remove any remaining HA-ERα-FLAG protein still bound to the column 
(lane C) The results in figure 3.16b show that acid elution method yielded very little 
HA-ERα-FLAG from the column (lane B). Indeed, addition of Laemmli buffer following 
acid elution (lane C) shows that a similar level of HA-ERα-FLAG remained bound to 
the column as was eluted by the addition of Laemmli buffer alone (lane D).  
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Figure 3.16 Testing methods of elution of bound proteins after 
immunoaffinity purification 
(a) Sample buffer elution (lane 2 and 3) and peptide elution techniques (lane 4 and 
5) were compared after immunoaffinity purification of whole cell lysate from clone 
WT02 using the FLAG-tag (lane 3 and 4) and HA-tag (lane 2 and 5). 10% of the 
eluate was loaded in each case. The equivalent of 1% of the volume of whole cell 
lysate added to the immunoaffinity purification column was loaded in lane 1 (Input). 
(b) Acid elution (B) was compared to the sample buffer elution technique (D) after 
immunoaffinity purification of whole cell lysate from clone WT02 using the FLAG-tag. 
Sample buffer elution was carried out on the column after acid elution (C). 10% of 
the eluate was loaded in each case. The equivalent of 1% of the volume of whole cell 
lysate added to the immunoaffinity purification column was loaded in lane A. HA-ERα-
FLAG was identified using HA-hrp (HA) and ER6F11. 
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Figure 3.17 Western blot showing artefacts detected during sample buffer 
elution of immunopurified proteins 
(A) 1% of the volume of whole cell extract added to agarose gel for IP. B) 1% of the 
volume of whole cell extract after IP using the FLAG tag. C) 1% of the volume of the 
first wash of the agarose gel after IP. D) 10% of the immunopurified protein. 
Samples probed with α-mouse-hrp secondary antibody, ERα followed by α-mouse-hrp 
secondary antibody and HA-hrp conjugated antibody. 
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These results would suggest that elution with Laemmli buffer was the preferred 
method as it yielded higher levels of HA-ERα-FLAG from the column compared to 
acid elution and peptide elution. However, as seen following immunoblotting for ERα 
(ER6F11 antibody) in figures 3.16a and 3.16b, a number of polypeptides not related 
to ERα were also identified. These were investigated further, and as shown in figure 
3.17, they were also seen when a secondary anti- mouse hrp-conjugated antibody 
was used on its own of in order to identify the ER6F11 primary antibody, suggesting 
that the additional bands are immunoglobulins and are not related to ERα. 
  
3.7.3  Testing methods of band identification 
Eluted proteins were separated using SDS-PAGE, followed by staining of the 
gel to highlight separate bands. Two methods of gel staining were investigated for 
this use; SYPRO Ruby staining and silver staining. Identification of a range between 
1-1000ng of protein marker, recombinant ERα and BSA were tested using the two 
methods, as shown in figure 3.18. Silver staining of the gel produced clearer protein 
bands and also allowed identification of lower amounts of protein compared to 
SYPRO Ruby staining. Silver staining was therefore used to identify HA-ERα-FLAG 
and associated proteins from the immunoaffinity purification eluates. 
 
3.7.4  Identification of ERα and associated proteins  
Immunoaffinity purification was carried out using the FLAG tag and HA tag 
separately and also using FLAG tag followed by immunnoaffinity purification of the 
eluate using the HA tag. Clone WT02 was again used and compared to the control 
MCF7-TO which contains no HA-ERα-FLAG and therefore no protein should bind to or 
be eluted from the column. Peptide elution was used to minimise IgG elution and 
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Figure 3.18 Silver stain and SYPRO Ruby staining of resolving gels 
1000ng, 100ng, 10ng and 1ng of protein marker, BSA and recombinant ERα were 
separated using SDS-PAGE and either SYPRO Ruby staining or silver staining was 
carried out on the resolving gel 
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Figure 3.19 Silver stain of immunoaffinity purified proteins 
FLAG-tag (FLAG) and HA-tag (HA) immunoaffinity purifications were carried out using 
WT02 whole cell lysate and MCF7-TO as a control. HA-tag immunoaffinity purification 
was carried out on elute from FLAG-tag immunoaffinity purification (Re-IP). 
Recombinant ERα was loaded as an indicator. HA-ERα-FLAG was identified by Western 
blot using HA-hrp antibody (a) and silver stain was carried out on the samples to 
identify total protein (b). The equivilant of 0.5% of the total volume loaded onto the 
column was loaded as input. 10% of the eluate from the column was loaded for each 
sample. 
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silver staining was carried out on the resolving gel after SDS-PAGE. The result 
displayed in figure 3.19b shows that although peptide elution does not appear to 
elute IgG compared to Laemmli buffer elution when analysed by Western blotting, 
the silver stain clearly shows non-specific binding of proteins which have been eluted 
as the majority of the bands present in the WT02 lanes are also present for MCF7-
TO. The results in figure 3.19a and 3.19b also show, as seen in figure 3.16, that 
immunoaffinity purification using the FLAG tag produces a higher yield of HA-ERα-
FLAG than when using the HA tag. This may explain why FLAG tag followed by HA 
tag immunoaffinity purification (Re-IP) yielded such low levels of protein.  
FLAG tag immunoaffinity purification was carried out for clone MCF7-TO-ERα 
WT02 with increased wash steps to try to reduce non-specific binding. MALDI-TOF 
mass spectrometory was then used to identify protein bands from the gel and to see 
if ERα could be identified from the gel using this method. As seen in figure 3.20, the 
majority of bands were similar to non-specific bands seen in figure 3.19b. Mass 
spectrometory carried out on these bands (table 3.2) did not identify ERα and the 
majority of the bands tested were abundant ribosomal proteins involved with 
translation, tubulin or keratin. These are unlikely to represent ERα interacting 
proteins, so should therefore not have been present on the column after washing. 
Due to time constraints this was not pursued any further. 
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Figure 3.20 Silver stain of immunoaffinity purified proteins which 
were carried forward for mass spectrometory 
FLAG-tag (FLAG) and HA-tag (HA) immunoaffinity purifications were carried 
out using WT02 whole cell lysate. HA-tag immunoaffinity purification was 
carried out on elute from FLAG-tag immunoaffinity purification (Re-IP). The 
equivilant of 0.2% of the total volume loaded onto the column was loaded as 
input. 10% of the eluate from the column was loaded for each sample. 
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Protein Molecular weight (Da)
60S ribosomal protein L18 21485
40S ribosomal protein S7 22108
40S ribosomal protein S9 22442
40S ribosomal unit S8 24056
Ribosomal protein L13 24247
60S ribosomal protein L10a (CSA-19) 24682
Ribosomal protein LP0 27280
DNA-binding protein TAXREB107 32707
Ribosomal protein L6 32723
60S acidic ribosomal protein P0 (L10E) 34255
Keratin 19 44074
Ribosomal protein L3 46101
Keratin 18 47908
Tubulin alpha-1 49906
Tubulin alpha-6 49877
Tubulin alpha-8 50075
Tubulin alpha-3 50117
Keratin 8 53525
Keratin 9 62111
Heat shock-related 70kDa protein 2 70003
Heat shock 70kDa protein 1A 70020
Polyadenylate-binding protein 1 70653
Heat shock protein CA 73581
Nucleolin (protein C23) 76194
Heat shock protein 75 kDa 79993
TRAP1 (fragment) 79339  
 
Table 3.2  Proteins identified using MALDI-TOF mass spectrometory 
Carried out by Robin Wait at Imperial College Charing Cross Hospital 
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4 DISCUSSION 
 ERα is a steroid hormone receptor which is required for the growth and  
development of the male and female reproductive systems (Hewitt et al., 2005). 
Ligand binding results in the recruitment of coactivator complexes to the ERα which 
promotes its activation, allowing stimulation or inhibition of the expression of 
estrogen-regulated genes (Ali and Coombes, 2002; Doisneau-Sixou et al., 2003; 
Glass and Rosenfeld, 2000). Under normal circumstances, ERα expressing cells in 
breast tissue do not proliferate but stimulate the proliferation of surrounding ERα-
negative epithelial cells (Clarke et al., 1997; Russo et al., 1999). In breast tumours, 
ERα expressing cells are converted from non-dividing cells into proliferating cells, the 
growth of which is stimulated by estrogen. However, how cells are converted from 
non-proliferating to proliferating, is unclear (Ali and Coombes, 2002). It has been 
hypothesised that aberrant signalling of ERα could lead to abnormal cellular 
proliferation and survival, potentially resulting in the development and progression of 
breast cancer (Herynk and Fuqua, 2004).  
The SERM, tamoxifen, is used to treat ERα-positive breast cancer and works 
by binding to and blocking the activity of the AF2 domain, which is required for 
estrogen-regulated activation of ERα. A large proportion of patients who present 
with primary breast cancer and all those with metastatic disease, who initially 
respond to tamoxifen, eventually acquire resistance to tamoxifen and relapse (Likhite 
et al. 2006). However, ERα continues to play an important role in many tamoxifen-
resistant cases (Morris and Wakeling 2002), suggesting a mechanism of resistance 
whereby the activity of ERα is altered in some way to overcome the inhibition of AF2 
activity by tamoxifen. Although tamoxifen blocks ERα activity through the AF2, it has 
partial agonist properties through the activation of the second transactivation 
domain, AF1 (Berry, Metzger et al. 1990; Metzger, Losson et al. 1992; Tzukerman, 
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Esty et al. 1994), and it has been suggested that activation of the AF1 domain is 
involved in tamoxifen-resistant cell growth. 
There is considerable evidence that ERα activity can be regulated by post-
translational modification, including acetylation, glycosylation and phosphorylation 
(Cheng and Hart 2000; Lannigan 2003; Kim, Woo et al. 2006). Serines 104, 106 and 
118 within the AF1 region of ERα have been identified as major sites of 
phosphorylation and their mutation has been shown to reduce the transcriptional 
activity of ERα (Ali et al. 1993; Le Goff et al. 1994; Joel et al. 1995; Kato et al. 1995; 
Chen et al. 2000; Chen et al. 2002). These three residues have all been shown to be 
phosphorylated by MAPK and are required for the agonist functions of tamoxifen 
(Bunone et al., 1996; Chen et al., 2002; Joel et al., 1998; Kato et al., 1995; Thomas 
et al., 2008). These and other studies have suggested that elevated S118 
phosphorylation may be indicative of non-response to endocrine therapies. However, 
immunohistochemical studies reported since the initiation of the current project, 
have shown that ERα is phosphorylated at S118 in 62% of ERα-positive tumours 
(Murphy et al., 2004b), but that S118 phosphorylation is associated with better 
prognosis (Bergqvist et al., 2006; Britton et al., 2006; Bunone et al., 1996; Joel et 
al., 1998; Murphy et al., 2004a; Murphy et al., 2004b; Sarwar et al., 2006), although 
another study showed that low phosphorylation of S118, at least when accompanied 
by high-level S167 phosphorylation is associated with a better outcome (Yamashita 
et al., 2008). Furthermore, S118 phosphorylation has been reported to be higher in 
biopsies taken from recurrent tumours in patients who had received tamoxifen, 
compared to the pre-tamoxifen treatment biopsies from the same patients (Sarwar 
et al., 2006). Hence, the picture remains far from clear, with respect to S118 
phosphorylation in vivo. No immunohistochemical studies for ERα phosphorylated at 
S104 and/or S106 have been reported to date. This thesis attempts to ascertain how 
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phosphorylation of S104, S106 and S118, affects the function of ERα in the presence 
of estrogen and anti-estrogens and what impact this has on cell growth using the 
MCF7 breast cancer cell line as a model system. 
 
4.1 Characterising the MCF7-TO cell lines 
MCF7-TO lines were generated in order to assess the effects of phosphorylation 
at the three residues S104, S106 and S118 within the AF1 domain. Generated were 
lines expressing ERα, or mutant forms of ERα in which S104, S106 and S118 were 
substituted by glutamic acid or alanines. The MCF7 human breast cancer cell line 
was used as it is a commonly used model of breast cancer, in that it expresses ERα, 
requires estrogen for its growth, and its growth is inhibited by anti-estrogens 
(Buluwela et al., 2005). The Tet-Off system was used as it enabled controlled 
expression of the mutant and wild type forms of ERα by removal of Dox from the 
growth medium which prevented any possible long-term changes that high levels of 
ERα expression might cause. The mutant and wild type forms of ERα introduced into 
the cells were N- and C-terminally tagged with HA and FLAG epitope tags, 
respectively. This was carried out so that it would be possible to identify these forms 
of ERα from the endogenous ERα present in the cells. 
 Immunoblotting of whole cell lysates in the absence of Dox demonstrated 
successful generation of lines expressing each introduced form of ERα, at varying 
levels, in a Dox-regulated manner (Figure 3.1). Clones expressing HA-ERα-FLAG, HA-
ERα(EEE)-FLAG and HA-ERα(AAA)-FLAG were then taken forward to test for Dox 
control of the tagged ERα (Fig. 3.2) and based on these results, three clones from 
each cell line were chosen according to the level of introduced ERα expression 
compared to endogenous ERα; one with high, one medium and one with low levels 
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of tagged ERα compared to endogenous ERα. This was done so that any effects due 
to the level of tagged ERα expression in subsequent experiments would be identified. 
 
4.2 The effect of phosphorylation on the activity of ERα 
Luciferase reporter gene assays were carried out to assess how the 
expression of ERα, ERα(EEE) and ERα(AAA) affected the activity of the ERα relative 
to endogenous ERα expressed in MCF7-TO (Fig. 3.4). Expression of WT ERα, 
ERα(EEE) and ERα(AAA) caused an increase in the overall levels of ERα expression, 
and a consequent increase in the levels of ERα activity in the absence of ligand and 
presence of estrogen. Although all clones expressing WT ERα, ERα(EEE) and 
ERα(AAA) caused an increase in ligand-independent activity, expression of ERα(EEE) 
displayed the greatest increase in activity, suggesting that phosphorylation at S104, 
S106 and S118 within the AF1 may promote the activity of ERα in the absence of 
ligand.  
Tamoxifen stimulated ERα activity to a lesser extent than estrogen. 
Interestingly, there was increased ERα activity in the presence of OHT in the case of 
the MCF7-TO- ERα and ERα(EEE) lines and activity in the presence of OHT was 
reduced in MCF7-TO-ERα(AAA) compared to the parental cells. These results suggest 
that the ability to phosphorylate these three residues within AF1 stimulates the 
activity of ERα in the presence of OHT as expression of ERα(AAA), which cannot be 
phosphorylated, was less active, whilst ERα(EEE) was more active, than WT ERα. 
The results also suggest that there is moderate stimulation of phosphorylation of 
these residues under the culture conditions used, as expression of WT ERα increases 
activity more than expression of ERα(AAA), possibly because WT ERα is being 
phosphorylated by endogenous signalling mechanisms. It is of course possible that 
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the reduction in ERα activity for the ERα(AAA) mutant is due to the replacement of 
the serines, rather than due to phosphorylation of the serines residues, although the 
higher activity of the ERα(EEE) mutant suggests that phosphorylation is an important 
feature of ERα activity.  
ICI inhibited ERα activity, regardless of the phosphorylation status of the 
residues at positions 104, 106 and 118, which is in agreement with the previous 
findings showing that ICI inhibits the activity of AF1, as well as AF2 (Wakeling et al., 
1991). 
 
4.3 The effect of ERα phosphorylation on the expression of endogenous 
estrogen-regulated genes 
The effect of the phosphorylation status of S104, S106 and S118 on the 
expression of a number of estrogen-regulated genes in response to estrogen was 
investigated at the protein level and at the mRNA level. Analysis of all the genes 
studied showed a level of estrogen-stimulation within all the cell lines at either the 
protein level or the mRNA level or both. Overall, these data show that over-
expression of ERα causes an increase in expression of estrogen-responsive genes 
and that protein expression of some genes are also affected by the phosphorylation 
status of S104, S106 and S118 within the ERα. 
Data shown in figure 3.5 suggests that over-expression of ERα causes an 
increase in ligand-independent and estrogen-dependent expression of pS2 and 
cathepsin D at the protein level. Expression of ERα(EEE) appears to promote ligand-
independent pS2 protein expression, however, levels of cathepsin D, pS2 and also 
GREB1 mRNA were not seen to increase significantly due to overexpression of ERα 
or due to expression of phosphorylation mutants (Fig. 3.6b and c, Fig. 3.7). This 
suggests that phosphorylation of S104, S106 and S118 causes an increase protein 
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expression of at least some estrogen-regulated genes but also that this effect may 
be gene-specific and that not all estrogen-regulated genes respond in the same way.  
Microarray analysis of the whole genome allowed for further analysis of how 
phosphorylation of the AF1 may affect other genes, both estrogen-regulated and not. 
By comparing whole-genome gene analysis of MCF7-TO-ERα(EEE) with MCF7-TO, 60 
genes were identified as being up-regulated due to expression of ERα(EEE) in the 
absence of E2. The majority of these genes were seen to be involved in gene 
transcription and protein degradation; however, LOC643287, PPIL1, p32r1 and 
IGFBP5 appeared to be of particular interest.  
 LOC643287 has a similar sequence to the more widely studied protein, 
ProTα. ProTα is a highly conserved nuclear protein which is ubiquitously expressed in 
mammalian tissues and is involved with chromatin remodelling (Diaz-Jullien et al., 
1996; Papamarcaki and Tsolas, 1994) and cellular proliferation (Clinton et al., 1991; 
Eschenfeldt and Berger, 1986; Gomez-Marquez et al., 1989; Sburlati et al., 1991). 
Levels of ProTα are increased in proliferating cells (Tsitsiloni et al., 1993) whilst 
repressed in quiescent cells (Dominguez et al., 1993); in accordance with this 
involvement in cell growth, ProTα has also been shown to be expressed in various 
tumours of different origins. Overexpression of ProTα in a rat fibroblast cell line has 
been shown to result in loss of contact inhibition, anchorage-independent growth, 
and decreased serum dependence (Orre et al., 2001) whereas inhibition of ProTα 
using antisense oligomers causes an inhibition of myeloma cell growth (Sburlati et 
al., 1991). Most interestingly in respect to this project, not only has ERα been shown 
to regulate the transcriptional activity of the ProTα gene in response to E2 (Bianco 
and Montano, 2002), but levels of ProTα have been shown to be higher in breast 
tumours compared to normal breast tissue (Magdalena et al., 2000), indicating a 
possible role in breast cancer progression. A number of studies raise possible reasons 
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as to why an increase in ProTα may be involved in breast cancer progression, 
including reported interactions with the transcriptional co-activator CBP, both in vivo 
and in vitro, acting as a co-factor stimulating the transcriptional activity of CBP 
(Karetsou et al., 2002). Expression of ProTα has also been shown to interact with the 
co-repressor REA (repressor of estrogen receptor activity) causing an increase in ERα 
activity by sequestering the co-repressor (Martini et al., 2000).  
The results of this study appear to suggest that ERα phosphorylated within 
the AF1 causes an increase in expression of LOC643287, a gene similar to ProTα. 
Phosphorylation of the AF1 has been shown to cause an increase in activity of ERα 
(Ali et al., 1993; Chen et al., 2000; Kato et al., 1995) and levels of phosphorylated 
AF1 have been shown to be increased in breast cancer (Murphy et al., 2004a; Sarwar 
et al., 2006). These results could indicate a possible mechanism whereby 
phosphorylation of the AF1 causes an increase in cell proliferation by increasing the 
expression of LOC643287 which may act in a similar manner to ProTα in promoting 
cellular proliferation. Unfortunately no probe for ProTα is included in the microarray 
carried out and it would be interesting in the future to identify how ProTα regulation 
is affected by ERα phosphorylation. 
PPIL1 is a cyclophilin-related protein, sharing 41.6% identity of the amino 
acid sequence with human cyclophilin A (Ozaki et al., 1996). Cyclophilins are one of 
three families of peptidyl-prolyl isomerases; the cyclophilin family which form 
complexes with the immunosuppressant cyclosporin A, the immunosuppresant FK506 
binding protein (FKBP) family and the parvulin family (Hunter, 1998). Peptidyl prolyl 
isomerases carry out cis-trans isomerization of the peptide bond on the N-terminal 
side of proline residues in proteins – a process which plays a role in protein folding, 
the assembly and disassembly of protein complexes, protein trafficking and 
regulation of protein activity (Schmid, 1995; Shaw, 2002). Microarray studies carried 
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out using colon cancer tissues identified PPIL1 as being specifically up-regulated in 
tumours compared to normal colon tissue (Lin et al., 2002). Further studies showed 
that expression of PPIL1 promotes growth of colon cancer cells and that the protein 
interacts with SNW1/SKIP and stathmin (Obama et al., 2006). SNW1/SKIP is a 
transcriptional coactivator which plays an important role in transcriptional regulation, 
pre-mRNA splicing and cell cycle regulation (Folk et al., 2004). Stathmin, also known 
as oncoprotein 18, is over-expressed in luekaemia (Hanash et al., 1988), highly 
proliferative breast cancers (Curmi et al., 2000) and malignant ovarian cancers (Price 
et al., 2000) causing microtubule destabalization by stimulating microtubule 
catastrophes and sequestering tubulin dimers - a process involved with 
transformation allowing cancer cells to grow independently of substrate anchorage 
(Cassimeris, 2002). The authors suggest that elevated expression of PPIL1 may play 
an important role in the proliferation of cancer cells through the control of 
SNW1/SKIP modulated genes associated with proliferation and cell cycle progression 
through association with stathmin (Obama et al., 2006). Microarray studies also 
showed that expression of PPIL1 was elevated in cervical, pancreatic and gastric 
cancers (Obama et al., 2006) and the data from the microarray data here suggest 
that the expression could also be elevated in breast cancers, possibly due to 
phosphorylation of ERα. 
The pp32r1 gene (or ANP32C) is a member of the acidic leucine-rich nuclear 
phosphoprotein 32 family (ANP32). Whereas the closely-related family member pp32 
has anti-oncogenic properties and is involved with controlling gene expression, 
signalling pathways and apoptotic pathways, pp32r1 has been shown to have 
oncogenic properties (Brody et al., 1999; Kadkol et al., 1999). Transfection of NIH-
3T3 cells over-expressing pp32r1 into nude mice has been shown to lead to the 
formation of tumours, suggesting that over-expression of pp32r1 stimulates 
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transformation and tumourigenesis (Bai et al., 2001). Studies have identified pp32r1 
as being highly expressed in prostatic adenocarcinoma cell lines with little expression 
shown in breast cancer cell lines (Kochevar et al., 2004). The data presented here 
suggests that pp32r1 expression is increased in response to ERα phosphorylation, 
possibly stimulating tumourigenesis.  
IGFBP5 is one of six members of the IGFBP family and binds IGF, enhancing 
or suppressing its activity in a tissue and cell-specific manner (Beattie et al., 2006; 
Schneider et al., 2002). Studies have shown expression of IGFBP5 causes a decrease 
in tumour growth and tumour vascularity in a xenograft model of human ovarian 
cancer (Chun et al., 2008). Although very low levels of IGFBP5 were detected in 
normal breast epithelium, moderate to high levels of IGFBP5 were detected in 50% 
of invasive breast carcinomas tested in a recent study carried out by Wang et al. 
(Wang et al., 2008). Although expression of IGFBP5 correlated with the expression of 
PR and Her2, no correlation was shown with tumour size or the expression of ERα 
(Wang et al., 2008). The data here suggests that over-expression of ERα causes a 
decrease in the levels of IGFBP5 expression and presumably the anti-tumuorigenic 
affect of IGFBP5.  
Taken together, initial analysis of the microarray studies carried out suggests that 
phosphorylation within the AF1 of ERα promotes tumour cell growth by causing an 
increase in expression of at least two genes involved in tumourigenesis, PPIL1 and 
pp32r1, and potentially a third also, LOC643287. Over-expression of ERα appears to 
causes a decrease in at least one gene, IGFBP5, which has anti-tumourigenic 
properties, therefore also promoting tumourigenic activity. 
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4.4 The effect of ERα phosphorylation on cell growth 
The above-described data indicate that ERα over-expression results in an 
increased expression of estrogen-regulated genes. Moreover, the activity of 
ERα(EEE) was higher in the presence of estrogen and OHT, as well as in the absence 
of ligand, when compared with WT ERα, suggesting that the glutamic acid residues 
at these positions stimulate ERα activity. In growth assays, however, the picture was 
clearly more complex. In the presence of Dox, all of the lines showed a similar 
growth profile to MCF7-TO, as expected, with little or no growth in the presence of 
OHT, ICI or in the absence of ligand. In the MCF7-TO-ERα, ERα(EEE) and ERα(AAA) 
lines, there was significant growth in the absence of ligand in all cases, when Dox 
was removed, indicating that the growth stimulation was due to the over-expression 
of ERα and not the phosphorylation status of the S104, S106 and S118 residues 
within the AF1. Growth in the presence of estrogen, tamoxifen and ICI was not 
stimulated in the ERα, ERα(EEE) or ERα(AAA) lines, even though the levels of ERα 
activity as assessed by gene expression analysis and reporter gene assays suggested 
that cell growth might be stimulated in the presence of tamoxifen. These growth 
assays suggest that phosphorylation of the residues within the AF1 does not play a 
significant part in regulating MCF7 cell growth. A number of studies have shown that 
re-introducing ERα expression into ERα-negative breast cancer cell lines such as 
MDA-MB 231 cells, re-sensitizes the cells to hormone treatment; however, 
subsequent E2 treatment suppresses cell proliferation (Jiang and Jordan, 1992; 
Lazennec and Katzenellenbogen, 1999; Zajchowski et al., 1993). These results 
described here however, are similar to a number of studies carried out using MCF7 
cell lines which have shown that over-expression of ERα causes an increase in 
ligand-independent cell proliferation, but does not affect estrogen-stimulated cell 
growth (Fowler et al., 2004; Fowler et al., 2006).  It has also been shown that 
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increased activity due to over-expression of ERα requires the AF1, but is independent 
of AF1 phosphorylation (Fowler et al., 2004) which is supported by the results 
presented here.  
Since S104, S106 and S118 phosphorylation is stimulated by the MAPK 
pathway, stimulators of cell surface receptors that activate this pathway were carried 
out. However, neither EGF nor insulin stimulated the growth of these lines in a 
differential manner, indicating that mutation of S104, S106 and S118 is insufficient to 
prevent the growth stimulation through the MAPK pathway, at least in this context, 
where ERα is over-expressed.   
There is relatively little EGF receptor expression in MCF7 cells, although IGF 
receptors are expressed (Pacher et al., 2007). Additionally, other tyrosine kinase 
receptors might provide sufficient MAPK activation for additional EGF or insulin to 
make an insufficient difference in this study. Indeed, MAPK activation by EGF and 
insulin was not determined. In order to address this issue, growth assays were 
carried out in the presence of the MEK inhibitor, U0126, caused inhibition of cell 
growth for all cell lines under all conditions in the presence and absence of Dox. 
Growth inhibition by U0126 was observed, with the inhibition not being rescued by 
ERα over-expression, or indeed by the ERα(EEE) mutant.  
Together, these findings indicate that MAPK activation is important for the 
growth of MCF7 cells, but that the growth stimulation is independent of a 
requirement for phosphorylation at S104, S106 or S118. There are a number of 
potential reasons for these findings. The simplest is that over-expression of ERα is 
sufficient to provide the growth benefit that phosphorylation might provide. There 
are other protein kinases that have been shown to phosphorylate these residues, 
namely CDK2 and GSK3 in the case of S104, S106, CDK7 in the case of S118. These 
kinases may provide sufficient phosphorylation at these sites to prevent evident 
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differences between ERα and ERα(EEE) lines to be observed. However, differences 
might have been expected for the ERα(AAA), which also did not show any 
differences. It is also possible, as discussed in Chapter 1, that MAPK-mediated 
phosphorylation of coactivators, in particular AIB1 and SRC1, and/or the 
corepressors NCoR and SMRT, is rather more important for ERα function than the 
phosphorylation of the residues in AF1, at least when ERα is over-expressed.   
 
4.5 Identification of ERα co-immunoprecipitating proteins 
The MCF7-TO lines described here were generated by stable integration of 
ERα HA and FLAG epitope tagged at the N- and C-terminus, respectively. This 
allowed the immunoaffinity purification of HA-ERα-FLAG, HA-ERα(EEE)-FLAG and 
HA-ERα(AAA)-FLAG polypeptides from cell extracts, with the aim of co-purifying 
proteins that interact with ERα and specifically, by comparison of proteins that 
interact with ERα and ERα phosphorylation site mutants, of proteins that interact 
preferentially with phosphorylated ERα. However, a number of problems occurred 
using this method, firstly, the difficulties associated with generation of sufficiently 
large amounts of cell extracts to allow the purification of interacting proteins. 
Further, although the immunoprecipitation of ERα was extremely easy, the process 
was inefficient, with much of the ERα remaining bound to the antibody agarose 
beads, at least using the gentle methods of elution required to maintain ERα 
interacting proteins. Finally, despite the fact that HA and FLAG antibodies coupled 
directly to agarose beads were used, considerable amounts of antibody were eluted 
from the gels using the Laemmli buffer method of elution, but also using the rather 
more gentle peptide elution method, whilst acid elution proved to be inefficient. 
When immunoprecipitates were subjected to mass spectrometric sequencing, the 
major proteins were immunoglobulin’s and tubulin. Indeed, it was not possible even 
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to identify ERα in the immunoprecipitates following silver staining, although there 
was some ERα in the immunoprecipitates as demonstrated by Western blotting. This 
could be due to other more abundant protein bands at a similar molecular mass 
masking the presence of ERα, or it could be due to the fact that samples were not 
concentrated enough for silver staining of gels to highlight the protein. Silver staining 
of gels is considerably less sensitive than Western blotting so a larger amount of 
protein would be required in order for the protein to be visualised on a gel by silver 
stain compared to that required by Western blotting.  
 This work shows that in order for silver staining to be used as a method of 
visualising co-immunoprecipitating proteins of ERα, the method of washing the 
column of un-bound proteins requires improving and the elute needs to be 
concentrated in order to reach high enough levels of protein to be visualised on the 
gel by silver stain. Unfortunately, there was not enough time to explore this further 
during this project. The problems encountered using silver stain and mass 
spectrometry to identify novel ERα-interacting proteins could possibly be overcome 
by using the tandem affinity purification (TAP)-tag method. This method involves 
fusion of the TAP tag to the target protein and then introduction of the construct into 
the host. The TAP tag consists of two protein tags separated by a cleavage site. For 
example, the yeast TAP tag consists of two IgG binding units of protein A from 
Staphylococcus aureus, a cleavage site for the tobacco etch virus (TEV) protease and 
a calmodulin binding peptide (CBP). The target protein is first purified by protein A 
binding to IgG sepharose, then separated using TEV-protesase cleavage. The eluate 
is then incubated with calmodulin sepharose and released with ethylene glycol 
tetraacetic acid. This method has been shown to increase the amount of target 
protein recovered and the increased efficiency compared to immunoaffinity 
purification with other tags, including HA and FLAG, reduces the amount of cellular 
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starting material required (Burckstummer et al., 2006; Collins and Choudhary, 2008; 
Tsai and Carstens, 2006). 
 
4.6 Final conclusions and future work 
These results show, in agreement with other studies carried out, that over-
expression of ERα causes an increase in levels of receptor activity and cell 
proliferation. Although an increase in ERα activity was observed in the presence and 
absence of E2 due to over-expression of ERα, as seen by reporter gene assays and 
an increase in pS2 and cathepsin D protein expression, cell growth was only 
increased in the absence of ligand due to ERα over-expression, with no additional 
effect when S104, S106 and S118 were substituted by glutamic acid residues, 
despite the fact that these substitutions increase ERα activity in reporter gene 
assays. However, microarray analysis does suggest that phosphorylation within the 
AF1 leads to a ligand-independent increase in certain genes – most interestingly with 
respect to this project was the upregulation of at least two genes previously shown 
to be involved with cancer cell progression (PPIL1 and pp32r1) and the 
downregulation of a tumour suppressor gene (IGFBP5). This does suggest that AF1 
phosphorylation could promote cancer cell growth progression.  
However, data shown here indicates that phosphorylation at these sites does not 
contribute greatly to cell growth, at least when ERα is over-expressed. A study 
carried out using MCF7 cells over-expressing ERα in a tetracycline-inducible manner 
suggested that increased levels of ERα protein results in an increased occupancy of 
EREs by ERα at promoter sites of estrogen-regulated genes, independent of estrogen 
binding (Fowler et al., 2004). Although this was seen to result in increased pS2 
mRNA levels in the presence and absence of E2 this study showed that, in 
agreement with the results presented here, over-expression of ERα was not capable 
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of increasing cell growth in the presence of E2 and the authors suggested that 
increased levels of ERα have a squelching effect on co-repressors in the absence of 
ligand (Fowler et al., 2004). This means that the cells effectively ‘run-out’ of co-
repressors that are thought to normally bind ERα in the unliganded state due to the 
abnormally high levels of ERα protein, allowing for un-bound ERα protein to take on 
an active role resulting in an increase in ligand-independent cellular proliferation. In 
a similar way, in the presence of estrogen the increased levels of ERα protein may 
potentially put such a demand on available co-activators that levels of activity, 
although increased for some genes, do not increase sufficiently to cause an increase 
in cell proliferation. 
Due to the method used in this study of expressing ERα, ERα(EEE) and 
ERα(AAA) in the ERα-positive MCF7 cell, the effect of ERα phosphorylation was 
difficult to elucidate as results were complicated by the effects of ERα 
overexpression. The MCF7 cell line was chosen due to the fact that it represents an 
anti-estrogen-sensitive cell line which expresses estrogen-regulated genes and these 
characteristics were important for these studies. To avoid the added affect of ERα 
over-expression, gene knock-in techniques could be used in future. This has been 
widely used to introduce small changes in mice through homologous recombination 
(Christian et al., 2008; McDevitt et al., 2008; Sinkevicius et al., 2008). Short 
interfering RNA (siRNA) is a method of ‘silencing’ gene expression in vitro and as 
such could be used to prevent endogenous ERα expression, although the knock-
down effect on the gene of interest is only transient, the level of reduction in gene 
expression may be incomplete, and whilst such a method could be used to 
knockdown expression of endogenous ERα, the over-expression provided by the 
introduced gene may still be problematic. Further, expression of the introduced gene 
is mediated by a CMV promoter and TetR-VP16, whose regulation in the cell cycle 
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will be distinct from that of the endogenous ERα gene, which may also influence 
estrogen responses in MCF-7 cells. Recent reports have utilised a homologous 
recombination system that has been used to generate knock-in mutations in cell 
lines. The method uses the adenovirus associated virus (AAV) based vectors to allow 
infection for high-level cell take up of the vector, thereby maximising the chances of 
homologous recombination. However, most genes in cell lines are present as two 
copies (and in many cases, due to chromosomal instability, there may be additional 
copies of some genes), so two homologous recombination events are required, 
making this a difficult task to achieve. Nevertheless, several reports of gene 
knockouts and knockins have used this methodology (Arena et al., 2007; Kim et al., 
2008) and it may provide a method for introduction of the substitutions in ERα 
phosphorylation sites.  
Increased expression of ERα is a common phenotype in many post-
menopausal breast cancer cases and is linked to an increase in cell growth and poor 
patient survival (Black et al., 1983; Fabris et al., 1987; Holst et al., 2007; Hupperets 
et al., 1997; Masters et al., 1978; Sancho-Garnier et al., 1995; Thorpe et al., 1993). 
The work described here supports the hypothesis that this increased ERα expression 
leads to an increase in estrogen-independent cell growth. However, phosphorylation 
of ERα at S104, S106 and S118 within the AF1 does not appear to further regulate 
breast cancer cell growth, despite previous findings using reporter gene studies 
showing that phosphorylation at these sites stimulates ERα activity. Although a 
number of studies have been carried out which show that MAPK signalling pathways 
increase phosphorylation of these residues, resulting in increased ERα activity, this 
study shows that the stimulation of this pathway increases cell growth independently 
of the phosphorylation status of ERα. This is interesting given recent 
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immunohsitochemical staining studies showing that increased levels of S118 
phosphorylation are indicative of a better prognosis in breast cancer patients.  
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